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SUMMARY
During the fed state energy requirements are met by glycolysis of carbohydrates. 
When the stores of carbohydrates are diminished, for example during prolonged 
fasting, metabolism switches to that of fatty acids. Fatty acids are broken down 
by fi-oxidation within the mitochondrial matrix. Prolonged fasting results in the 
production of ketone bodies. These can also be used as an energy source by the 
brain.
In defects of fatty acid metabolism where individual steps are inhibited or 
blocked, such as medium chain acyl-CoA dehydrogenase deficiency, an abnormal 
accumulation of the metabolites that lead up to the block, or their breakdown 
products, is often seen. Non-compensatory levels of metabolites following the site 
of the defect also occur.
In the fed state, when flux through the defective fatty acid pathway is minimal, 
metabolic profiles can appear completely normal. It is therefore often necessary to 
induce metabolic stress before a full laboratory investigation can proceed.
Interpretation of individual metabolite quantitations can often be difficult and a 
variation of 'normal values' according to metabolic state can lead to 
misinterpretation. Comparison between the concentrations of related metabolites 
along the fatty acid metabolic pathway may diminish the need for exact 
knowledge of the metabolic state and by correlation plotting could clearly identify 
abnormal relationships.
This thesis describes an investigation into the efficacy of paired metabolite
correlation plots in preliminary detection of defects in fatty acid metabolism.
In certain inborn errors of fatty acid metabolism where the fi-oxidation cycle is 
affected, abnormal urine metabolite patterns have been used as diagnostic 
markers. Similar patterns have been reported in the urine of healthy newborns 
and termed generalised neonatal dicarboxylic aciduria177.
This report documents an investigation of the connections between generalised 
neonatal dicarboxylic aciduria and a number of overlying factors (vis type of feed, 
gender, sibling history of sudden infant death syndrome and urine carnitine 
levels).
Also discussed is the development of two laboratory assays. A radio-enzymatic 
method was developed and used to determine the levels of total, free and acyl 
carnitine in urine or blood. Suberyl, hexanoyl, and phenylpropionyl glycine in 
urine can be quantitated by use of stable isotope internal standards and gas 
chromatography /  electron impact mode mass spectrometry. Synthesis and 
calibration of such internal standards is described.
Finally, methods used to culture and store skin fibroblasts from biopsy samples 
are included as an appendix. These fibroblasts can then be used in various 
diagnostic tests such as carbon dioxide release and electron transfer flavoprotein 
enzyme analysis. The costs encountered during tissue culture could be avoided 
by medium term storage of the biopsy material prior to culture to await sufficient 
clinical evidence to merit such analyses. Preliminary results of extended cryogenic 
storage and viability of recovered specimens are also included.
CHAPTER 1 
INTRODUCTION
1.1 A BRIEF HISTORY
Fatty acids have two major roles throughout the mammalian kingdom; as integral 
components of membrane lipids and as the body's main energy store in the form of 
triacylglycerols.
Under energy stress, when carbohydrate supply is low, triacylglycerols are oxidised 
to yield relatively large amounts of energy. Mole for mole, the oxidation of fatty 
acids such as oleic acid yields more than three times the amount of ATP than does 
the oxidation of glucose.
The theory of fatty acid oxidation has existed since the beginning of the century. 
Geelmugden found ketones to be produced from fatty acids in 1897. In 1904 Knoop 
was revolutionary in his use of synthetically labelled fatty acids. He fed dogs odd 
and even, straight chain fatty acids with phenyl groups attached to the co-carbon and 
deduced that fatty acids were shortened by 2 carbon units at a time starting at the 
carbonyl end. He thus devised the theory of fi-oxidation. It was not until the 1950's 
that the organisation of such a pathway began to unfold. The mid 1950's saw the 
discovery of co-enzyme A, CoA, and its role as carrier molecule for fatty acids. 
Tissue fractionation was also developed around this time and paved the way to the 
discovery not only of subcellular particles such as mitochondria but also the acylation 
of carnitine. Work involving the acylation of carnitine and its action as cofactor 
during fatty acid oxidation then led to the elucidation of its role as carrier for fatty 
acyl groups as they cross the inner mitochondrial membrane.
1.2 OVERVIEW OF OXIDATIVE METABOLISM
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Fig. 1.01. The processes involved in oxidative metabolism.
On average a well-fed 70kg man has a calorie distribution as shown in table 1.01. 
Depending on his activity his body energy requirements can range from 1600kcal to 
6000kcal per 24 hours. The carbohydrate pool could be exhausted by just one day's 
fast.
The production of energy and synthetic material is accomplished essentially by the 
six metabolic pathways.
1. Glycolysis
2. Gluconeogenesis
3. Pentose phosphate pathway
4. Fatty acid synthesis /  fi-oxidation
5. Glycogen synthesis /  degradation
6. Citric acid cycle
Table 1.01. Calorific distribution of energy in an average 70kg man2.
AVAILABLE ENERGY (kcal)ORGAN ___________________________________________________
Glucose Triglycerides Mobilizableor Glycogen Proteins
Blood 60 45 0
Liver 400 450 400
Brain 8 0 0
Muscle 1,200 450 24,000
Adipose 80 135,000 40tissue
The brain's predominant fuel source is glucose. It is therefore important to maintain 
tolerable blood glucose levels (greater than 3 mmol/1) at all times. This is achieved 
during times of low blood glucose by the body producing glucose from glycogen 
breakdown and gluconeogenesis. At the same time maximum supply to the brain is 
ensured by a switch of the major peripheral organs from glycolysis to fatty acid 
oxidation. Muscle protein breakdown may also occur supplying gluconeogenesis 
with pyruvate, lactate and alanine. However, as this would be detrimental to the 
activity of the body, and therefore its capability to find food or defend itself, 
proteolysis is limited until starvation is severe.
1.2.1 METABOLIC FLOW DURING THE WELL FED STATE
During well fed states glycolytic breakdown of glucose produces biosynthetic 
precursors (pyruvate and NADH) and energy (ATP).
C6Hi206 + NAD+ -------------=► CH3-C-COO" + 2ATP + 2NADH
0
These compete with fi-oxidation for NAD and electron transport chain access, 
minimising fatty acid oxidation. Work with isolated mitochondria has shown fatty 
acids, once in the matrix, to be oxidised in preference to pyruvate and citrate. 
Pyruvate and most other citric acid cycle intermediates only slightly effect fi-oxidation 
whilst fatty acids can almost halt pyruvate and citrate oxidation3,4.
Insulin secreted from the pancreas stimulates glycogen synthesis and hepatic 
glycolysis. Uptake of glucose by muscle and liver is enhanced along with uptake by 
muscle of the branched amino acids valine, leucine and isoleucine to supply protein 
synthesis. General protein synthesis is increased and proteolysis inhibited. Acetyl- 
CoA carboxylation in the liver is stimulated increasing malonyl-CoA levels and 
inhibiting fi-oxidation of longer chain fatty acids (see section 1.6.2). Glycerol 
phosphate acyl transferase is the enzyme responsible for the conversion of glycerol-3-
-14-
phosphate to phosphatidate which is subsequently converted to triacylglycerol. Its 
activity in the mitochondria is enhanced by insulin thereby further increasing 
lipogenic rates. The synthesised fatty acids travel to adipose tissue in the form of 
very low density lipoprotein, VLDL, where their abundance, along with glucose, 
leads to triacylglycerol formation and storage. Lipolysis is inhibited.
Vasopressin with Ca2+ ions inhibit fatty acid oxidation5 by increasing glycolysis, 
lactate formation6, and acetyl-CoA carboxylation.
The effect of the adrenal cortex hormones on fatty acid oxidation is unclear. 
Mineralocorticoids, in general, suppress ketone levels by inhibiting fi-oxidation 
probably via the malonyl-CoA mechanism7,8 (see section 1.6.2). However, the 
glucocorticoids stimulate adipose fatty acid release9 which increases the supply to 
fi-oxidation. They also promote gluconeogenesis and a primary deficiency in 
glucocorticoids is often associated with an elevated rate of ketogenesis. This is 
thought to be a result of an increased reliance on ketone bodies for energy due to a 
decreased supply from glycolysis.
The sex hormones have opposite effects on the formation of the fatty acid binding 
protein that transports fatty acids to the endoplasmic reticulum for esterification. 
Oestradiol elevates the proteins formation whilst testosterone suppresses. Therefore, 
females are more prone to the esterification pathway whereas males favour fi- 
oxidation.
1.2.2 METABOLIC FLOW DURING FASTING
Upon fasting, glucagon along with catecholamine hormones act in a very similar 
fashion opposing the action of insulin. Glucagon targets the liver whereas the 
catecholamines act mainly on muscle. Glycogenolysis, fatty acid oxidation, 
gluconeogenesis, muscle proteolysis and brown adipose cell lipolysis are all 
enhanced. Glycogen synthesis, fatty acid synthesis, insulin production and uptake of
-15-
glucose by muscle are inhibited.
Thyroid hormones stimulate triglyceride release from adipose tissue10 and regulate 
fi-oxidation in the liver. The triglycerides are hydrolysed to free fatty acids and travel 
to the muscle and liver to undergo fi-oxidised.
Such a change in fuel supply to the muscle prevents pyruvate conversion to acetyl- 
CoA. Instead pyruvate with lactate and alanine travel to the liver to be incorporated 
into glucose production. By the same pathway glycerol produced during 
triacylglycerol breakdown is also used to produce glucose. Hepatic fatty acid 
oxidation elevates citrate and acetyl-CoA levels leading to the switching off of 
glycolysis.
As fatty acid oxidation continues acetyl-CoA levels rise. High gluconeogenic rates 
deplete oxaloacetate concentrations. Under these conditions the tri-carboxylic acid 
cycle cannot complete the oxidation of the acetyl groups rapidly enough. The ketone 
bodies acetoacetate and 3-hydroxybutyrate are then produced. Their build up 
increases as the fast progresses. Brain is capable of using such metabolites as a fuel 
source and after 3 days a third of its total fuel supply consists of ketone bodies. After 
several weeks this proportion rises to dominate the supply. Heart and muscle can 
also utilise these ketone bodies, in fact in vitro acetoacetate is metabolised in 
preference to glucose, (see section 1.8.1 for further discussion of ketogenesis).
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1.3 DEVELOPMENT AND CONTROL OF 6-OXIDATION 
DURING THE PERINATAL PERIOD
Long chain fatty acids are essential during embryonic and fetal development.
They are used both for structural esterification as well as serving as a major 
energy source postnatally.
Prenatal supply is either from fetal tissue or from the mother. Studies on rodents 
show synthetic rates to be high in a variety of tissues, in particular liver, lung and 
brain. Synthesis is mostly by the de novo pathway in the cytosol but also occurs 
via chain elongation in mitochondria11 and in microsomes12. Such synthesis 
decreases at birth with an increase in fat intake and again increases upon 
weaning13,14 as a less fatty diet is adopted.
The sudden removal of maternal blood nutrient supply and the abrupt change in 
environment at birth creates significant metabolic stress. As a result there is a 
switch from glucose metabolism to fatty acid metabolism. A preparation for this 
switch can be seen in the latter stages of gestation. Fat depots increase and 
mitochondria are seen to associate with myofibrils in readiness for a more efficient 
energy production.
At birth a sudden increase in free fatty acids precedes an increase in serum ketone 
levels a few hours later. A drop in the respiratory quotient from 1 to 0.8 over the 
next few days, highlights an increase in fatty acid oxidation15,16. Hepatic glycogen 
depletion indicates the demand for glucose in maintaining metabolic homeostasis.
Main regulatory factors affecting such a switch in metabolism from glycolysis to fi- 
oxidation are :-
1. Fatty acid availability - suggested by the increase in serum fatty acids
prior to fatty acid oxidation increase and also a drop in fatty acid and
-19-
ketone oxidation upon weaning when fat intake is decreased.
2. Rates of fatty acid transfer, including levels of intracellular fatty acid 
binding proteins.
3. Activity of the key enzymes acyl-CoA synthase and carnitine acyl 
transferase. These enzymes show an increase in activity correlating with 
increase fatty acid oxidation17.
4. Oxygen supply - emergence into the more aerobic postnatal environment 
enhances tissue oxygen supply and facilitates the aerobic oxidation of 
fatty acids.
5. Carnitine supply.
A correlation has been found between fi-oxidation rates and the amount of 
carnitine in feed. Breast milk, richer in carnitine than artificial feeds is 
accompanied by higher plasma carnitine and ketone levels as early as 42 hours 
after birth18,19. This, in turn, leads to a higher rate of increase of fi-oxidation 
during metabolic stress.
Hepatic fatty acid de novo synthesis varies over birth, suckling and weaning, 
whereas that in lung20 and brain21 remains relatively constantly high. This is 
thought to be a result of brain and lung requirements for myelin and surfactant 
respectively for which fatty acids are precursors.
1.4 COMPARTMENTATION OF THE B-OXIDATION 
PATHWAY
Cell membrane Mitochondrion
3-OH—but
AcAcPeroxisome Ac
Ac-CoA
B—oxidation■>vl. Acyl-CoAFFA — C18-C24 CoA CoA B—oxidation
m&s. Acyl—CoA-> l&m.Acyl—CoAFFAC10-C20
G-3-P
Triacylglycerides & PhospholipidsFFAC4-C10
Fig. 1.04. Distribution of B-oxidation within the cell.Abbreviations: FFA, free fatty acid; Ac—CoA, acetyl- CoA; Ac, acetate; G-3-P, glycerol-3- phosphate; s, short; m, medium; 1, long; vl, very long chain length.
There is an amount of uncertainty in the short, medium, long and very long 
nomenclature used to describe the carbon chain lengths of fatty acids. As a result 
in referencing current literature these categories may be seen to overlap slightly.
Fatty acid oxidation operates in three main subcellular compartments.
1. Extramitochondrial compartment.
2. Peroxisomes.
3. Mitochondrial matrix.
1.4.1 EXTRA - MITOCHONDRIAL COMPARTMENT
This includes the endoplasmic reticulum, cytosol and outer mitochondrial 
membrane. Here long chain (C12-26) fatty acids passing into the cell are 
converted to acyl-CoA esters by the action of acyl-CoA synthases.
FA + ATP + CoA = Acyl-CoA + AMP + PPi
These esters can then be either incorporated into phospholipids and 
triacylglycerides or oxidised by the fi-oxidation pathway.
Shorter chain free fatty acids (C4-10) can pass directly into the mitochondrion 
prior to CoA esterification.
1.4.2 PEROXISOMAL fi-OXIDATION
In the peroxisomes partial fi-oxidation has a chain shortening effect, particularly 
important for the longer fatty acids (C22-C26)22-24.
Although the steps involved in this fi-oxidation are the same as those of the 
mitochondrial pathway, the enzymes involved differ. Carnitine, carnitine-acyl 
transferase and carnitine translocase are not required for transport of long acyl- 
CoA's into the organelle. However, medium-chain carnitine acyltransferase and 
carnitine acetyl transferase proteins have been isolated25,26. These are thought to 
play a role in transfer of partial oxidation products to the tri-carboxylic acid cycle
-22-
and electron transport chain of the mitochondria.
Acyl-CoA oxidase catalyses the first step in the pathway. Fatty acyl-CoA is 
converted to trans-2-enoyl-CoA with concomitant reduction of the enzyme's 
prosthetic group FAD to FADH2. The reduced prosthetic group is then re­
oxidised by direct interaction with oxygen.
FAD FADH2
/  0  /  0r -c h2-c h2-c h2-c x   > r -c h 2-c h=c h -c  ^^  S-CoA ^  S-CoA
Acyl—CoA trans—2-enoyl—CoA
+02 +H202
The enoyl-CoA is acted upon by a bifunctional protein. Possessing both 2-enoyl- 
CoA hydratase and 3-hydroxyacyl-CoA dehydrogenase activity this protein 
hydrates enoyl-CoA to L-(+)-hydroxyacyl-CoA and converts this to 3-ketoacyl-CoA 
with simultaneous reduction of NAD+ to NADH.
H20 OH0 v I /O
^   > r-ch2-ch-ch2-c /x SCoA 1 NSCoA
L— (+)—hydroxyacyl—CoA 
NAD+ NADH O
^  ^  II— -— — --- > r -c h2-c -c h2-c
2 ^ S C o A
3—ketoacyl—CoA
1 - 2-enoyl-CoA hydratase activity2 - 3-hydroxyacyl-CoA dehydrogenase activity
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Finally, acetyl-CoA is produced by 3-ketoacyl-CoA thiolase.
O CoA-SH
II ^ 0  V  /O  . 0r-ch2-c-ch2-c  ^ ---> r-ch2-c + ch3-cX  SCoA X SCoA ^  SCoA
This enzyme has been seen to have maximal activity for long chain length 
substrates indicating peroxisomal 13-oxidation's preference for long chain fatty 
acids. Best substrates for peroxisomal 13-oxidation are saturated C12-C26 and 
unsaturated C18:l, C18:2 and C22:l chain length fatty acids. C8 and CIO chain 
lengths are oxidised to a lesser extent. C6 and C4 oxidation is inappreciable27. 
Affinity for dicarboxylic acids is even greater than that for the corresponding fatty 
acids (monocarboxylic acids)28'30.
An important difference between the two 13-oxidation pathways is in the first step. 
The mitochondrial pathway is connected to the electron transport chain via an 
acyl-CoA dehydrogenase flavoprotein. In the peroxisome oxidation of the FADH2 
is directly by oxygen.
Defective peroxisomal 13-oxidation results in the accumulation of the longer chain 
fatty acids. Adrenoleukodystrophy, an 'X'-linked disorder resulting from 
peroxisomal very long chain acyl-CoA synthetase deficiency, causes an 
accumulation of C24 and C26 fatty acids in the adrenals and central nervous 
system31.
1.4.3 MITOCHONDRIAL 13-OXIDATION
Of main interest in this study is mitochondrial 13-oxidation. It is here where acyl- 
CoA esters undergo complete 13-oxidation ultimately producing acetyl-CoA. This 
pathway shall now be discussed.
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1.5 ACYL-CoA PRODUCTION FOR 6-OXIDATION
1.5.1 THE SYNTHASES
Fatty acids enter the cell by simple diffusion after binding to a lipoprotein receptor 
on the cell membrane.
Once in the cytosol two classes of enzymes are involved in their conversion to 
acyl-CoA esters. The acyl-CoA synthases catalyse their formation whilst acyl-CoA 
hydrolases facilitate the reverse reaction ensuring a constant supply of CoA for 
other metabolic processes.
The enzymes within each class differ in their carbon chain length specificities for 
free fatty acids. This, along with a wide distribution throughout many body 
tissues, ensures the activation of a wide range of free fatty acid lengths in a wide 
variety of tissues.
The synthases involved in the supply of fatty acyl-CoA esters for fi-oxidation are
1. Butyryl-CoA synthase (EC 6.2.1.?)
2. Medium chain acyl-CoA synthase (EC 6.2.1.2)
3. Long chain acyl-CoA synthase (EC 6.2.1.3)
1.5.1.1 Butyryl-CoA synthase
This enzyme exists solely within the mitochondrial matrix of extrahepatic tissues 
such as heart36. It has not been isolated in liver and has only limited importance 
in fi-oxidation.
1.5.1.2 Medium chain acyl-CoA synthase
Heptanoate and octanoate are the preferred substrates for medium chain acyl-CoA 
synthase however activity throughout carbon chain lengths C4 -C l2 is also 
exhibited. A second enzyme present within the mitochondrial matrix acts upon 
medium chain fatty acids. Its specificity for benzoate and also activity towards 
salicylate indicates an involvement in the production of glycine conjugates of 
aromatic carboxylic acids37.
1.5.1.3 Long chain acyl-CoA synthase
Long chain acyl-CoA synthase activity has been found in the microsome38 and 
peroxisomes39,40 of the liver and in the outer mitochondrial membrane41,42. Such a 
distribution gives each organelle its own capacity to activate long chain free fatty 
acids. However it is not known for sure whether separate acyl-CoA pools exist.
In the liver activity is concentrated in the peroxisomes with the remainder spread 
uniformly between the mitochondria and endoplasmic reticulum.
Regulation is mainly via substrate availability and acyl-CoA product inhibition.
1.6 THE ROLE OF CARNITINE IN 6-OXIDATION
1.6.1 TRANSPORT ACROSS THE INNER MITOCHONDRIAL MEMBRANE
OUTER INNER MATRIXMEMBRANE MEMBRANE
RCOCT + ATP
carnitine
Fig. 1.05. Carnitine dependant transport of long chain fatty acids into the mitochondrial matrix.1 - Long chain acyl-CoA synthase2 - Carnitine-palmitoyl transferase I3 - Carnitine-palmitoyl transferase II4 - Carnitine translocase
The inner mitochondrial membrane is impermeable to acyl-CoA's of lengths in 
excess of Cl 6 which make up a large proportion of available fatty acids. Such 
esters are carried across this barrier by carnitine, carnitine acyltransferase and 
acyl-camitine translocase interaction.
Firstly the CoA ester is converted to acyl-camitine by a carnitine-palmitoyl
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transferase I bound to the outer surface of the inner mitochondrial membrane43,44. 
Acyl-camitine translocase then carries the carnitine ester across the membrane. 
Once on the matrix side acyl-CoA is regenerated by carnitine-palmitoyl transferase 
II and the carnitine recycled back across the membrane on a 1:1 basis with the 
influx of acyl-carnitine4^ 47. There also appears to be a slow, unidirectional, inward 
flow of carnitine which may be involved in preventing intra-mitochondrial acyl- 
CoA build up. During times of low tissue acylcamitine concentrations the 
translocase process may become rate limiting to 6-oxidation. This inward flow of 
carnitine would then become more significant and may help to prevent an 
excessive build up of intra-mitochondrial acyl-CoA concentrations by decreasing 
the inner acylcamitine /carnitine ratio relative to that outside the mitochondria.
Carnitine uptake by the liver during times of fast is stimulated by glucagon45,48. 
However, a correlation between carnitine concentration and 13-oxidation is difficult 
to distinguish because of interference from other regulatory factors.
Tissue carnitine depletion results in lipidosis (accumulation of triacylglycerol). 
Lipidosis in heart muscle caused by the diphtheria toxin can be decreased by 
carnitine therapy48.
1.6.2 CARNITINE-PALMITOYL TRANSFERASE
There are thought to be three carnitine acyltransferases involved in 6-oxidation49. 
The roles of carnitine-octanoyl transferase, found in the peroxisomes49, and 
carnitine-acetyl transferase, found in both peroxisomes and mitochondria50, are 
unclear. Of greatest importance is the involvement of carnitine-palmitoyl 
transferase.
There are thought to be two separate isoenzymic forms of carnitine-palmitoyl 
transferase. Coded for on separate gene loci, they are carnitine palmitoyl
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transferase I, CPT I, and carnitine-palmitoyl transferase n, CPT n. They are 
localised on the outer and inner surface respectively, of the inner mitochondrial 
membrane51.
Both long chain acyl-CoA and long chain acyl-carnitine are amphipathic, capable 
of binding to protein and membrane surfaces therefore the enzyme kinetics vary 
with surrounding environment and membrane constitutions52,53. This may be one 
source of discrepancy between results from different workers in this area54,55.
An interesting observation with carnitine-palmitoyl transferase (EC 2.3.1.21) is that 
one substrate, palmitoyl-CoA competitively inhibits the attachment of the second 
substrate, carnitine. This effect may be used to prevent flooding of the matrix 
with long chain acyl-CoA under rapid fatty acid intake. It has also been noticed 
that the outer transferase shows lowest and limiting activity.
During high carbohydrate states elevated acetyl-CoA carboxylation results in an 
increase in malonyl-CoA levels. Malonyl-CoA inhibits CPT I56 and is a key 
regulatory factor in fatty acid oxidation. The effect is most prominent in muscle 
and adipose tissue57, areas of high fi-oxidation capability. It has been shown that 
in rat mitochondria prolonged fasting results in a drop not only in the level of 
malonyl-CoA, as one would expect, but also in its inhibitory power on 6- 
oxidation58,59,8. This is due to both a decrease in sensitivity of CPT I to malonyl- 
CoA and a shift of activity from CPT I to CPT II (total CPT activity remaining 
relatively constant).
Triacylglycerol (adipose tissue)
^hormone-sensitive lipase ( i n s u l i n  — ) 
Fatty acid (blood)
Malonyl—CoA ---> Acyl-CoA
acetyl—CoA 
carboxylase 
( c i t r a t e  + ) 
(acy l-C oA - )
Acetyl-CoA
A
Citrate <■
L
-> Triacylglycerol
 carnitine acyltransferase----------- 1
^ (m alonyl CoA — )Acyl-CoA
B—oxidation 
Acetyl-CoA ----- > Ketone bodiesV
Citrate  A___ CO, + H,0
Pyruvate
(g lucagon - )
Glucose
Fig. 1.06. The action (- inhibitory; + stimulatory) of key metabolites on fatty acid oxidation60.
Glycerol phosphate acyl transferase is the principal enzyme involved in the 
synthesis of phosphoglyceride and triacylglycerol from glycerol phosphate. It 
exists in the endoplasmic reticulum and outer mitochondrial membrane61. During 
well fed states its activity increases as that of CPT I falls. Having a lower Km for 
palmitoyl-CoA, glycerol phosphate acyl transferase competes with CPT I and 
inhibits C-oxidation62,63.
1.7 THE MAJOR ENZYMES OF THE E-OXIDATION 
PATHWAY
1.7.1 MITOCHONDRIAL fi-OXIDATION OF STRAIGHT CHAIN 
SATURATED FATTY ACIDS
Unsaturated-odd no. Saturated Unsaturated—even no
n Ac—CoA
RCC=CC—CO—CoA 5
cis or trans
RCCCC—CO—CoA
(FAD)
RCCC=C—CO—CoA
trans <r
(NADPH)
6
n Ac—CoA
RC=CC=C—CO—CoA 
cis or trans
OH
RCCCC—CO—CoA (L)
(NAD)
RCCCC—CO—CoA
LAc—CoA
\!/RC=C—CO-CoA 
cis
RCC-CO-CoA
IOH (D)
(CoA)
RCC-CO-CoA + Ac-CoA■<
1 - Acyl-CoA dehydrogenases.2 - Enoyl-CoA hydratases (crotonases) .3 - L— (+)—3—Hydroxyacyl—CoA dehydrogenases.4 — Acetyl—CoA acyItransferases (thiolases).5 - Enoyl-CoA isomerase.
6 — 2,4—dienoyl—CoA 4—reductase.7 - 3-hydroxyacyl-CoA epimerase.
Fig. 1.07. The enzymes involved in the B-Oxidation of straight chain saturated and unsaturated fatty acids.
The extreme low levels of fi-oxidation intermediates is extraordinary even when 
considering the ability of the enzymes involved to suppress such build up. These 
intermediates have been seen not to act as true intermediates, that is they have 
insufficient turnover and no precursor product relationships (as shown by isotope 
trace experiments64). The probable explanation for such low levels would be the 
existence of the fi-oxidation enzymes within a complex. A complex that would be 
loosely constructed so as to fall apart upon mitochondrial disruption, thus 
evading detection. The detectable intermediates would represent true 
intermediates that have temporarily escaped the complex. Acetyl-CoA would 
possess the ability to escape such a complex permanently.
The enzymes involved in mitochondrial fi-oxidation of saturated, straight chain 
acyl-CoA esters can be grouped into four main classes.
1) Acyl-CoA dehydrogenases.
2) Enoyl-CoA hydratases (crotonases).
3) L-(+)-3-Hydroxyacyl-CoA dehydrogenases.
4) Acetyl-CoA acyltransferases (thiolases).
1.7.1.1 Acyl-CoA dehydrogenases
Three different acyl-CoA dehydrogenases are involved in mammalian 
mitochondrial fi-oxidation of straight chain fatty acids. They have over-lapping 
specificities65'68 and similar structures67. Short chain acyl-CoA dehydrogenase 
(SCAD), medium chain acyl-CoA dehydrogenase (MCAD) and long chain acyl- 
CoA dehydrogenase (LCAD) show significant activity for acyl-CoA's with carbon 
chain lengths 4 to 6, 6 to 12, and 12 to 20 respectively. They act sequentially on 
acyl-CoA esters that are continuously being shortened by fi-oxidation69. All 
possess an FAD prosthetic group that is reduced as trans 2-enoyl-CoA is 
produced. FADH2 is then re-oxidised by the action of electron transfer 
flavoprotein (ETF), and electron transfer flavoprotein dehydrogenase (ETFD)70 also 
known as ETF: ubiquinone oxidoreductase (ETF:QO). These feed the electrons
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into the mitochondrial electron transport pathway (respiratory chain) at the 
coenzyme Q - cytochrome b level.
/ RCH,
CH,
\
/
2\
CH,
CO-SCoA
Acyl—CoA
acyl-Coa
DHFAD FADH.
FADH. FADETF
FAD FADH.ETF DH
/ RCH,
CH
CH
\ CO-SCoA 
t r a n s 2—enoyl CoA
CoQH. Cyt Cyt
■H20
Fig.1.08. Interaction of the acyl-CoA dehydrogenases with the electron transport 
chain, (cyt = cytochrome, DH = dehydrogenase, CoQH2 = coenzyme Q - 
reduced form).
The three 13-oxidation acyl-CoA dehydrogenases are strongly inhibited by a 
product further down the 13-oxidation pathway 3-ketoacyl-CoA68. In this way this 
class of enzymes supply a certain amount of regulation to the pathway.
1.7.1.2 Enoyl-CoA hydratases
The hydratases facilitate the addition of water to the trans carbon double bond of 
trans-2-enoyl-CoA producing L-(+)-3-hydroxyacyl-CoA. They also show a lower
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activity towards cis double bonds often contained in unsaturated fatty acids such 
as linoleic acid where D-(-)-3-hydroxyacyl-CoA is formed (see section 1.7.2).
Two enoyl-CoA hydratases have been isolated one with short, the other with long 
chain length specificity71'72,75,. The former reacts only poorly with 2,4 dienoyl-CoA 
esters73,74, a product of oxidation of some unsaturated fatty acids. It also shows 
activity towards branched enoyl-CoA esters, evidence of its involvement in the 
breakdown of branched chain amino acids and other compounds.
1.7.1.3 L-(+)-3-hydroxyacyl-CoA dehydrogenases
Two L-(+)-3-hydroxyacyl-CoA dehydrogenases have been isolated with 
overlapping specificities. Once again one short chain and one long chain specific 
form.
They catalyse the oxidation of L-(+)-3-hydroxyacyl-CoA with the simultaneous 
reduction of NAD, whilst showing no activity for the D-(-)-hydroxyacyl-CoA 
product of ds-enoyl-CoA hydration.
1.7.1.4 Acetyl-CoA acyltransferases (thiolases)
Finally at least two thiolases76,77 of similar structure catalyse the thiolytic cleavage 
of 3-ketoacyl-CoA via an acetylated enzyme intermediate78,79. Acetyl-CoA is 
produced along with an acyl-CoA two carbon units shorter than its pre-fi- 
oxidation cycle parent molecule.
Whilst one thiolase shows broad chain length specificity the other is specific for 
acetoacetyl-CoA76 as is a third cytosolic enzyme80 involved in cholesterol 
biosynthesis76.
A heavy displacement of the general thiolase reaction towards acetyl-CoA 
production along with an inverse relationship between Km and substrate carbon 
chain length helps to prevent build up of 13-oxidation intermediates76,81,82.
Whilst the acetyl-CoA/CoA ratio within the mitochondrial matrix increases with 
13-oxidation that within the cytosol does not83. This is important as acetyl-CoA 
inhibits pantothenate kinase within the cytosol, the rate limiting enzyme of CoA 
production. Otherwise, as 13-oxidation progressed, CoA levels would drop which 
would be counter productive towards acyl-CoA production and hence 13-oxidation.
1.7.2 MITOCHONDRIAL 6-OXIDATION OF UNSATURATED FATTY ACIDS
Unsaturated fatty acids such as linoleic acid possess cis carbon double bonds 
(figure 1.09.). 6-Oxidation of these fatty acids eventually results in the production 
of two particular esters 53-czs-enoyl-CoA and S2-trans-S4-ds-dienoyl-CoA. The 
hydratases cannot react with the first and only poorly with the second, probably 
due to resonance between the two double bonds creating a significant amount of 
83 carbon double bond character. In addition hydratase action on 82-cis-dienoyl- 
CoA leads the pathway down another fruitless road in the production of D-(-)-3- 
hydroxyacyl-CoA inactive towards hydroxyacyl-CoA dehydrogenase.
6-oxidation is continued pass these stumbling blocks by three additional enzymes 
(figure 1.07),
1. Enoyl-CoA isomerase,
2. Dienoyl-CoA reductase,
3. Hydroxyacyl-CoA epimerase.
1.7.2.1 Enoyl-CoA isomerase
This isomerase (EC.5.3.3) shows a preference for cis but can convert both cis and 
trans 83 carbon double bonds to 82 trans84_87.
1.7.2.2 Dienoyl-CoA reductase
Two dienoyl-CoA reductases are found in mitochondria 2-enoyl reductase 
(EC.1.3.1.8.) and 2,4-dienoyl-CoA 4-reductase (EC I.3.I.-)88. The reason for the 
former is unsure however, the latter, also found in peroxisomes reduces both cis 
and trans 84 carbon double bonds. Both use NADPH in their action which is 
regenerated mainly by the energy dependant NADH:NADP fnms-hydrogenase
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(EC.l .6.1.1.). This explains why 6-oxidation of 84 unsaturated fatty acids is 
strongly suppressed in uncoupled mitochondria, where NADPH levels will be 
depleted.
1.7.2.3 Hydroxyacyl-CoA epimerase
The 3-hydroxyacyl-CoA epimerase (EC.5.1.2.-) converts non-oxidisable D-(-)-3- 
hydroxyacyl-CoA to the dehydrogenase substrate L-(+)-3-hydroxyacyl-CoA. The 
importance of such an epimerase is diminished by two factors. Firstly, enoyl-CoA 
hydratase has a low affinity for 2,4-dienoyl-CoA and therefore production of 
D-(-)-3-hydroxyacyl-CoA is limited. Secondly, 2,4-dienoyl-CoA is more readily 
converted to 2-enoyl-CoA by 2,4-Dienoyl-CoA 4-reductase.
Linoleoyl-CoA SCoA
13 12 I o 9
3 cycles B-ox
3-cis,6-cis -dodecadienoyl-CoA
IIo
SCoA
Enoyl-CoA isomerase
(cis —d3 —trans-d2-enoy1—CoA isomerase)
2-trans,6-cis-dodecadienoyl-CoA
A— cis —decenoyl-CoA
Acyl—CoA dehydrogenase (MCAD) 
2-trans, A-cis decadienoyl-CoA
1 cycle B—ox
5 4 SCoA
5 4 2 SCoA
H+ + NADPH
2,4-Dienoyl-CoA reductase
NADP+V
3— trans —decenoyl—CoA SCoA
0
Enoyl-CoA isomerase
2-trajns-decenoyl-CoA SCoA
0
SCoA
0
Acetyl-CoA
Fig.1.09. Mitochondrial B-Oxidation of Linoleoyl-CoA100
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1.7.3 INDUCTION OF THE ENZYMES INVOLVED IN fi-OXIDATION
fi-Oxidation is induced by prolonged carbohydrate depletion. That is to say, 
during fasting fatty acid oxidation rates per mitochondrial mass are higher (an 
increase of 50% in some cases89) in animals that have already fasted for some time 
than in those previously well fed90-92. Mitochondrial CPT93, acyl-CoA 
dehydrogenase94, and 2,4-dienoyl-CoA 4-reductase95 and ETF96 have all been seen 
to be induced in this way. Total mitochondrial mass can also increase.
Similarly, diets high in long chain trans fatty acids and C22 fatty acids, poorly 
oxidised in the mitochondria, induce peroxisomal C-oxidation97" .
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1.8 KETONE PRODUCTION VIA THE 
HYDROXYMETHYLGLUTARYL-CoA CYCLE
CoA
acetyl—CoA
CH,-C
CH^ C —CH2—c SCoA
acetoacetyl-CoA
C—CH,—C
NADH
c-c h2-c h
^cetyl-CoA +H20
c—c h2—c—CH2—c 0_/ I 'SCoACH,
3—Hydroxy—3—methylglutaryl—CoA
Acetoacetate
D—3—hydroxybutyrate
CH,-C  > CH3-C 'SCoA O'
Acetyl—CoA Acetate
1 = 3 —Keto thiolase2 = 3—Hydroxy-methylglutaryl-CoA synthase3 = 3-Hydroxy-methylglutaryl-CoA lyase4 = D— (—)—3—hydroxybutyrate dehydrogenase5 = Acetyl-CoA hydrolase
Fig. 1.10. The production of ketone bodies via hydroxymethylglut aryl-CoA.
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In the liver and kidneys the main fi-oxidation product, acetyl-CoA, has three fates. 
It can be completely oxidised to carbon dioxide and water by the tri-carboxylic 
acid cycle, form a substrate for lipogenesis (significant only during well fed 
conditions) or be converted to the ketone bodies, 3-hydroxybutyrate, acetoacetate 
and the hydrolysis product acetate.
1.8.1 MECHANISM OF KETOGENESIS
During prolonged fast acetyl-CoA levels rise due to increased fi-oxidation rates 
and the oxaloacetate levels fall due to utilisation by gluconeogenesis. In addition, 
the electron transport chain will be further reduced by high fi-oxidation rates and 
the NADH /NAD ratio will increase. The steps of the citric acid that are 
dependant on the NAD concentration, such as the oxidation of isocitrate, a-keto- 
glutarate and malate, will therefore be suppressed. The net result is that the rate 
of production of acetyl-CoA will exceed the capability of the citric acid cycle to 
complete oxidation. When this occurs, acetyl-CoA is utilised by ketogenesis at an 
increasing rate.
Initial assumptions were that ketones were an incidental by product of elevated fi- 
oxidation. However, current thinking tends to regard ketone production as a 
deliberate means to compensate for the lack of ability to metabolise fatty acids at 
an appreciable rate.
Acetoacetate is formed from the condensation of acetyl-CoA and acetoacetyl-CoA 
via 3-hydroxy-3-methylglutaryl-CoA. The rate limiting step of the condensation is 
catalysed by 3-hydroxy-methylglutaryl-CoA synthase (EC.4.1.3.5). 3-Hydroxy- 
methylglutaryl-CoA lyase (EC.4.1.3.4), in the presence of Mg2* 101, then facilitates 
the cleavage of hydroxy-methylglutaryl-CoA to form acetoacetate and acetyl- 
CoA102. This enzyme is localised exclusively in the mitochondria of organs with 
high ketogenic potential, such as the liver and kidneys103. Hydrolase action on 
acetoacetyl-CoA would also produce acetoacetate, however, such an enzyme has
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not been isolated.
D-(-)-3-hydroxybutyrate is formed by D-(-)-3-hydroxybutyrate dehydrogenase (EC 
.1.1.1.30) action on acetoacetate with NADH. This enzyme is present in all tissues 
and is bound firmly to the inner membrane of the mitochondria facing towards 
the matrix. This position suggests that 3-hydroxybutyrate/acetoacetate in the liver 
is in equilibrium with NADH /NAD in the mitochondrial matrix104. Phosphatidyl 
choline is also required for activity105,106.
Acetate production in the mitochondria is facilitated by acetyl-CoA hydrolase107.
It has also been found in the liver cytosol108. In rat brown adipose tissue this 
enzyme is strongly inhibited by CoA therefore limiting acetate formation to 
conditions of high acetyl-CoA/CoA ratios109,110.
These ketone bodies can then travel to other tissues where -
1) 3-hydroxybutyrate is converted to acetoacetate by 3-hydroxybutyrate 
dehydrogenase,
2) acetoacetate is converted to acetoacetyl-CoA by succinyl-CoAiacetoacetyl- 
CoA transferase111,112 and subsequently to acetyl-CoA by thiolase,
3) acetate is converted to acetyl-CoA by acetyl-CoA synthase.
Oxidation is then completed by the entrance of the acetyl-CoA into the tri­
carboxylic acid cycle at these sites.
Acetate
3—Hydroxybutyrate
3—Hydroxybutyrate dehydrogenase 
Acetoacetate
V
Succinyl-CoA:acetoacetyl—CoA 
transferase
Acetyl—CoA synthase
Acetoacetyl-CoA
Thiolase
yAcetyl-CoA
Fig. 1.11. The reconversion of ketone bodies to acetyl-CoA in extrahepatic tissue.
1.9 cd-OXIDATION OF FATTY ACIDS
©-Oxidation, first demonstrated in 1934113 occurs within the microsomes (ie the 
endoplasmic reticulum) in organs such as liver and kidney. The initial step, the 
hydroxylation of the last (co) or the next to last (oo-l) carbon of the fatty acid, is 
catalysed by a mixed function oxidase system within the endoplasmic reticulum. 
Cytochrome P450 and cytochrome P450 reductase are involved and the presence 
of NADPH and oxygen is necessary for activity. ©-Hydroxy fatty acids are 
formed along with a small amount of (co-1)-hydroxy fatty acid. ©-Hydroxy fatty 
acids are oxidised to dicarboxylic acids by alcohol and acetaldehyde 
dehydrogenases in the endoplasmic reticulum or cytosol117 and the longer 
dicarboxylic acids converted to dicarboxylic mono-CoA esters by long chain acyl- 
CoA synthase in the endoplasmic reticulum or mitochondria118,119. A certain 
amount of chain shortening by peroxisomal C-oxidation may also occur. 
Monocarboxyl esters of carnitine can be produced119 but are less well oxidised in 
the mitochondria.
HoO
NADPH
NADP
P450
P450 red. -CH.
02
Fig. 1.13. The mixed function oxidase system of ©-oxidation.
Although it is conceivable that co-oxidation can produce succinate and therefore 
glucose, this effect is thought to be gluconeogenicaly insignificant.
Under normal conditions only 4-5% of straight chain fatty acids (monocarboxylic 
acids) undergo co-oxidation with a preference for medium chain lengths C10-C14. 
The pathway plays a significant role in the oxidation of branched and substituted 
fatty acids114,115 which are poor substrates for 6-oxidation such as 2,2- 
dimethylstearate. The dicarboxylic acids that are produced are then 6-oxidised116 
forming either shorter dicarboxylic acids or acetyl-CoA. During times of high 
fatty acid oxidation flux these dicarboxylic acids build up and along with the 
concomitant ketone bodies are excreted in the urine to create a ketotic dicarboxylic 
aciduria. When there is a block in fi-oxidation the production of acetyl-CoA and 
therefore ketogenesis is diminished. A build up in fatty acids accelerates oa- 
oxidation increasing production of dicarboxylic acids. Depending on the position 
of the block in fi-oxidation pathway subsequent dicarboxylic acid shortening will 
be constrained. For example in MCAD deficiency 6-oxidation will halt at C6 chain 
lengths. This along with an absence of ketones results in the characteristic 
hypoketotic C6, C8 and CIO (adipate, suberate, sebacate) dicarboxylic aciduria 
profile associated with this disease.
B-oxidationMonocarboxylic ---------- j— > Acetyl-CoAacids
TCA
V
CO CO
vDicarboxylicacids
-> Energy
Ketones
vE X C R E T E D  I N  T H E  U R I N E
Fig. 1.12. The production of a ketotic dicarboxylicaciduria. (TCA = tri-carboxylic acid cycle)
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1.10 CLINICAL FEATURES OF DEFECTS IN FATTY ACID
OXIDATION
To date (1991) there are 9 documented errors in fatty acid metabolism (table 1.02). 
When one considers the number of enzymic steps involved in the pathway there 
may be a possible ten or eleven yet to be reported. The first six defects, 
deficiencies in LCAD, MCAD, SCAD, LCHAD, ETF and ETFD of which MCAD 
deficiency is the most common have all been implicated in sudden infant death 
syndrome, SIDS. All disorders are inherited in an autosomal recessive way with a 
1 in 4 chance of inheritance.
1.10.1 GENERAL PRESENTATION
Most of the disorders in fatty acid metabolism show acute decompensation and 
Reye like symptoms of hypoketotic hypoglycaemia, elevated free fatty acids, 
hyperammonaemia and hepatic fat accumulation, during times when fatty acid 
oxidation is needed. Symptoms are of three basic types:
1. Symptomatic hypoglycaemia121,122;
2. Hepatic encephalopathy and Reyes like illness123-123;
3. Sudden unexpected death129-137.
They result from either fatty acid build up, fatty acid metabolic intermediate build 
up or hypoglycaemia and as such show fasting intolerance. The two CPT 
deficiencies138 and carnitine transport defect show slightly different patterns of 
presentation (see section 1.10.8)
Presentation is often preceded by an independent illness often too mild to merit 
hospitalisation. An increase in body energy requirement during illness, 
concomitant loss of appetite, vomiting and diarrhoea all diminish carbohydrate
stores and place emphasis on fatty acid metabolism. Any fault in this pathway 
will then be magnified and, if untreated, could result in coma and death.
It is often the case that laboratory profiles appear normal whilst the patient is 
metabolically balanced. This limits the detection of any disorder to times when 
the particular defective step of the pathway is required. However, it is now 
evident that measurement of glycine and carnitine conjugates may provide a 
method of detection of such defects during the asymptomatic period (see section
1.11.2 and 1.11.3).
Table 1.02. Clinical features and acute sample organic acid profiles of fatty acid oxidation defects.
DEFEC T C L IN IC A L  FEA TU R ES ORGANIC A C ID S
LCAD Fasting intolerance,
SIDS, cardiomyopathy 
MCAD Fasting intolerance,
SIDS
SCAD Fasting intolerance,
neurological seizures, 
acidaemia, myopathy 
Fasting intolerance 
progressive liver 
disease
(a)Severe form: 
Hypoglycaemia, 
acidaemia, 
neonatal death
(b)Mild form:
Fasting intolerance, 
muscle weakness
C P T l iv e r  F a s t in g  in t o l e r a n c e
C P T m u scle  E x e r c is e  in d u c e d
Carnitine P r o g r e s s iv e  s k e l e t a l
transport & c a r d ia c  m u sc le
defect w ea k n ess  ( e n d o c a r d ia l
f i b r o e l a s t o s i s )  , 
f a s t i n g  i n t o l e r a n c e
LCHAD
ETF&
ETFD
Adipic, suberic, sebacic, C12—,C14— 
dicarboxylic acids
Adipic, suberic, sebacic (saturated 
and unsaturated), hexanoyl—, suberyl— 
and 3—phenylpropionylglycine, 
octanoylcarnitine, 5-hydroxyhexanoic,
7—hydroxyoctanoic acid 
Ethylmalonic, methylsuccinic 
butyrylglycine, butyrylcarnitine
Adipic, suberic, sebacic (saturated and 
unsaturated) 3-hydroxy C8, CIO, C12, C14 
dicarboxylic acids
Same as LCAD, MCAD, SCAD plus glutaric,2 —hydroxyglut a ri c, isovale rylglycine, 
isobutyrylglycine, isovalerylcarnitine, 
glut a ry1carnitine
None
None (myoglobinuria) 
None
1.-10.2 GENERAL MANAGEMENT
On identification management is usually straight forward. Carbohydrate supply 
should be ensured and periods of fast minimised thus avoiding the need for fatty 
acid metabolism. Special diets can be used to avoid the step in the pathway 
which is defective. For example, medium chain triglyceride oil alleviates the need 
for LCAD and is a useful addition to glucose therapy in deficiency of this enzyme.
1.10.3 LONG CHAIN ACYL-CoA DEHYDROGENASE DEFICIENCY
Initially described in 1985127 to date fourteen cases, nine females and five males, 
have been documented eleven of which have been positively identified by ETF 
assay. A deficiency in this enzyme essentially blocks long chain acyl-CoA 
production and hence fi-oxidation of C l6 to C20 fatty acids. LCAD deficiency 
seems to follow one of 3 clinical pathways.
1. Onset in the first six months with high mortality rate.
2. Onset between six months and one year with acute decompensation
similar to MCAD deficiency.
3. Onset approximately one year of age with stress induced rhabdomyolisis
similar to muscular CPT II deficiency139.
One case presented at 8 years of age140.
Most patients have had reported hepatomegaly and were detected to be 
hypoglycaemic (glucose level of 1.2 mmol/1140) with inappropriately low urine 
ketone levels. Elevated ammonia and transaminase levels have been reported in 
several but not all patients. Low serum carnitine and increased percent esterified 
carnitine have been reported140 (table 1.03) with acetyl-carnitine the predominant 
acyl-camitine. Liver biopsy and necropsy investigations have shown fatty 
infiltrations. Organic acid profiles during balanced metabolic states appear 
normal. During presentation C6, C8, CIO, C l2 and C l4 dicarboxylic are present.
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Suberyl, hexanoyl and phenylpropionyl-glycines are not detected and no carnitine 
conjugates have been seen.
Table 1.03. Plasma total (TOT) and percentage esterifledcarnitine levels in LCAD deficiency140.
MEAN RANGE NORM.
TOT (pmol/1) 16 10-28 46±10
% Esterified 80 48-100 <25
Direct enzyme assay remains the only reliable means of diagnosis of this defect.
1.10.4 MEDIUM CHAIN ACYL-CoA DEHYDROGENASE DEFICIENCY
The most common of the disorders of 13-oxidation is medium chain acyl-CoA 
dehydrogenase deficiency with an incidence of 1:5000 to 1:10,000. Initially 
described in 1976123 the age at onset usually ranges from 2-47 months141 although 
cases have been reported presenting as early as two days and as late as eight 
years of age.
Urine organic acid analysis, during onset, has detected the medium chain 
dicarboxylic acids, adipic, suberic, and sebacic acids, the carnitine conjugates 
octanoyl-, hexanoyl-, and ds-4-decenoylcarnitine, and the glycine conjugates 
hexanoyl- and suberylglycine. The presence of phenylpropionyl glycine, a product 
of intestinal 3-phenylpropionic acid has been proposed as a pathagnomic 
marker142'145 although it may be absent in the newborn because of insufficient gut 
colonisation146. In addition, the presence of 5-hydroxyhexanoic and 7- 
hydroxyoctanoic acids, products of oo-l oxidation, may also prove useful. In some 
cases, plasma GC/MS organic acid analysis has also shown increased octanoic, 
decanoic and c/s-4-decenoic acids73,74, even during the asymptomatic period .
High esterified and low free carnitine values occur. Muscle, liver, and plasma 
total carnitine is usually approximately 25% of normal148. The mechanism for this 
secondary carnitine deficiency, often seen in many of the 13-oxidation disorders, is 
unclear but is probably due to impaired renal handling of free and esterified 
carnitine149,161. Carnitine treatment does not prevent illness during fasting148.
1.10.5 SYSTEMIC SHORT CHAIN ACYL-CoA DEHYDROGENASE
DEFICIENCY
There have been three documented cases of systemic short chain acyl-CoA 
dehydrogenase, SCAD, deficiency. Initial presentation is within the first few days 
of life and in one case has proved fatal. There is also a second myopathic form of 
the disease, detected in 2 patients over 30 years of age.
The three cases of systemic SCAD deficiency presented with abnormal organic 
aciduria but with varying profiles. Major metabolites lactate, 3-hydroxybutyrate,
2-hydroxybutyrate, butyrate, ethylmalonate, methylsuccinate, adipate, 3- 
hydroxyisovalerate were also detected. Similar organic acid profiles have been 
seen in two patients shown not to be SCAD deficient by enzyme analysis50.
As with MCAD deficiency low free and high esterified plasma carnitines have 
been noticed.
Tritium and carbon-14 release assays on skin fibroblast indicate impaired butyrate 
oxidation but normal octanoate and palmitate metabolism151,152.
ETF linked assay shows only partially defective butyrate oxidation due to 
overlapping MCAD activity. In one patient octanoate oxidation was also 
diminished indicating MCAD deficiency.
Difficulties in the diagnosis of such a rare and symptomatically variable disorder 
are exaggerated by interference from MCAD activity. Direct enzyme analysis 
remains the only reliable diagnostic assay.
1.10.6 LONG CHAIN HYDROXYACYL-CoA DEHYDROGENASE
DEFICIENCY
Long chain hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency is very similar 
to LCAD and MCAD deficiencies in presentation. Routine laboratory analysis 
provides little indication of the disease but fasting produces marked 
hypoglycaemia with inappropriately low ketosis and elevated lactate, pyruvate 
and urate levels. Serum free carnitine levels can be suppressed to 60% whilst long 
chain acyl carnitine increases (similarly in liver and muscle). Organic acid profiles 
at presentation show 3-hydroxydicarboxylic acids (C6, C8, CIO, C12, C l4), and 
medium chain saturated and mono unsaturated dicarboxylic acids. As the assay 
for this enzyme becomes more widely available the number of diagnoses will no 
doubt increase. Other metabolic blocks after the acyl-CoA dehydrogenase step 
have been seen to produce 3-hydroxydicarboxylic acidurias. For example thiolase 
defects can result in the excretion of 3-hydroxycarboxylic acids resulting from an 
accumulation of unstable 3-keto compounds.
1.10.7 ELECTRON TRANSFER FLAVOPROTEIN AND ELECTRON
TRANSFER FLAVOPROTEIN DEHYDROGENASE DEFICIENCY 
(glutaric aciduria type II and ethylmalonic adipic aciduria)
1.10.7.1 Glutaric aciduria type II
First documented in 1976153, this disease presents soon after birth in either a mild 
or severe, often fatal, form. The defect is at the electron transfer flavoprotein or 
electron transfer flavoprotein - ubiquinone oxidoreductase level154. Because of the 
involvement of ETF and ETFD in the acyl-CoA dehydrogenase reactions, 
presentation is often suggestive of a multiple acyl-CoA dehydrogenase deficiency. 
Of particular importance is the presence of glutaric acid in the urine. As a result 
this deficiency is often referred to as glutaric aciduria type n. During presentation 
glutarate appears as a substantial peak on a gas-liquid chromatography organic 
acid profile and also occurs in smaller amounts during the asymptomatic period. 
The metabolism of branched chain amino acids and lysine is also effected.
Studies on skin fibroblasts show diminished oxidation of butyrate octanoate and 
palmitate.
1.10.7.2 Ethylmalonic adipic aciduria
This related disorder has been detected in many patients126,155 where ethylmalonate 
is the predominant peak during the asymptomatic period. The position of the 
block within fatty acid metabolism is still unsure and therefore no direct enzyme 
assay is available.
Often patients suffering from ethylmalonic adipic aciduria respond well to 
riboflavin supplementation.
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1.10.8 SYSTEMIC CARNITINE DEFICIENCY AND CARNITINE TRANSPORT 
DEFECT
The three possible carnitine related disorders affecting the transfer of long chain 
fatty acids across the mitochondrial membrane are:
1) Carnitine transport defect.
2) Carnitine-palmitoyl transferase deficiency (CPT I and n).
3) Systemic carnitine deficiency.
Carnitine transport defect presents usually within the first year of life. Symptoms 
include cardiomyopathy (thought to be the cause of death in some cases), skeletal 
muscle weakness156, marked hypoglycaemia with inappropriately low ketosis, 
hyperammonaemia and raised transaminases with total plasma carnitine levels 
that can be as low as 10% of normal. In 50% of cases encephalopathy has been 
reported.
The few cases of reported CPT I deficiency have a very similar presentation to 
carnitine transport defect all have shown encephalopathy. Slightly more cases of 
muscular CPT II than CPT I have been documented. Onset is generally much 
later than CPT I deficiency, between 6 years to late adulthood. There appears to 
be two clinical forms of CPT II deficiency189. Both show muscular symptoms such 
as skeletal muscle weakness and pain on exercise, but in the second there is also 
hepatic and cardiac dysfunction with rhabdomyolisis myoglobinuria sometimes 
leading to renal failure. It has been suggested189 that CPT II activity is 
insufficiently low, in the more common muscle form, to impair long chain fatty 
acid oxidation in liver and heart. Residual activity in fibroblasts of 25% for the 
muscular form and 10% for the hepato-cardio-muscular form have been recently 
quoted along with the observation that palmitate oxidation is not significantly 
effected until such a residual activity falls below 20%.
Systemic carnitine deficiency, as suggested by subnormal non-crisis plasma free
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carnitine levels, has often proved to be a secondary effect of an enzyme defect 
such as MCAD deficiency157,158 or carnitine transport defect156,159. Further, low free 
carnitine may be a reflection of an elevated acyl-camitine level and not a result of 
carnitine deficiency (paired correlation plots would be of use here - see sections
3.2.1 and 4.1). There is therefore conjecture as to the existence of any definite 
systemic carnitine defect.
1.11 LABORATORY EVALUATIONS OF ERRORS IN FATTY 
ACID METABOLISM
1.11.1 CLINICAL LABORATORY ASSAYS
Clinical laboratory assays useful during assessment of fatty acid oxidation defects 
are
BLOOD ANALYSIS
Acid-base studies.Glucose quantitation.Ammonia and liver enzyme measurements.Plasma carnitine evaluations.— Total plasma carnitine.— Free plasma carnitine.— Esterified / total - This often providesa more reliable indicator than 
just TOTAL or ESTERIFIED and can 
act as a diagnostic indicator 
during the well period. (See later 
chapters)
Free fatty acid quantitation.3—Hydroxybutyrate measurements.- FFA / 3HB - Once again a ratio of values is more
diagnostically u s e f u l . High r atiosr 
double normal in some casesr indicate 
metabolic d e f e c t . Normal ratios are 
approximately unity (see l a t e r ) .
URINE ANALYSIS
Ketone evaluation. — It is possible that crisis urine ketones
levels can be of sufficient abundance to 
register positive on spot tests 
contradicting the hypoketotic 
presentation of the fatty acid oxidation 
defects.
Organic acid analysis. - Qualitatively b y  GC. A  growing
number of centres are n o w  using 
more sensitive GC/MS methods.
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One limitation of urinary organic acid analysis during acute crisis is that a fatty 
acid metabolic defect lying prior to mitochondrial fi-oxidation would not produce 
a build up of oxidation metabolites and therefore no such abnormal organic acid 
pattern would occur. Defects in fatty acid transport into the mitochondria (acyl- 
CoA activation, CPT deficiency or carnitine transport defect) do not produce 
abnormal urinary organic acid patterns (see section 1.10.8).
1.11.2 GLYCINE CONJUGATE QUANTITATION
The glycine conjugates hexanoyl-, suberyl-, and 3-phenylpropionyl-glycine 
occurring in the acyl-CoA dehydrogenase deficiencies may be present, but in very 
small amounts, during the asymptomatic period.
Use of stable isotopic internal standards provides a means of quantifying glycine 
conjugates making early diagnosis of deficiencies such as that of MCAD possible. 
Such assays involving advanced chemical ionisation mode GC/MS have been used 
with very high success rates160. However,* use of single ion monitoring, electron 
impact mode GC/MS provides a more widely available means of glycine 
conjugate quantitation, (see section 2.4).
The basic idea behind using an internal standard in GC quantitation assays is to 
use a standard with chromatographic properties as similar as possible to those of 
the compound to be quantitated (the quantitate), whilst maintaining a detectable 
difference in elution times between the two. A deuterated form of the quantitate 
has almost identical properties but is eluted slightly earlier. Total ion GC/MS 
methods lack the sensitivity to distinguish compounds with such similar retention 
times. However, with the MS running in selective ion monitoring mode the 
difference between similar ion' fragments from both molecules can be 
distinguished. Ions from the IS will be a number of AMU heavier (depending on 
the number of deuteriums on the molecule) than those from the quantitate.
1.11.3 CARNITINE CONJUGATE QUANTITATION
Sophisticated assays for carnitine conjugate quantitation are available involving 
fast atom bombardment mass spectrometry (FAB/MS). Even greater sensitivity is 
gained by use of FAB MS/MS (two MS used in tandem)161'163. Acyl carnitines can 
be detected by TLC164 although this method lacks sufficient sensitivity to detect 
such low levels as are present outside crisis.
Other methods have been investigated to replace GC/MS such as high 
performance liquid chromatography (HPLC)165,166, HPLC/MS167, thin layer 
chromatography and nuclear magnetic resonance spectroscopy168. However, to 
date all lack sufficient sensitivity to be of any great use for carnitine quantitation 
in fatty acid oxidation defect diagnosis. My own experience with HPLC, GC and 
GC/MS upholds this statement.
Radio-isotope exchange HPLC has been used to determine octanoyl carnitine 
levels but this method is still under development.
1.11.4 USE OF METABOLIC STRESS INDUCTION IN THE EVALUATION 
OF METABOLIC DEFECTS
It is not always possible to obtain laboratory samples during spontaneous 
presentation. However, crisis can be forced whilst the patient is available for 
testing by subjecting them to metabolic stress. There are three principle methods 
used to induce metabolic stress. They are;
1. Controlled fasting,
2. High fat dieting,
3. Metabolite loading tests.
Fasting or subjecting a patient with a fatty acid metabolic defect to a high fat diet 
must be rigorously supervised and has proved fatal169. Loading tests involve the 
administration of high concentrations of fatty acid metabolic pathway 
intermediates, that precede the suspected block, to magnify any abnormal 
metabolic trait. Carnitine loading elevates the levels of diagnostic acylcamitine in 
MCAD deficiency134. 3-Phenyl-propionic acid, PPA, loading increases urinaiy 3- 
phenyl-propionyl glycine concentrations detected by HPLC or GC/MS170. The 
PPA loading test is used as a specific test for MCAD deficiency where 
phenylpropionyl glycine is excreted in the urine as well as hippuric acid the 
normal metabolite of PPA. The test may prove to be useful in other metabolic 
defects. For example, an LCHAD deficient patient undergoing PPA loading tests 
has been reported to produce small amounts of 3'-hydroxyphenylpropionyl 
glycine171.
1.11.5 FATTY ACID OXIDATION DEFECT IDENTIFICATION BY USE OF 
FIBROBLAST CULTURE
Work with skin fibroblasts provides a relatively non-invasive technique to 
evaluate fatty acid metabolic defects in the laboratory without the need for 
metabolically stressing the patient.
Fatty acids labelled with either tritium or carbon-14 are oxidised to produce 3H20 
or 14C02 respectively. Use of such radio labelling can be employed in the 
elucidation of the position of a metabolic block172. However, such assays cannot 
identify specific enzyme defects and false negative results can occur. These may 
be connected with the presence of non-mitochondrial 13-oxidation or overlapping 
chain length specificities of related enzymes.
Because of the expense and time required for fibroblast culture it is an advantage 
to be able to store the biopsy material without immediate culture (see appendix 1). 
In this way the investigator can await sufficient evidence of fatty acid metabolic 
defect to merit further investigation. Cryoscopic storage techniques published by 
K.J. Fowler173 have been further developed and evaluated by the author and are 
discussed in appendix 1.
1.11.6 DIRECT ENZYME ANALYSIS OF DEFECTS IN FATTY ACID 
METABOLISM
Work in this area concentrates around the acyl-CoA dehydrogenase defects. 
Necessary for enzyme activity is the presence of ETF a natural electron acceptor 
for the dehydrogenase reaction as acyl-CoA is dehydrogenated to enoyl-CoA. The 
absence of a commercial supply of ETF adds to the complexity of an already time 
consuming and technically demanding assay. Development is still under way of 
an assay involving a synthetic electron acceptor and incorporating a colour end 
point174.
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As well as the three acyl-CoA dehydrogenases, direct enzyme assays have been 
used to measure CPT, enoyl-CoA hydratase, 3-hydroxyacyl-CoA dehydrogenase 
and 3-ketoacyl-CoA thiolase activities. Carnitine transport protein can also be 
measured by indirect assay. However, none of these assays are, by any means, 
routine.
CHAPTER 2 
METHODS AND MATERIALS
2.1 ROUTINE CLINICAL LABORATORY ASSAYS
2.1.1 BLOOD SAMPLING PROCEDURE FOR LABORATORY ANALYSIS
The following assays were all carried out on the Cobas Bio spectrometric 
autoanalyser. The quality control used, unless otherwise stated, was the standard 
procedure well established within the laboratory.
Blood samples were collected by thumb prick from young children presenting at 
the Sheffield Childrens Hospital with febrile illness, and a control group of 
children awaiting unrelated surgical procedure.
The plasma or serum was separated by centrifugation at approximately 3500 
revs/min for 5 minutes on a Heraeus Christ Minifuge2 centrifuge (Heraeus 
Equipment Ltd) and stored at -20°C for a maximum of two weeks prior to assay.
2.1.2 PLASMA GLUCOSE QUANTITATION
Samples were collected into glass containers pretreated with sodium fluoride 
preservative. A minimum volume of 50 pi serum was used in the assay.
This assay incorporated (+)Glucose GDH single shot assay kit marketed by Roche 
MA (Kit no. 0715182). The procedure relied on the conversion of 3-D-glucose to 
D-gluconate in the presence of NAD by glucose dehydrogenase (GDH).
GDH3—D—Glucose + NAD + H20 —------------> D—Gluconate + NADH
Mutarotase was added to accelerate the transition from a  to C isomeric forms of
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D-glucose. The decrease in absorbance at 340nm was directly proportional to the 
original glucose concentration.
2.1.3 PLASMA LACTATE QUANTITATION
Collection and storage of samples was identical to the procedure adopted for 
serum plasma glucose quantitation. A minimum assay sample size of 50 pi 
plasma was used.
Lactate levels were measured using the (+)lactate two shot assay kit marketed by 
Boehringer Manheim GmbH, W.Germany (kit no. 149993). Lactate 5m m ol/l (BCL) 
stored at 4°C was used as standard. The principle of the assay relied on lactate 
dehydrogenase (LDH) action in converting lactate to pyruvate with concomitant 
reduction of NAD. The pyruvate was then reacted with glutamate in the presence 
of glutamate-pyruvate transaminase (GPT) producing alanine and oxoglutarate.
An increase in absorbance at 340 run was directly proportional to the original 
lactate concentration.
LDHLactate + NAD -------------> Pyruvate + NADH
GPTPyruvate + Glutamate ------------ > Alanine + Oxoglutarate
2.1.4 PLASMA 3-HYDROXYBUTYRATE QUANTITATION
Collection and storage of samples was identical to the procedure adopted for 
plasma glucose quantitation.
(+)3-Hydroxybutyrate dehydrogenase, HBDH (Sigma, type 2; stored at 4°C) action 
on 3-hydroxybutyrate in the presence of NAD (BDH Ltd.) produced acetoacetate.
There was a concomitant rise in absorbance at 340 nm that was directly 
proportional to the original level of 3-hydroxybutyrate. Tris-(hydroxymethyl)- 
methylamine-[2-amino-2-(hydroxymethyl)propane-l, 3-diol], (BDH Ltd) was used 
to maintain an optimal working pH 8.5 (1.2g Tris, 74mg EDTA in 100ml deionised 
water, adjusted to pH8.5 with 8M sodium hydroxide, stored at 4°C) and to this 
0.25g oxalic acid (Sigma) was added to prevent interference from lactate. 3- 
Hydroxybutyrate (Sigma) calibration concentrations of 0.96, 2.4 and 7.2 mmol/I 
were used.
HBDH3—Hydroxybutyrate + NAD ---------- > Acetoacetate + NADH
2.1.5 PLASMA FREE FATTY ACID QUANTITATION
Heparin stimulates lipoprotein lipase which releases free (non-esterified) fatty 
acids from triglycerides. Hence, blood samples collected in heparinised containers 
were not suitable for assay.
The method used the (+)Free fatty acids two shot kit marketed by WAKO 
Chemicals (kit no. 994-75409). Oleic acid, 1 mmol/1, was used as standard. In the 
presence of ATP, Mg2*, CoA and acyl-CoA synthase (ACS) free fatty acids were 
converted to acyl-CoA.
ACSRCOOH + ATP + CoA  ------------> Acyl-CoA + AMP + PP±(FFA)
These thiol esters were then oxidised in the presence of acyl-CoA oxidase (ACO) 
producing hydrogen peroxide.
ACOAcyl-CoA + 02  -> 2,3-trans-enoyl-CoA + H202
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Oxidative condensation of 3-methyl-N-ethyl-N-(3-hydroxyethyl)-aniline and 4- 
aminoantipyrine in the presence of hydrogen peroxide and peroxidase (POD) 
produced a purple colour complex with an absorption maximum of 550nm.
H3C-C = C-NH2
I I2H202 + H3C-N C=0
+
POD
CH,
C-N
HoC—N C=0
,C2H5
c2h4oh
purpleproduct
CH,
C2H5
C,HaOH
+
4H,0
The density of this colour provided a direct indication of the original 
concentration of free fatty acid.
Interference from vitamin C 's antioxidant qualities and its ability to react with 
hydrogen peroxide is eliminated by the addition of ascorbate oxidase at the outset 
of the reaction.
2.2 CARNITINE QUANTITATION BY RADIO-ENZYMATIC 
ASSAY
2.2.1 OVERVIEW
This method was developed from those of Cederblad & Lindstedt175 and Jalaludin 
Bhuiyan et al176.
Free carnitine in urine or plasma was converted to [C14] labelled acetylcarnitine by 
the addition of [C14] labelled acetyl-CoA in the presence of carnitine-acetyl 
transferase (CAT). N-Ethylmaleimide was used to capture the acetyl-carnitine and 
prevent the reverse reaction thus avoiding falsely lowered results.
CATFree carnitine + [C14]Acetyl-CoA ------- > [C14]Acetylcarnitine
[C14]Acetylcarnitine was then separated from unreacted [C14]acetyl-CoA on a 
Dowex anion exchange resin column. Total carnitine content was measured as 
free carnitine after alkaline hydrolysis. The amount of esterified carnitine (long 
and short) was calculated as the difference between total and free concentrations.
2.2.2 PREPARATION
The assay was run in duplicate and a separate standard curve set up with 
concentrations of 0,10, 20, 40pM carnitine (Sigma) every assay run. Initially, a 
60pM concentration was also used, but as the intra assay variation became less 
this point was exclude.
The standards were subjected to the same conditions as the samples undergoing 
free carnitine quantitation. That is, not including the hydrolysis step. Similar 
standards subjected to the hydrolysis did not give any significantly different 
results. Therefore it was not thought necessary to run independent standard 
curves for free and acylated carnitine evaluation.
Dowex standard grade columns were prepared from Dowex 1-X8(C1) particle size 
0.075-0.150mm (100-200 mesh), BDH Ltd. This was purified and fined by mixing 
with an equal volume of 1M sodium hydroxide for approximately 1 hour and 
bringing back to neutrality by repeated washing with physiological saline. This 
slurry was then used immediately or stored, submersed in saline, at 4°C until 
required. Standard glass pasteur pipettes cut at their construction and plugged 
with silanised glass wool were filled to a depth of 4cm with the Dowex sluriy and 
washed through with saline prior to use.
[C14]Acetyl~CoA 100pM(0.2pCi/ml) was prepared from lOpCi [C14]acetyl-CoA 
(Amersham CFA390) mixed with 2.64mg unlabelled acetyl-CoA (Sigma) made up 
to 50ml with deionised water and stored at -20°C in batch size aliquots.
The carnitine-acetyl transferase was stored undiluted at 4°C.
2.2.3 PROCEDURE
Hydrolysis of the sample (50pl) was carried out by incubation at 37°C for 1 hour 
with 1M potassium hydroxide (lOOpl), subsequently returning to neutrality with 
1M hydrochloric acid (lOOpl).
To 20pl of 40mM N-ethylmaleimide (Sigma) and 50pl 1M Hepes buffer (Sigma) 
either 50pl of hydrolysed sample or 25pi of both neat sample (or standard) and 
deionised water was added.
lOOpl Of lOOpM [C14]acetyl-CoA was then added and the reaction initiated by the 
addition of 30pl dilute (1 part enzyme to 10 parts deionised water) camitine-acetyl 
transferase. After incubation at 37°C for 1 hour the reaction mixture was passed 
onto the Dowex column and washed through with two lots of 0.75ml deionised 
water. Any unreacted [C14]acetyl-CoA was retained. The eluent, containing 
[C14]acetylcarnitine, was collected in miniature polyethylene reactavials (Cannberra 
Packard) and mixed with 10ml scintillation fluid (Packard Picofluor40 Universal 
liquid scintillation solution - aqueous capacity 5-6cm3 aq in 10ml). The fi activity 
was then counted for two minutes on a scintillation counter (Miniaxi Tri-carb 4000 
series) and used as an indication of the isotope content of the solution. A 
standard curve was set up to evaluate the carnitine content in the original sample.
2.2.4 ASSAY OF LONG AND SHORT CHAIN ACYLCARNITINES
Although not used during this assay, it is also possible to differentiate between 
long chain acylcarnitines (LCAC) or acid insoluble acylcarnitines and short chain 
acylcarnitines (SCAC) or acid soluble acylcarnitines176,185,188
The protein and LCAC are precipitated from the plasma sample by perchloric 
acid. The supernatant is then neutralised with potassium hydroxide and 
centrifuged to remove potassium chlorate. The difference between total and free 
carnitine results (measured by the same methods as already described) represents 
the SCAC content of the original sample. The pellet is hydrolysed by potassium 
hydroxide at 60°C for 1 hour to release all LCAC as free carnitine. The protein is 
then precipitated with further perchloric acid and the supernatant neutralised with 
potassium hydroxide and assayed as normal. The result is a measurement of the 
original LCAC in the plasma sample.
2.3 ORGANIC ACID ANALYSIS BY GAS
CHROMATOGRAPHY / MASS SPECTROMETRY
This procedure involved two steps, an initial solvent extraction and trimethylsilyl 
derivatisation, followed by injection onto a gas chromatograph or gas 
chromatograph - mass spectrometer.
2.3.1 SOLVENT EXTRACTION AND DERIVATISATION
Either of three sample volumes were used depending on the creatinine level of the 
urine. These were 2.0,1.0 or 0.5ml according to creatinine values of less than 0.5, 
0.5 to 2.0 and greater than 2.0 mmol/1 respectively. In the latter two cases the 
volume was made up to 2ml with deionised water. In the event of insufficient 
urine availability creatinine quantitation was omitted and the maximum volume 
possible was used in the extraction. In this case no water was added if the urine 
looked particularly dilute.
1 ml Of heptadecanoic acid (15mg to 100ml with water) internal standard was 
added to the urine solution which was acidified with 5N hydrochloric acid and 
extracted in the presence of sodium chloride with two 5ml aliquots of ethyl acetate 
and two 5ml diethyl ether. Water was removed from the pooled organic layer 
over anhydrous granular sodium sulphate (BDH Ltd.). After drying under 
nitrogen the extract was derivatised by redissolving in two drops pyridine and 
mixing with six drops bis-(trimethylsilyl)- trifluoroacetamide with 1% 
trimethylchlorosilane added (BSTFA) (Sigma). This was then left for at least 1 
hour at room temperature. At least 0.5pl of derivasate was used for analysis.
2.3.2 ANALYSIS BY GAS CHROMATOGRAPHY
Initial analysis was by flame ionisation gas chromatography on a Philips PU4500 
chromatograph fitted with an SGE bonded phase fused silica BP10 column 
(moderately polar OV1701 equivalent) 25m x 0.22mm (internal diameter) x 
0.33mm (outer diameter) x 0.25pM (film thickness). Elution was carried out under 
a programmed temperature gradient of 80°C for 5 minutes followed by a rise of 
8°C per minute to a final temperature of 260°C and held for a further 5 minutes. 
The injector temperature was set to 250°C and that of the detector to 300°C. A 
column pressure of approximately 5 PSI and a flow rate of lm l/m in  through the 
column was established with helium carrier gas. An insert split ratio of 20:1 was 
used.
2.3.3 ANALYSIS BY GAS CHROMATOGRAPHY / MASS SPECTROMETRY
On the occurrence of abnormal spectra the sample was analysed by electron 
impact mode gas chromatography /  mass spectrometry using a Hewlett Packard 
5890 series II gas chromatograph fitted with a Hewlett Packard HP.l crossed 
linked methyl silicone gum column 12m x 0.2mm(internal diameter) x 0.33pM 
(film thickness) with a Hewlett Packard 5971A mass selective detector. The 
temperatures and flow rates were identical to those used for the preliminary gas 
chromatography (section 2.3.2). A scan rate of 1 per second with an inter-scan 
delay of 0.03 seconds was used. The mass spectrum was viewed and investigated 
through Hewlett Packard G1030A MS Chemstation (DOS series) software in a 
Microsoft Windows3 environment installed on a Hewlitt Packard Vectra QS/165 
personal computer.
2.4 PREPARATION OF ISOTOPE INTERNAL STANDARDS 
FOR THE QUANTITATION OF URINARY GLYCINE 
CONJUGATES BY GAS CHROMATOGRAPHY / MASS 
SPECTROMETRY
The initial intention was to synthesise deuterated suberylglycine (SG), 
hexanoylglycine (HG), and phenylpropionylglycine (PPG), not available 
commercially, and use these to quantitate any non-deuterated conjugates in urine 
of children (see section 1.11.2). In order to quantitate the amount of deuterated 
glycine conjugate in each internal standard (IS) it was necessary to synthesise non- 
deuterated forms of each compound also commercially unavailable.
Unfortunately, time constraints prevented any full analysis of the synthesised IS. 
Further, although initial calibration results seemed acceptable (see section 3.5), 
difficulty was experienced in reproducing the data. The main problem seemed to 
lie with the sensitivity of the chromatography. Running the assay in splitless 
mode to concentrate the amount of sample passing onto the column did not 
alleviate the problem.
The procedures used were adaptations of those described by Kolvraa and 
Gregersen30.
Choice of solvent combinations for extraction and recrystallisation procedures 
resulted from lengthy assessments of the effectiveness of a variety of different 
arrangements including types and volumes of solvents to be used and 
recrystallisation procedures. Analysis procedures to confirm the presence of the 
chloride derivatives and glycine conjugates were similar to those used for regular 
urinary organic acid analysis (see section 2.3.3) but with the mass spectrometer 
running in single ion monitoring mode. The ion fragments monitored for the 
acylglycines are shown in results table 3.21.
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It was decided to aiim for significant synthesis of deuterated glycine conjugates 
carrying 4 or more deuterium groups. In this way identical natural isotopic 
abundance in urine samples would be insignificant and similar ion fragments from 
quantitate and IS would be nicely separated by the chromatography (see section 
1.11.2).
Resultant deuterated acylglycine product mixtures contain several isotopic 
compounds deuterated to various degrees (see results table 3.20.). In choosing the 
isotopic compound to be used as IS abundance was also taken into account. For 
each of the three conjugates the final isotopes chosen were those possessing four 
deuterium groups.
2.4.1 DEUTERATED SUBERYLGLYCINE INTERNAL STANDARD 
PREPARATION
2.4.1.1 Deuterated suberylchloride synthesis
Because of thionyl chloride's explosive reaction with water all apparatus was oven 
dried.
To 0.2g previously prepared (2-2H2)-suberic acid, 5ml thionyl chloride (stored at 
4°C) was added drop wise. The mixture was refluxed for 1 hour, and left to cool. 
Excess thionyl chloride was removed under nitrogen leaving a dark yellow oil 
(approximately lOOpl). Presence of a number of deuterated suberylchloride 
isotopes was detected by GC/MS, the most abundant being (2-2H2)-suberyl- 
dichloride.
VCCH2(CH2)4C2H2C + S0C12  ----------- > CCH2(CH2)4C2H2C ^He/ OH Cl/ ^ C 1
(2—2H2) —suberic thionyl (2—2H2) —suberyl—acid chloride -dichloride
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2.4.1.2 Deuterated glycine solution preparation
A solution of 2H2-glycine was prepared at 4°C by dissolving 500mg 2H5-glycine 
(Sigma) in 5ml IN  sodium hydroxide.
2.4.1.3 Deuterated suberylglycine synthesis
At room temperature the suberate /  suberyl chloride reflux mixture was added to 
the deuterated glycine /  sodium hydroxide solution and mixed for 1 Vi hours over 
vortex. After centrifugation at 3000 revs/min for 5 minutes any precipitate was 
removed.
The supernatant was then acidified to pHl by 6N hydrochloric acid, and extracted 
into three volumes of 30ml ethylacetate and three volumes of 30ml diethyl ether. 
The pooled organic layer was dried over sodium sulphate and evaporated to 
dryness under nitrogen. The resultant solid contained (2-2H2)-suberyl-(2-2H2)- 
glycine.
O
O 0 IIN CCH2 (CH2) 4c2h2c ^ > CCH2 (CH2) 4c2h2cnhc2h2co2h
C l '  V C1 h o '
+ h2nc2h2co2h
(2—2H2) glycine (2-2H2) -suberyl- (2-2H2) -—glycine
2.4.1.4 Calibration solution synthesis
A similar procedure to that used for deuterated SG synthesis was used for the 
production of the non-deuterated conjugate.
0.5ml Suberoyldichloride (Aldrich Chemical Co. Ltd.) was added to previously 
prepared glycine solution (500mg glycine, Sigma, to 5ml sodium hydroxide). 
After mixing by vortex for IV2 hours the mixture was centrifuged and the 
supernatant extracted into three 30ml volumes of each ethylacetate and diethyl 
ether. Evaporation left a white residue containing both suberate and SG.
2.4.1.5 Calibration solution purification
It was only possible to purify the mixture to a 1:4 ratio of suberate to SG by 
extraction with hexane and petroleum ether. Much more success was achieved 
through recrystallisation from an ethylacetate, hexane, petroleum ether mixture.
The suberate /  SG powder was dissolved in a minimal volume of ethylacetate 
hexane and petroleum ether (approximately 1:1:1). This solution was then 
evaporated to approximately 50% volume in a water bath and left overnight at 
4°C. White granular crystals separated out of solution. GC/MS confirmed these 
to be SG with the absence of any detectable suberate.
2.4.2 DEUTERATED HEXANOYLGLYCINE INTERNAL STANDARD
PREPARATION
2.4.2.1 Deuteration of hexanoic acid
2ml Hexanoic acid (1.84g) was added to 2ml sodium deuteroxide. The salt that 
formed was then dissolved in 4ml deuterium oxide (2H20). The solution was 
placed in a 20ml tissue digestion vessel with teflon liner (Northern Media) and left 
at 140°C for 5 days. The resultant solid was acidified with concentrated 
hydrochloric acid, to convert from the sodium salt to the acid, and extracted into 
three volumes of 30ml ethylacetate and three volumes 30 ml diethyl ether. After 
evaporation of the organic layer under nitrogen the presence of (2-2H2)-hexanoic 
acid was confirmed by GC/MS.
2.4.2.2 Deuterated hexanoylchloride synthesis
The process was a repeat of the thionyl chloride reflux used to produce deuterated 
suberyl chloride. After reflux the apparatus containing the reaction mixture was 
left overnight under anhydrous conditions before removal of excess thionyl 
chloride under nitrogen. GC/MS confirmed the presence of a number of 
deuterated hexanoylchloride isotopic compounds. The most abundant being (2- 
2H2)-hexanoylchloride.
>0 pCH3(CH2)3C2H2C' + S0C12 -------- ^ CHafCH^a^HaCr'o h 'ci
(2-2H2) -hexanoic acid (2-2H2)-hexanoylchloride
2A.2.3 Deuterated hexanoylglycine synthesis
The mixture containing (2-2H2)-hexanoyl chloride was added to 5ml 1M sodium 
hydroxide. This solution was then mixed by vortex with deuterated glycine /  
sodium hydroxide solution. The mixture was left overnight at room temperature, 
centrifuged and the supernatant rotary-evaporated to a powder.
O
/> U CH3(CH2)3C2H2C /  > CH3 (CH2) 3c2h2cnhc2h2co2h'Cl 
+ h2nc2h2co2h (2-2H2) -hexanoyl— (2—2H2) -glycine
The powder was then acidified with IN  hydrochloric acid, extracted into three 
30ml volumes of each ethylacetate and diethyl ether, dried over sodium sulphate, 
evaporated to dryness and stored at -20°C. The presence of (2-2H2)-hexanoyl (2- 
2H2)-glycine was confirmed by GC/MS.
2.4.2.4 Calibration solution
Previously prepared and purified HG was used.
2.4.3 DEUTERATED PHENYLPROPIONYLGLYCINE INTERNAL
STANDARD PREPARATION
2.4.3.1 Deuteration of phenylpropionic acid
The method incorporated for the deuteration of hexanoic acid was used replacing 
the hexanoic acid with 0.5g of phenylpropionic acid. On cooling a white solid 
formed. This was acidified and extracted into three 30ml volumes of each 
ethylacetate and diethyl ether, and evaporated to a white solid. The presence of 
(2'-2H2)-phenylpropionic acid was confirmed by GC/MS.
2.4.3.2 Deuterated phenylpropionylchloride synthesis
Again a similar method as for deuterated suberyl chloride was used, with the (2'- 
2H2)-phenylpropionic acid and thionyl chloride, to produce a white powder 
containing (2'-2H2)-phenylpropionyl chloride.
c6h5ch2c2h2c/ + S0C12  > c6h5ch2c2h2c ^N OH N Cl
(2' -2H2) -phenyl- (2r -2H2) -phenyl­propionic acid -propionyl chloride
2.4.3.3 Deuterated phenylpropionylglycine synthesis
The powder was dissolved in 6-7ml IN sodium hydroxide and added to 
previously prepared deuterated glycine /  sodium hydroxide solution and mixed 
for lVz hours over vortex. The solution was then acidified with hydrochloric acid,
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extracted into three volumes of 30ml ethylacetate and three volumes of 30ml 
diethyl ether, dried over sodium sulphate and evaporated to dryness. The 
presence of (2'-2H2),3-phenylpropionyl-(2-2H2)-glycine was confirmed by GC/MS.
O
c 6h 5c h2c2h 2c c 6h 5c h2c2h 2c n h c2h 2c o2hN Cl  ^
+ h 2n c 2h 2c o2h (2' —2H2) , 3-phenylpropionyT (2-2H2) —glycine
2.4.3.4 Calibration solution synthesis
lm l Commercial phenylpropionyl chloride (Hydrocinnamoyl chloride 98%,
Aldrich Chemical Co. Ltd.) was added to lg  glycine in 7ml sodium hydroxide and 
mixed for 1 Vi hours by vortex. The whole reactant mixture (no supernatant was 
obtainable) was acidified to pHl with IN  hydrochloric acid and extracted into 
three volumes of 15ml ethylacetate and three volumes of 15ml diethyl ether. The 
extract, containing PPG, was evaporated to an oil and stored at 4°C.
2.4.3.5 Calibration solution purification
The glycine conjugate /  carboxylic acid mixture was dissolved in hexane and 
ethylacetate (5-10ml) and evaporated to 50% volume. Storing at 4°C for 2 hours 
resulted in the separation of white crystals subsequently shown to be PPG with 
the absence of any detectable phenylpropionic acid.
2.4.4 CALIBRATION OF DEUTERATED CONJUGATES
2.4.4.1 Initial concentration approximations
Approximately half of each deuterated HG and PPG and all of the SG (see section
3.5.2.1) were dissolved in 100ml volumes of methanol. For each non-deuterated 
conjugate approximately 2.5mg (the exact weight was recorded) was dissolved in 
a 100 ml volume of methanol. The concentration of each solution was calculated 
(see section 3.5.2).
lm l Of each non-deuterated standard and lOOpl of each deuterated solution were 
mixed, acidified with IN  hydrochloric acid and extracted in the presence of 
sodium chloride into two 5ml volumes of ethylacetate and two 5ml volumes of 
diethyl ether. The organic layer was dried over sodium sulphate and evaporated 
to dryness under nitrogen. The solid was TMS derivatised with 2 drops of 
pyridine and 8 drops of BSTFA, as used for standard organic acid analysis (see 
section 2.3.1). The derivasate was analyzed by GC/MS under operating 
conditions previously described (see section 2.3.3).
Selective ion monitoring was used to detect ion fragments for each of the TMS 
derivatives TMS1 and TMS2 for the deuterated and non-deuterated conjugates (see 
section 3.5.2). A dwell time of 0.08 seconds with an inter-scan delay of 0.02 
seconds was used. The abundances of these ion fragments, as indicated by the 
peak areas, were calculated by integration. For each compound the areas from 
both derivatives (TMS1 and TMS2) were summed and the ratio of deuterated to 
non-deuterated conjugate areas evaluated. These values were multiplied by the 
known concentration of non-deuterated compound to calculate that of the 
deuterated conjugate. This was then extrapolated back, accounting for the 1:10 
mix of deuterated to non-deuterated conjugate, to determine the concentration of 
the original stock (see section 3.5.2.1).
The volume of stock solution required in 100ml with methanol to provide the
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required working concentration (see section 3.5.2.1) was then calculated for 
deuterated HG and PPG. For deuterated SG the working concentration obtained 
by dissolving the total yield in 100ml of methanol was calculated (see section
3.5.2.1).
It was intended that once calibrated equal volumes of the three deuterated 
conjugates would be mixed and a lOOpl aliquot of this cocktail added to lm l of 
the urine sample to be extracted. Therefore, it was necessary to account for a 
dilution factor of 30 fold when extrapolating from working to stock concentrations.
2.4.4.2 Accurate calibrations
A cocktail of equal volumes of the three deuterated conjugates was mixed and 
lOOpl aliquots of this was used in five assays with varying concentrations of non- 
deuterated standards. The conditions for these assays were identical to those of 
section 2.4.4.1 and each was run in quadruplicate. Calibration curves were drawn 
for deuterated to non-deuterated conjugate peak area ratios (see section 3.5.3).
2.5 INTERMEDIARY METABOLITES INVESTIGATION
2.5.1 AIMS OF THE INVESTIGATION
To determine the quality of any correlations between fasting values of various 
metabolites involved in fatty acid oxidation. The efficacy of such correlations as 
diagnostic tools for errors in fatty acid oxidation was then investigated by the 
inclusion of data from patients with known or suspected defects. The effect of 
length of fast on the metabolite levels was also examined by means of correlation 
plotting. Finally, the use of these fasting profiles in conjunction with the paired 
metabolite correlations for fatty acid oxidation defect elucidation was discussed.
2.5.2 SAMPLE COLLECTION, STORAGE AND ANALYSES
Approximately 5ml venous samples were collected by venepuncture from children 
either before feeding and admitted to the Sheffield Childrens Hospital with febrile 
illness or having been fasted overnight (4 hours minimum) either to await 
surgical procedure or in order to investigate suspected metabolic defect. The 
metabolic stress required for the investigation was a result of either the febrile 
illness or the fast. The specimens were separated and the plasma stored at -4°C. 
The following analyses were performed;
Glucose
Lactate
3-Hydroxybutyrate 
Free fatty acids
Total, free and esterified carnitine.
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2.5.3 CHOICE OF SAMPLE
Any deviations from normal intermediary metabolite levels caused by errors in 
fatty acid metabolism would be expected to increase with length of fast as 
demand on the fi-oxidation pathway rises. It was therefore decided where a series 
of samples were taken from a patient as the fast progressed the last collected was 
to be used for the following investigation. In this way length of fast would be 
maximised within the constraints of the study and any deviations from normality 
would be emphasised. It was hoped that any abnormal trends as a result of 
defective fatty acid metabolism would therefore be clearer and more defined.
2.5.4 PAIRED METABOLITE CORRELATIONS
Correlations between pairs of metabolites were investigated using patients with no 
diagnosed or suspected metabolic defect (ie. a zero value for the variable 
DIAGNOSE - see appendix 2). The efficacy of the use of these plots as indicators 
in the diagnosis of fatty acid metabolic defects was then investigated. To do this 
data from a number of patients having diagnosed metabolic defects were 
incorporated into the plots and their positions in relation to the non diagnosed 
points discussed. In addition data from several children suspected of having a 
fatty acid metabolic defect were incorporated into the study to provide examples 
of the use of paired metabolite correlation to indicate more precisely the site of 
such defects.
2.5.5 RESPONSE TO FAST
The response of these metabolites to fasting was then studied. An evaluation of 
the usefulness of such fasting profiles in conjunction with paired metabolite 
correlations as indicators of fatty acid metabolic defect was severely limited by a 
difficulty in obtaining exact fasting times (see Discussion).
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2.6 GENERALISED DICARBOXYLIC ACIDURIA 
INVESTIGATION
2.6.1 AIMS OF THE INVESTIGATION
This investigation formed part of a larger study to evaluate the use of GC and 
GC/MS urine organic acid analysis in the neonatal diagnosis of errors in fatty acid 
oxidation.
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Fig.2. 01 GC/MS trace showing generalised DCA in a oneday old child. The peaks are: 1, 3-hydroxybutyric acid; 2, ethylmalonic acid; 3, adipic acid; 4, lactone of 3-hydroxy adipic acid; 5, octenedioic acid; 6, suberic acid; 7, 3—hydroxyoctenedioic acid; 8, 3—hydroxysuberic acid; 9, 3—hydroxysebacic acid; 10, internal standard; 11, 3-hydroxdodecenedioic acid; 12 3-hydroxydodecanedioic acid.
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Fig.2.02 GC/MS trace showing classic urine metabolitetrace in a child presenting with MCAD deficiency. The peaks are: lf 3-hydroxybutyric acid; 2, ethylmalonic acid; 3, adipic acid; 4r hexanoyl glycine; 5, suberic acid; 6, sebacic acid; 7, 3-hydroxysebacic acid; 8, internal standard; 9, suberyl glycine.177
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During the course of this larger study a urinary organic acid pattern containing 
low levels of ethylmalonic, adipic, suberic and octenedioic acids as well as 3- 
hydroxy-adipic, -suberic and -sebacic acids (see figure 2.01) was often seen177 in 
both siblings of SIDS patients and control urines. This pattern, whilst being 
quantitatively much lower, was similar to that considered to be a diagnostic 
finding in crisis samples from patients with fatty acid oxidation defects such as 
MCAD deficiency (see figure 2.02.). The cause of this finding, referred to as 
generalised neonatal dicarboxylic aciduria (generalised DCA), is investigated 
further in this thesis as detailed below.
2.6.2 SAMPLE COLLECTION, STORAGE AND ANALYSES
Random urine samples were collected onto cotton wool balls during the first five 
days of life, preferably days 1, 3 and 5, from siblings of sudden infant death 
syndrome patients. Matched control urine samples were also collected from 
babies born on the same day in the same unit.
The urine was stored at -20°C as soon as possible, within 24 hours of collection, 
until required for investigation. The analyses performed were organic acid 
analysis by either gas chromatography or gas chromatography mass spectrometry 
and total, free and esterified carnitine quantitations.
2.6.3 CHOICE OF SAMPLE
Where samples were taken on successive days of life the results obtained from the 
earliest sample were used. In this way the period of greatest metabolic stress, ie 
that closest to the time of birth, was analysed. Also, it has been shown that the 
occurrence of generalised DCA is most prominent on the first day of life177.
2.6.4 GENERALISED DICARBOXYLIC ACIDURIA RELATIONSHIPS
The relationship between generalised dicarboxylic aciduria and a number of 
overlying factors was investigated. These factors were; sibling history of sudden 
infant death syndrome, gender, whether the baby was bottle or breast fed and the 
number of days elapsed between birth and sample collection.
2.6.5 CARNITINE EVALUATIONS
Measurements of carnitine values (total, free, esterified) for all patients allowed 
reference range calculations for urinary carnitine levels in newborns, and an 
investigation of their reliance on the above mentioned factors. Separate reference 
ranges were calculated for those subjects exhibiting, not exhibiting, or regardless 
of generalised DCA.
Variations in urine concentrations were corrected for by dividing by the level of 
creatinine.
Because of a skewed distribution, reference ranges were calculated as the 2.5th to 
97.5th inter percentile range. Appendix 4 shows normal ranges (mean ± 2 SD) 
calculated based on normal distributions of raw data. The differences between 
these and the inter-percentile ranges indicate the amount of skew in the sample 
distributions. Also included, for reference, are normal ranges calculated from 
logarithms of the total and free carnitine values and inverse of the logarithm of 
the percent esterified values. Some of the distributions still showed slight skew 
after logarithmic conversion and therefore the percentile ranges were used in 
preference.
2.6.6 STATISTICAL ANALYSIS
2.6.6.1 Two Tailed Fisher's Exact Method
This test was used to test the null hypotheses that there is no association between 
the presence of generalised dicarboxylic aciduria and;
1. sibling history of sudden infant death syndrome,
2. method of feed - breast or artificial, and
3. gender.
The p value for each frequency distribution is calculated as;
rx! r2! s2!
N! a ! b ! c ! d !
where rx = The frequency of generalised DCA.r2 = The frequency of no generalised DCA.sx = The frequency of one of the values for the possiblyassociated factor (one of the three listed above). s2 = The frequency of the alternative value for the possibly associated factor.N = Total sample size for the test. a,b,c,d = The frequencies of the four possible combinationsof the groups used for rlf r2, Si and s2.
The two tailed Fisher's probability represents the probability of obtaining the 
observed or a more extreme distribution given that there is no association between 
the presence of generalised DCA and the three possibly associated factors being 
tested. This is achieved by calculating the probabilities for all possible 
distributions that would produce equivalent rlf xv  Sj and s2 values to those 
observed. All p values less than or equal to that of the observed distribution are 
then summed. The result is the two tailed Fisher's probability. Alternatively the 
more widely known chi-squared test could have been used. However, this is only 
an approximation to Fisher's exact test and should not be used with expected 
frequencies of less than five as was the case here.
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2.6.6.2 The Wilcoxon Rank Sinn Test
The Wilcoxon rank sum test was used to distinguish any significant differences 
between the medians of total, free and esterified carnitine data in relation to 
gender, feed (artificial or breast) presence of generalised dicarboxylic aciduria and 
whether the patient was a sibling of a sudden infant death syndrome victim.
Significance testing was carried out on the null hypothesis that the medians of 
each sample were equal. Calculation of the level of significance of this hypothesis 
was based on the formula;
V27C
i^ t2 dt
where the Wilcoxon rank sum statistic Z was calculated as;
(smallest sum of ranks) - (expected sum of ranks)
(standard deviation of ranks)
2.7 MISCELLANEOUS
2.7.1 DATA ANALYSIS COMPUTER SOFTWARE
Data manipulation was aided by use of Statistical Analysis System version 6.03 
software (SAS Institute Inc. USA), run on various IBM compatible personal 
computers.
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CHAPTER 3 
RESULTS
3.1 ROUTINE LABORATORY ASSAY QUALITY CONTROL 
DATA
When measuring plasma free fatty acid, lactate, 3-hydroxybutyrate and glucose for 
the intermediary metabolites investigation samples were incorporated into routine 
laboratory batches. Table 3.01 shows coefficients of variation (CV%) and a 
description of the two quality control materials (QCI and QCII) used in theses 
batches.
Table. 3.01. Quality control results for routine intermediate metabolite assays.
Assay Year CV% QCI QCII
Free fatty 1988 4.2 Nycomed lo Ciba Corningacids bovine serum bovine 31989 4.4
1990 4.0
Lactate 1988 5.2 Sigma Sigmametabolite metabolite1989 4.9 control control
1990 3.6
3-Hydroxy- 1988 9.7 Sigma Sigmabutyrate metabolite metabolite1989 9.6 control control
1990 9.0
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3.2 INTERMEDIARY METABOLITES INVESTIGATION
Exact fasting times were not recorded in many cases. Therefore it would be 
unwise to attempt any reference range evaluations on such a non homogeneous 
population. Never the less summary statistics for data collected are very 
comparable to those quoted by JP Bonnefont178, JI Wolfsdorf179 and KJB Lamers180. 
These workers quoted exact fasting times between 15 and 24 hours and it was 
seen that the change in metabolite levels within this range was small.
Table 3.02 shows sample size, median, minimum and maximum for the 
intermediary metabolites from patients with no diagnosed disorder of fatty acid 
metabolism (ie variable DIAGNOSE = 0, see appendix table A2.2).
Table 3.02. Basic statistical analysis.
Glucose(mmol/1 ) Lactate(mmol/1 ) Free fatty acids (mmol/1 )
TotalCarnitine(jlmol/1 )
Sample size 106 113 113 31
Median 4.4 1.4 0.9 35.0
Minimum 1 . 0 0 . 6 0 . 1 15.0
Maximum 10.4 6 . 2 3.3 8 8 . 0
All values were taken from plasma samples
Table 3.02. continued
FreeCarnitine(jimol/1 )
EsterifiedCarnitine(%)
3-Hydroxy-butyrate(mmol/1 )
FFA 3 -HB
Sample size 32 31 112 109
Median 23.5 35.4 0.7 1.3
Minimum 1 0 . 0 0 0 CO
Maximum 45.0 73.3 4.6 16.5
All values were taken from plasma samples
3.2.1 PAIRED METABOLITE CORRELATION PLOTS
The following plots and statistics show the correlation between plasma 
intermediary metabolite levels for patients having no diagnosed irregularity in 
fatty acid metabolism. Superimposed on these are data from infants with various 
errors of fatty acid metabolism. All points for the non-diagnosed patients are 
represented by a cross whilst those for the diagnosed children are shown by the 
value of the variable DIAGNOSE (see appendix table A2.2).
All lactate plots (figures 3.01. and 3.07 to 3.11.) showed poor correlations. This 
was probably an indication of the weak link between lactate levels and the other 
intermediary metabolite levels due to factors extraneous to fatty acid oxidation 
(see section 4.1.1.4).
All plots against total carnitine (figures 3.03., 3.08., 3.12. and 3.16.) showed poor 
correlation, so too did the plot of free carnitine against glucose (figure 3.04.).
Infact, all plots between the three carnitine values (total, free and esterified) were 
thought to be of little use in the diagnosis of errors in fat metabolism and were 
not included in these results. Similarly, plots against FFA/3HB were also 
excluded on the basis that any note worthy points would also be exhibited in the 
plots of the single metabolites.
A very good correlation was seen between 3HB and %CE (figure 3.18., cc = 0.8). 
Further, all of the plots against %CE (excluding those involving total and free 
carnitine and lactate) possessed correlation coefficients with modulus values above 
0.6 (figures 3.05 and 3.14 and table 3.03). %CE values were chosen in preference 
to straight forward acylcamitine values during the early stages of this study as it 
became apparent that stronger correlations would be exhibited using the 
percentage values.
The remaining plots all showed recognisable correlations with correlation 
coefficient modulus values above 0.4.
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Fig.3.01. Plot of lactate against glucose.
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Fig.3.02. Plot of free fatty acids against glucose.
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Fig.3.03. Plot of total carnitine against glucose.
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Fig.3.04. Plot of free carnitine against glucose.
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Fig.3.05. Plot of % esterified carnitine against glucose.
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Fig.3.06. Plot of 3-hydroxybutyrate against glucose.
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Fig.3.10. Plot of % esterified carnitine against lactate.
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Fig.3.11. Plot of 3-hydroxybutyrate against lactate.
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Fig.3.14. Plot of % carnitine esters against free fatty acids.
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wFig.3.15. Plot of 3-hydroxybutyrate against free fatty acids.
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Fig.3.16. Plot of total carnitine against 3-hydroxybutyrate.
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Fig.3.18. Plot of 3-hydroxybutyrate against % esterified carnitine.
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Table 3.03 summarises the correlation coefficients, p values of no correlation and 
sample sizes for all possible correlations between the metabolite values collected 
from subjects with no diagnosed fatty acid oxidation defect (ie variable 
DIAGNOSE = 0 - see appendix table A2.2). Spearman correlation coefficients were 
used in preference to the more standard Pearson values. In dealing with the rank 
values of the variables as opposed to the numeric the Spearman correlation 
coefficients are less affected by outliers than would be the Pearson counterparts.
It was seen however, that conclusions drawn during this study were still evident 
if Pearson calculations were used.
Table 3 . 0 3  Correlation coefficients, p value of nocorrelation, and sample sizes for data collected from subjects with, no diagnosed fatty acid oxidation defect.
Spearman Corr. Coef. / Prob > |R| under Ho: Rho=0 / Nunber of Observations
KB CARHT CARNF CARNE FFA3HB FFA LACT
GLUC
‘lucose
-0.53096
0.0001
101
-0.26620
0.1551
30
0.22576
0.2220
31
-0.61140
0.0003
30
0.38865
0.0001
99
-0.42110
0.0001
102
-0.07606
0.4451
103
LACT
Lactate
-0.06270
0.5191
108
0.29468
0.1139
30
0.14765
0.4280
31
0.17351
0.3592
30
0.13169
0.1805
105
0.05730
0.5558
108
FFA
Free fatty acids
0.58376
0.0001
110
0.05585
0.7735
29
-0.44738
0.0150
29
0.62528
0.0003
29
-0.14151
0.1422
109
FFA3HB 
FFA / 3HB
-0.86067
0.0001
109
-0.15569
0.4200
29
0.41209
0.0263
29
-0.66371
0.0001
29
iRNEX Esterified carnitine 0.829530.0001
30
0.30139
0.0994
31
-0.49667
0.0045
31
CARNF
Free carnitine
-0.57316
0.0009
30
0.57981
0.0006
31
CARNT
Total carnitine
0.14790
0.4354
30
-1 0 8 -
3.2.2 FASTING PROFILES
Data from patients with no diagnosed error of fatty acid metabolism and for 
which exact fasting times were recorded were used to provide the following plots 
(figures 3.19. to 3.24.) These, along with the accompanying statistics, show the 
effect of fasting on intermediary metabolite levels. Also included are data taken 
from patients with defects in fatty acid metabolism. Unfortunately, because of a 
lack of exact fasting times the patients included here were limited to those 
diagnosed as hypoglycaemic hyperinsulinaemic and patient 69 with a suspected 
defect in glycogen storage or mobilisation. All points for the non-diagnosed 
patients are represented by a cross whilst those for the diagnosed children are 
shown by the value of the variable DIAGNOSE (see appendix table A2.2).
The lactate and total carnitine profiles showed poor correlations and therefore are 
not shown. Notably, although the correlation coefficient for the FFA/3HB profile 
(figure 3.24) was only -0.3, visually there did appear to be a more clear correlation, 
The poor coefficient appeared to be a result of a wide spread of values between 
fast times of 5.5 and 8.5 hours. All other plots showed good correlations with 
modulus correlation coefficients between 0.49 and 0.63.
Table 3.04. summarises the Spearman correlation coefficients, p value of no 
correlation and sample size for the effect of fast on metabolite values measured in 
subjects with no diagnosed defects in fatty acid oxidation.
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Fig.3.19. Plot of glucose against length of fast.
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Fig.3.20. Plot of free fatty acids against length of fast.
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Fig.3.21. Plot of free carnitine against length of fast.
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Fig.3.22. Plot of esterified carnitine against length of fast.
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Fig.3.23. Plot of 3-hydroxybutyrate against length of fast.
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Fig.3.24. Plot of free fatty acids / 3-hydroxybutyrate against length of fast.
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Table 3 . 04 . Spearman correlation coefficients (C) , p value of no correlation (P), and number of observations (N) for the effect of length of fast on intermediary metabolites
C P N
GLUCGlucose -0.62747 0 . 0 0 0 2 31
LACTLactate 0.49234 0.0057 30
FFAFree fatty acids 0.59656 0.0004 31
FFA3HBFree fatty acids / 3-hb -0.31120 0.0941 30
CARNE% Esterified carnitine 0.58518 0.0279 14
CARNFFree carnitine -0.52222 0.0554 14
CARNTTotal carnitine -0.07200 0.8068 14
HB3-Hydroxybutyrate 0.52571 0.0028 30
All correlations were against length of fast
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3.3 GENERALISED DICARBOXYLIC ACIDURIA 
INVESTIGATION
3.3.1 SUBSET DEPENDENCY
Fisher's two tailed exact method was used to test the hypothesis that generalised 
DCA was not associated to; 1. Sibling history of sudden infant death (SIB of SIDS);
2. Method of feeding - breast or artificial; and 3. Gender. The resultant p values 
are shown in table 3.05. High values for 'SIB of SIDS' and 'Gender' indicate no 
connection between these parameters and the occurrence of generalised DCA, 
whereas, the value for 'Feed' is much lower.
In addition, table 3.06. shows the distribution of subjects within the subsets set up 
by the possible combinations of the three parameters mentioned above against 
presence and absence of generalised DCA. The percentage of all breast fed 
neonates that showed generalised DCA is more then twice the percentage of all 
bottle fed neonates that showed similar patterns, whilst, the percentage of breast 
feeders that showed no DCA is less than half that for bottle feeders.
These points indicate a connection between generalised DCA and method of 
feeding.
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Table 3.05. Table of p values based on non-association of generalised dicarboxylic aciduria and; 1. Sibling history of sudden infant death; 2. Method of feeding; 3. Gender.
C L A S S
SIB of SIDS Feed Gender
Gen. DCA or 0.77 0.08 0.73
non gen. DCA
Table 3.06 Distribution of patients exhibiting generalised dicarboxylic aciduria (Gen. DCA) and those with no detectable urinary dicarboxylic acids (Non DCA) according to sibling history of SIDS, type of feed, and gender.
Class N
Distribution of patents
Gen. DCA Non DCA
Fqy % Fqy %
Sibling of SIDS 55 28 50.9 27 49.1
No history of SIDS 14 8 57.1 6 42.9
Breast feed 13 9 69.2 4 30.8
Artificial feed 9 2 2 2 . 2 7 77.8
Male 16 11 6 8 . 8 5 31.3
Female 18 11 61.1 7 38.9
N = number in class, Fqy = frequency of patients within subclass, % = percentage of class within subclass.
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3.3.2 STATISTICAL ANALYSIS AND REFERENCE RANGE 
EVALUATIONS FOR NEONATAL URINARY CARNITINE LEVELS
3.3.2.1 Frequency plots and statistics
Because of an apparent association between carnitine values and generalised DCA 
(see later) separate statistical investigation and reference range evaluations were 
also carried out on two subsets of the study group, one contained babies showing 
generalised DCA and the other contained babies that do not.
The following frequency plots, figures 3.25., 3.26. and 3.27. and summary statistics 
tables 3.07, 3.08. and 3.09 show the distributions of carnitine values with, without 
and regardless of presence of generalised DCA.
All total and free carnitine values are given in pmol/mmol creatinine.
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Fig.3.25.
Frequency plots of carnitine data (total, free and esterified) for all patients involved in the generalised DCA. investigation.
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Table 3.07. Basic statistical analysis of carnitine data(total, free and esterified) for all patients involved in the generalised DCA investigation.
URINE CARNITINE
Total Free Esters
Sample size 72 72 72
Mean 19.1 2.3 86.7
Standard deviation 18.0 2.7 1 0 . 1
Median 16.2 1.7 89.8
Upper quartile 20.5 2 . 2 93.1
Lower quartile 11.5 1 . 0 85.1
Minimum 1 . 1 0 . 2 50.0
Maximum 153.9 2 0 . 0 97.7
Coef. of variation 94.5 118.0 1 1 . 6
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Fig.3.26.
Frequency plots of carnitine data (A; total, B; free and C; esterified) for children exhibiting a generalised DCA.
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Table 3.08. Basic statistical analysis of carnitine data(totalr free and esterified) for children exhibiting a generalised DCA.
URINE CARNITINE
Total Free Esters
Sample size 39 39 39
Mean 2 1 . 6 1 . 8 91.0
Standard deviation 22.9 1.7 6 . 2
Median 17.4 1.3 92.2
Upper quartile 22.3 1.9 94.2
Lower quartile 13.2 0.9 88.9
Minimum 1 . 1 0 . 2 63.6
Maximum 153.8 1 0 . 8 97.6
Coef. of variation 106.4 96.4 6.9
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Fig.3.27.
Frequency plots of carnitine data (total, free and esterified) for children having no detectable DCA.
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Table 3.09. Basic statistical analysis of carnitine data(total, free and esterified) for children having no detectable DCA.
URINE CARNITINE
Total Free Esters
Sample size 33 33 33
Mean 16.1 2.9 82.4
Standard deviation 8.9 3.4 1 2 . 0
Median 13.5 2 . 0 85.7
Upper quartile 2 0 . 0 2,9 90.3
Lower quartile 9.4 1.3 77.4
Minimum 4.3 0 . 6 50.0
Maximum 42.0 2 0 . 0 95.9
Coef. of variation 55.4 120.4 14.6
3.3.2.2 Urinary carnitine reference ranges
All carnitine values showed a skewed distribution (see previous section). The 
reference ranges were therefore approximated. The representation used was the 
2.5th to 97.5th inter percentile range. The 2.5th percentile is that value below 
which 2.5% of all data lie whilst the 97.5th percentile is that value above which 
2.5% of all data lie. Below is an example calculation of the 2.5th to 97.5th 
percentile range using urinary total carnitine data for all patients in the study. 
Table 3.10. summarises the ranges calculated for the subsets mentioned previously.
Calculation of 2.5th percentile
The nth value corresponding to the 2.5th percentile
72
=   x 2.5 =   x 2.5 = 1.8 th
100  100
Nj. + 8 [ N2 — Nx ] 1.14 + 8 [ 4.34 - 1.14 ]
N i e  =    =  ---------------------------------------------------------
10  10
3.70
Calculation of 97.5th percentile
The nth value corresponding to the 97.5th percentile
72  x 97.5 =   x 97.5 = 70.2 th
100  100
N70 + 2 [N71 - N70 ] 40.00 + 2 [42.00 - 40.00]
7 0 . 2  =
* 7 0  '  ^  L i1 ,7 1  i , 7 0N 10 10
40 . 40
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Table 3.10. Table showing the 2.5th and 97.5th percentilescalculated; 1. regardless of presence of urinary DCA (ALL) ; 2. for patients exhibiting generalised DCA (DCA) ; and 3. for patients with no detectable DCA (NO DCA) .
Group Nth value 2.5% 97.5% Carnitinevalue 2. 5th percentile 97.5thpercentile
ALL 1.8 70.2 total 3.7 40.4
free 0.5 7.5
% esterified 51.9 96.6
DCA 1.0 38.0 total 1 . 1 39.7
free 0 . 2 4.6
% esterified 63.6 97.1
NO DCA 0.8 32.2 total 3.6 40.4
free 0.5 9.3
% esterified 41.3 95.7
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Median values were calculated for total, free and esterified carnitine for each 
condition of the four parameters - presence of generalised DCA, sib. of SIDS, feed 
and gender. Null hypotheses stating that these medians did not change with the 
condition of each parameter was tested using the Wilcoxon rank sum test. The 
medians and resultant p values are tabulated in tables 3.11. to 3.14..
Low p values of no association for free and particularly esterified carnitine in table 
3.11. indicates a high likelihood of an association between these values with 
generalised DCA.
Table 3.11. Table of medians and p values for the nullhypothesis that the carnitine values (total, free and esterified) do not differ with the presence or absence of generalised DCA.
Carnitinevalue
M E D  I A N
Generalised DCA present
V A L U E
Generalised DCA absent
p value of no association
Total 17.4 13.5 0.0723
Free 1.3 2 . 0 0.0292
% Esterified 92.2 85.7 0 . 0 0 0 2
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There does not seem to be a connection between any carnitine values and sibling 
history of SIDS, table 3.12.
Table 3.12. Table of medians and p values for -the nullhypothesis that the carnitine values (total, free and esterified) do not differ with the presence or absence of sibling history of sudden infant death.
Carnitinevalue
M E D I A N
Sibling of SIDS patient
V A L U E
No sibling history
p value of no association
Total 15.4 18.7 0.1652
Free 1.7 2 . 0 0.3666
% Esterified 89.8 8 8 . 2 0.8991
Low p values for total carnitine against type of feed, table 3.13., and gender, table 
3.14., suggests higher total carnitine for breast fed neonates over bottle feeders and 
for females in comparison to males.
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Table 3.13. Table of medians and p values for the nullhypothesis that the carnitine values (total, free and esterified) do not differ with the method of feeding - breast or artificial.
Carnitinevalue
M E D I A N
Breast
feed
V A L U E
Artificial
feed
p value of no association
Total 19.8 1 0 . 8 0.0275
Free 2 . 1 1 . 8 0.6163
% Esterified 89.8 81.3 0.0825
Table 3.14. Table of medians and p values for the null hypothesis that the carnitine values (total, free and esterified) do not differ with gender.
Carnitinevalue
M E D I 
Male
A N  V A L U E  
Female
p value of no association
Total 13.8 18.3 0.0310
Free 1 . 8 1.5 0.6662
% Esterified 90.0 91.5 0.2477
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3.3.3 RELATIONSHIP OF CARNITINE VALUES TO AGE WITHIN THE 
FIRST FIVE DAYS OF LIFE
Urinary total, free and esterified carnitine (pmmol/mmol creatinine) were plotted 
against age for all infants within the first week of life. These plots are shown in 
figures 3.28. to 3.30., and the associated correlation coefficients, p values of no 
correlation and sample sizes are shown in table 3.15.. Because of the possible 
relationship between carnitine values and generalised DCA separate correlation 
coefficients and p values of no correlation for those subjects showing generalised 
DCA and those not showing any DCA were also examined. These again are 
included in table 3.15. and provide evidence that there is no change in carnitine 
values, with or without generalised DCA, over the first five days of life.
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Fig.3.28. A plot of total urine carnitine against age.
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Fig.3.30. A plot of percentage esterified urine carnitineagainst age.
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Table 3.15. Correlation coefficients (C) , p value of nocorrelation (P) , and number of observations (N) for the plots of total (TC) , free (FC) , and esterified carnitine (AC) against age for data collected from; 1 . all neonates regardless of generalised DCA; 2. those exhibiting generalised DCA; 3. those not exhibiting DCA.
Spearman Correl. Coef, / Prob > |r | under Ho: Rho=0 / N
TC FC AC
DAY 0.23571 0.39886 -0.27663
Age at sampling (days) for neonates 0.0512 0.0007 0.0214
regardless of generalised DCA 69 69 69
DAY 0.15265 0.29451 -0.17779
Age at sampling (days) for neonates 0.3741 0.0812 0.2995
exhibiting generalised DCA 36 36 36
DAY 0.38587 0.36371 -0.17905
Age at sampling (days) for neonates 0.0266 0.0375 0.3188
not exhibiting any DCA 33 33 33
3.4 DEVELOPMENT OF A RADIO-ENZYMATIC ASSAY TO 
QUANTITATE CARNITINE IN URINE AND PLASMA
Total carnitine values where multiplied by 2.5 to correct for the dilution factor. It 
was found that values above 70pmol/l gave rise to unacceptable duplicate values. 
Therefore, samples recording levels in excess of 60pmol/l were diluted 
accordingly and re-assayed.
3.4.1 PRECISION
The intra-batch variation was calculated by assaying five aliquots from the same 
randomly collected plasma sample. Table 3.16. shows the results of the assay.
Table 3.16. Results of the radio-enzymatic assay to investigate precision and recovery
Aliquot Carnitine level ((imol/1 )Free Total
Spiked 1 
2 0|lmol/l Free
: 1 with carnitine Total
1 52 56 46 43
2 53 58 44 45
3 54 59 43 44
4 52 57 45 46
5 54 59 45 42
MEAN 53.0 57.8 44. 6 44.0
STANDARD DEVIATION 0.9 1 . 2 1 . 0 1.4
COEF. OF VARIATION 1 . 6 2 . 1 2 . 2 3.1
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3.4.2 RECOVERY
An aliquot of the plasma used for the above intra batch precision was spiked 1:1 
with 20 pmol/1 carnitine, split into five and assayed simultaneously with the 
unspiked batch. The results are shown in table 3.16. The mean free carnitine 
concentration of the plasma that was spiked was 53p mol/1. The expected overall 
free carnitine concentration was therefore,
53 + 20 = 36.5 pmol/1 
2
Observed overall free carnitine concentration was,
44.6 pmol/1 
Percentage recovery was therefore,
44.6 x 100 = 122%36.5
The mean total carnitine concentration of the plasma that was spiked was 57.8 
pmol/1. The expected overall total carnitine concentration was therefore,
57.8 + 20 =38.9 pmol/1 2
Observed overall total carnitine concentration was,
44 pm ol/1  
Percentage recovery was therefore,
44.0 x 100 = 113%38.9
In summary, the precision of this assay at approximately 50 to 60 pmol/1 has a 
standard deviation of 0.9 pmol/1 (CV 1.6) for free plasma carnitine and 1.2 pmol/1 
(CV 2.1) for total plasma carnitine. The recoveries for free and total carnitine were 
122% and 113% respectively.
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3.4.3 QUALITY ASSURANCE AND CONTROL
The quality control material used for the plasma carnitine quantitation was the 
investigators own plasma collected after 12 hr fast. Standard deviation and 
coefficient of variation results for total carnitine, table 3.17., are somewhat higher 
than those for free during both 1988 and 1989. This was assumed to be a 
reflection of an increase in experimental error due to the extra hydrolysis step and 
inherent dilutions involved in the total carnitine analysis. As one can see from 
figure 3.31. the quality control results could be somewhat erratic resulting in a 
number of batch rejections due to values outside the mean ± 2 SD range. Such a 
variation, whilst acceptable, is thought to be a reflection of the problematic nature 
of this assay. Overall CV's were all reasonable for a non-automated assay of this 
sort.
Table 3.17. Quality control results for radio-enzymatic assay of plasma carnitine during the period of the intermediate metabolites investigation.
P 1 a s m a c a r n i t i n e
Year Free Total
Mean SD CV% Mean SD CV%
1988 47.9 2.3 4.8 52.2 7.6 7.3
1989 24.2 1 . 2 5.0 65.4 5.7 8.7
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Fig.3.32. Example of quality control chart (1987-88) forTotal Plasma Carnitine showing the ± 2SD limits.
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The standard curve used during the assay was seen to vary a surprising amount 
between assays (figure 3.33. and table 3.18.). As a result the standard curve was 
recalculated for each assay.
a□a
5 03D 60 7 02 0
Fig.3.33. An example of the standard curve calculated during the radio-enzymatic evaluation of plasma carnitine. Also shown are the upper and lower limits for the variation of standard curve during the period July 1989 and February 1990.
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Table 3.18. Mean counts per minute values for four standards 10T 20r 40, and 60 |imol/l free carnitine along with standard deviations and coefficients of variation for values collected over the period July 1989 to February 1990.
Standard cone. C o u n t sMean p e rS.D. m i n u t e C.V.%
10
204050
1027192938665682
8080192
120
7.84.15.0
2 . 1
Table 3.19. assay run. shows an example of results taken from a typical
Table 3.19. Example of typical duplicate counts per minute results.
Sample CPM Mean Mean CPM CPM - Blank E.C.C.(jlmol/1 ) Multi. Factor A.C.C.(Jimol/l)
0 standard (blank) 262263 263 0 0
10 JIM std 11281125 1127 864 10 10
20 JIM std 20012042 2022 1759 20 20
40 JIM std 40404362 4201 3938 40 40
patient 1 (free) 35593436 3498 3235 35 35
patient 1 (total) 51745189 5182 4919 53.5 2.5 134
CPM = Counts per minute; E.C.C. = Equivalent carnitine concentration read from standard curve; A.C.C. = Actual carnitine concentration in original sample.
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3.5 PREPARATION OF ISOTOPE INTERNAL STANDARDS 
FOR THE QUANTITATION OF URINARY GLYCINE 
CONJUGATES BY GAS CHROMATOGRAPHY / MASS 
SPECTROMETRY
3.5.1 PREPARATION RESULTS
Table 3.20. shows the relative abundances of the six isotopic forms of the 
deuterated hexanoic acid and deuterated hexanoyl glycine (HG) following their 
respective syntheses. The tetra-deuterated HG was selected to be used as internal 
standard, IS. Similarly, the tetra-deuterated phenylpropionyl glycine (PPG), with a 
relative abundance of 31%, and tetra-deuterated suberyl glycine (SG), with a 
relative abundance of 43%, were selected as the IS isotopic compounds.
The ion fragments that were selectively scanned and used for quantitation are 
shown in table 3.21. and table 3.23.. Their retention times were seen to vary 
slightly. Table 3.21. shows an example of typical retention times and the retention 
time periods over which scanning was carried out. Also shown are published 
methylene unit values for both TMS derivatives of the non-deuterated conjugates.
-137-
Table 3.20. Abundances of hexanoic acid and hexanoyl glycine following their respective syntheses.
No. of deuterated hydrogen Percentage of total abundanceions on molecule Hexanoic acid Hexanoylglycine
0 0 * 19 1.07
1 5.40 0.85
2 77.01 2.513 1 2 . 8 8 9.974 4.31 73.475 0.39 1 2 . 1 2
Table 3.21. Typical retention times for the ion fragments scanned and the windows over which scanning was carried out for the detection of deuterated and non-deuterated glycine conjugates.
Parent TMS D or Meth. Ion Retention Scancompound deriv. N units fragment time window(AMU) (minutes) (minutes)
SG 1 D 22.34 364 23.17 22.5 - 24.0N 360 23.20
2 D 22.37 436 23.50N 432 23.55
HG 1 D 16.11 162 15.21 14.5 - 16.5N 158 15.25
2 D 16.48 204 15.78N 200 15.81
PPG 1 D 19.83 268 20.09 19.5 - 21.0N 264 2 0 . 1 1
2 D 19.96 355 2 0 . 2 2N 351 20.24
D = deuterated conjugater N = non-deuterated conjugate
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Fig.3.34. GC/MS spectrum (relative abundance against mass) for the TMS1 derivative of non-deuterated SG,
TMS1 and TMS2 derivatives were detected immediately following synthesis of 
both SG and deuterated SG. However, at the time of calibration each compound 
was present solely in the TMS1 form.
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Fig.3.35. GC/MS spectra (relative abundance against mass) for; A: TMS1 derivative of non-deuterated HG,B: TMS2 derivative of non-deuterated HG,C: TMSl derivative of (2H4)-HG,D: THS2~ derivative of (5H7) -HG .
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Fig.3.36. GC/MS specta (relative abundance against mass) for; A: TMSl derivative of non-deuterated PPG,B : TMSl" derivative of (^ H*) -PPG.
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3.5.2 CONCENTRATION EVALUATIONS
Table 3.22. shows the weights and calculated concentrations of the non-deuterated 
conjugates used to evaluate the concentrations of the deuterated conjugates.
Table 3.22. Calculations of non-deuterated glycine conjugate solution concentrations.
Glycineconjugate Molecular weight (AMU) Weight in 100ml Methanol (mg) Cone. (|lmol/l)
SG 303 2.54 83.8
HG 173 2.65 153.2
PPG 207 2.61 126.1
Table 3.23. summarises which ion fragments were used to detect each TMS 
derivative of each glycine conjugate deuterated or non-deuterated; resultant peak 
areas from a single ion monitoring GC/MS analysis; calculated deuterated/non- 
deuterated peak area ratios for each glycine conjugate; concentrations of the non- 
deuterated conjugates used (from table 3.22.);and resultant concentrations of the 
deuterated compounds in the assay.
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Table 3.23. Preliminary evaluations of deuterated glycine conjugate concentration.
Glycineconjugate TMSderiv D or Scan N ion Peakarea Ratio Cone. D/N N Cone. D
SG 1 D 364 428981 0.165 83.8 138N 360 2606297
No TMS2 present at. time of calibration.
HG 1 D 162 405011 0.318 153 487N 158 1843545
2 D 204 1563831N 200 4338218
PPG 1 D 268 20977302 10.321 126 13004N 264 1907429
2 D 355 25518423N 351 2597491
D = deuterated conjugate, N = non-deuterated conjugate. All concentrations in jimol/1. A dilution factor of xlO (see section 2.4.4.1) was taken into account when calculating the final column.
3.5.2.1 Choice of working concentration
It was important to supply deuterated IS working concentrations that were both 
close to the normal urinary glycine conjugate levels (expected to be seen in the 
vast majority of cases) and yet not too far removed from any abnormally elevated 
levels, such as those detected in medium chain acyl-CoA dehydrogenase 
deficiency. For this reason, it was decided to use working deuterated HG and 
PPG solutions equivalent to the upper limit of the normal control results 
published by Rinaldo et alU3 (table 3.24). Table 3.25 shows the data used to 
calculated the volumes required to produce such concentrations assuming a 
creatinine level of lmmol/1. Yields of deuterated SG proved insufficient, at such 
high concentrations, to supply a significant volume to cater for an adequate
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number of urine assays. It became apparent that in order to produce 100ml of 
working IS the total SG yield would produce a concentration of 4.6 pmol/1 (table 
3.26.). Such a concentration, whilst not as high as one would have 
liked, was acceptable.
Table 3.24. Ranges of normal control values for glycineconjugates found in the urine of children ranging from 1 week to 9 months of age.
GLYCINECONJUGATE MOLECULAR
RANGE OF NORMAL CONTROL VALUES
WEIGHT *pg/mg creat. pmol/mmol creat.
SG 303 0 - 95 0 - 3 5 . 4HG 173 0 . 2 1 - 1.9 0.14 - 1.24PPG 207 0 - 1 . 1 0 - 0 . 6
"Ranges taken from Rinaldo et al143. Unit conversions based on creatinine molecular weight of 113 AMU. Abbreviations: creat. = creatinine.
Table 3.25. Evaluation of the volume of stock deuterated H6 and PPG required in 100ml with methanol in order to create the concentrations recorded in table 3.24.
Glycineconjugate Stock cone. "Required working conc. Required stock conc. Required vol.in 1 0 0ml
HG 487 1.24 37.2 7.64
PPG 13005 0 . 6 18.0 0.14
All concentrations in pmol/1. "Upper limit of control values143 assuming creatinine of 1 mmol/1. A  factor of 30 was used in calculating the required stock concentration (sec. 2 .4.4.1 .)
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Table 3.26. Evaluation of the working concentration ofdeuterated suberylglycine obtained by using a stock solution of the total yield of conjugate in 
1 00ml methanol.
Glycine Stock Dilution Workingconjugate concentration factor concentration
SG 138 30 4.6
All concentrations in pmol/1.
3.5.3 CALIBRATION
Preliminary results for the accurate calibration of the deuterated glycine conjugates 
are listed in table 3.27.. The corresponding calibration curves are shown in figures 
3.37. to 3.39.. Whilst these preliminary results seemed acceptable they proved 
difficult to reproduce and time constraints prevented any further analyses.
Table 3.27. Calibration results for the accurate calibration of deuterated SG, HG and PPG.
Glycine STD conc. Quadruplicate N/D peak area ratiosconjugate |Xmol/l 1 2  3 4
0 0.035 0.057 0.072 0.088
1 0.175 0.155 0.181 0.169
2 0.312 0.299 0.295 0.3153 0.495 0.482 0.475 0.4914 0.645 0.6485 0.751 0.735 0 .725
0 . 0 0 0 0 0 00.25 0.275 0.243 0.2530.50 0.389 0.421 0.410 0.3780.75 0.606 0.556 0.691 0.589
1 . 0 0 0.812 0.855 0.805 0.9421.25 1.031 1.015 1.025
0 . 0 0 0 0 0
0 . 1 0 . 2 2 1 0.277
0 . 2 0.385 0.354 0 .244 0.4050.3 0.437 0.523 0.481 0.4440.4 0.584 0.568 0.608 0.564
0 . 6 0.865 0 . 8 8 8 0.935 0.955
N = non-deuterated conjugate; D = deuterated conjugate.
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Fig.3.37. Calibration curve for deuterated SG by linear regression.
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Fig.3.38. Calibration curve for deuterated HG by linear regression.
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Fig.3.39. Calibration curve for deuterated PPG by linear regression.
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CHAPTER 4 
DISCUSSION
4.1 INTERMEDIARY METABOLITES INVESTIGATION
4.1.1 PAIRED METABOLITE CORRELATION PLOTS AND FASTING 
PROFILES (NORMALS)
In considering paired metabolite correlation plots involving control patients one 
must expect variation as a result of differing glucose homeostasis, hormonal and 
metabolic adaptation178 and glycogen reserves. All of these factors may change 
with age178 (see section 4.1.4) as well as the general state of health of the subject.
4.1.1.1 Supply of free fatty acids to the mitochondria
As free fatty acids are release from adipose tissue in response to low blood 
carbohydrates one would expect a negative correlation between free fatty 
acids,FFA, and glucose values, figure 3.02.. A poor correlation (cc=-0.4 table 3.03) 
may be partly caused by unevenly distributed glucose values but may also be a 
sign of a successful homeostatic mechanism. This is now explained.
In response to low blood glucose levels, fat metabolism is increasingly used as a 
fuel source. If one were to plot activities of glycolysis and lipolysis against blood 
carbohydrate levels an initial relationship similar to that of region A in figure 4.01. 
would be seen.
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Fast time
Fig.4.01. Theoretical plot of activities of glycolysis and lipolysis against blood carbohydrate levels.
However, as glucose levels fall lower, glucose conservation techniques (see section 
1.2.2) become more pronounced. These have the effect of decreasing the rates of 
both the decline in glucose levels and the increase in fat metabolism (region B 
figure 4.01.).
In a healthy patient the level of FFA can be taken as an indicator of the rate of fat 
metabolism. Therefore, if the population of samples in this study extends into 
region B then the correlation of FFA(and to a lesser extent the %camitine esters 
and 3-hydroxybutyrate) against glucose will be diminished. Any such effect 
would be expected to show on fasting profiles for glucose and FFA. It is difficult 
to see any indicative pattern in Figures 3.19. and 3.20. although it should be noted 
that the patients used for these plots were only a proportion of all patients in the 
study. Therefore, it may be the case that some samples were taken outside region 
A of figure 4.01.
Finally, the p value of no correlation for FFA against glucose controls is very low  
(p=0.0001, table 3.03) and, even when considering such a large sample size, is 
quite significant providing further evidence of correlation.
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4.1.1.2 Transport into the mitochondrial matrix
As the CoA esters of the FFA reach the mitochondria they are converted to acyl 
carnitine to be transported across the inner mitochondrial membrane. Thus the 
level of esterified carnitine would be expected to increase with increasing FFA. As 
FFA increase in response to low blood glucose, carnitine esters should also be seen 
to increase. This is reflected in the plots of esterified carnitine against glucose 
(figure 3.05) and FFA (figure 3.14) which show very good linear correlations (CC=- 
0.6 P=0.0003, and CC=0.6 P=0.0003 respectively, table 3.03).
The overall poor appearance of the other carnitine correlation plots is thought to 
be partially attributable to a smaller sample size. One negative result for esterified 
carnitine was recorded (Patient 103). Here the total and free values were very 
similar 18 pmol/1 and 22 pmol/1 respectively. A difference of 4 pmol/1 at 
approximately the 20 pmol/1 level lay within the limits of the variation of the 
assay (±2SD = ±2.4 - Quality control results 1989) and on this basis the negative 
carnitine result was assumed to be zero in the correlation plots. This value 
remains the lowest carnitine value whether it is negative or zero. Therefore, the 
correlation coefficients, being calculated on the ranks of the values, will remain 
unaffected.
Expressing carnitine esters as a percentage of the total carnitine value was seen to 
produce better correlations with the other metabolites than did the straight 
forward esterified values. The reason for this is not clear but it may indicate some 
relationship between total and esterified values. For example, a diminished 
supply of carnitine would limit esterification. However, this would not be 
expected in normal healthy individuals. Further, if total carnitine was limiting to 
esterification the amount of free carnitine would be minimal. Low free carnitine 
values were not evident in these results.
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4.1.1.3 Production of ketone bodies
Production of 3-hydroxybutyrate, 3HB, one of the ketone bodies, in association 
with increasing 13-oxidation rates is shown in correlations of this metabolite against 
glucose, FFA and percent carnitine esters, %CE (figures 3.06, 3.15 and 3.18 
respectively).
Correlation of 3HB to %CE is extremely good (cc=0.8) possessing the highest 
correlation coefficients of all the plots. Interestingly the correlation coefficient for 
plots with metabolites involved in early stages of fatty acid metabolism decrease 
in accordance with how far one has travelled back along the pathway (see figure
4.03.). For example the correlation of 3HB against %CE is very high whilst that 
for 3HB against FFA is lower with 3HB against glucose lower still.
4.1.1.4 Correlation of intermediary metabolite values with lactate
There is no apparent correlation of lactate with any of the intermediary 
metabolites (figures 3.01. and 3.07. to 3.11.). KJB Lamers only reported a very 
slight correlation with glucose (cc=0.34) and JP Bonnefont178 reported no significant 
difference between 15 and 24 hour fasting lactate values from children between 
the age of 1 and 12 months.
Lactate is both utilised by gluconeogenesis and produced by active skeletal muscle 
as described by the Cori cycle (figure 4.02.). The activity of the subjects in this 
study was not controlled and therefore, neither was their production of lactate. 
Further, gluconeogenesis is not solely reliant on the levels of lactate. Glycerol and 
amino acids also feed this pathway. Therefore, it is difficult to predict whether 
lactate will increase or decrease with length of fast. It maybe that lactate is too 
separated from fatty acid metabolism to show any clear relationships in plots 
against the other intermediary metabolites.
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Fig.4.02. The Cori cycle (P = ATP equivalents).
4.1.1.5 Effects of length of fast on intermediary metabolite levels
The negative correlation between glucose and length of fast (figure 3.19.) was as 
expected. The lactate profile is again poor probably for the same reasons 
discussed earlier. The other intermediary metabolites FFA, %CE and 3HB all 
increase with fast (figures 3.20., 3.22., 3.23. respectively), as a result of rising 
demand for energy from non-glycolytic pathways. Total carnitine showed no 
change in response to fast and therefore because of the increase in %CE there was 
a necessary decrease in free carnitine (figure 3.21.). Interestingly, FFA/3HB 
decreased as the length of fast increased (figure 3.24.). This indicates a growing 
rate of 3HB production relative to that for FFA. From figure 3.23. the relationship 
between 3HB and fasting time may be non-linear suggesting an increase in the 
rate of 3HB production with fast, within the first 25 hours at least. Such a 
response may be connected to an increasing use of ketones as an energy source. 
From figure 3.20, the rate of FFA increase may also rise during fast but to a lesser 
extent.
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4.1.2 PAIRED METABOLITE CORRELATION PLOTS AND FASTING 
PROFILES WITH DEFECTS OF FATTY ACID OXIDATION
4.1.2.1 H ie basic principles
The basic principle involved in the use of paired metabolite correlations as 
indicators of fatty acid oxidation defects is to use the normality/abnormality of 
each plot as an indicator of the states of the pathway/s involved between the two 
metabolites in question. Obviously, the closer these metabolites are along the fatty 
acid metabolic pathway (as regards the number of basic stages in between) the 
fewer the number of metabolic processes involved. For example, a direct 
conversion of one metabolite into a second would normally only involve one basic 
process (although this may involve several chemical stages). A paired correlation 
of these two metabolites would then provide a direct indication of the state of this 
process. Similarly, comparison of results obtained from a plot involving say three 
successive metabolic processes and a paired plot involving just the latter two of 
these processes would deductively provide and indication of the state of the first. 
By such deductive reasoning and direct investigations each stage, from one 
metabolite to the next, along the metabolic pathway can be tested.
In short, for a section of the fatty acid oxidation pathway to be tested in this way . 
the initial and final metabolites involved within that section must be measured 
and included in appropriate paired metabolite correlations.
-155-
4.1.2.2 Medium chain acyl-CoA dehydrogenase deficiency
Appropriate samples from two diagnosed medium chain acyl-CoA dehydrogenase 
(MCAD) deficient patients, patients 40 and 94 (both shown by point 1 on the 
correlation plots), were available to the study.
In this disorder the metabolic block lies within the fi-oxidation cycle in the 
mitochondrial matrix (see section 1.10.4). Free fatty acid response to low  
carbohydrate levels is therefore unaffected. This is reflected in the normal 
position of patient 40 on the FFA against Glucose plot (figure 3.02.).
Unfortunately, patient 94 was treated with glucose prior to sampling. This 
resulted in her apparent non-fasted state (glucose = 7.6 mmol/1).
The increase in carnitine esters during fasting, as acyl groups are transferred 
across the inner mitochondrial membrane, is also unaffected by MCAD deficiency. 
This is indicated by the normal position of the values measured for patient 40 on 
the free and esterified carnitine against glucose plots (figures 3.04. and 3.05.). An 
apparent depletion of total carnitine for patient 40, noticed on the total carnitine 
against glucose plot (figure 3.03.), may be an indication of the secondary, systemic 
carnitine deficiency often associated with MCAD deficiency. Carnitine values for 
patient 94 were unavailable
Hypoketotic hypoglycaemia is evident for patient 40 on the plot of 3HB against 
glucose (figure 3.06.). Once again patient 94 did not appear to be sufficiently 
stressed to require fi-oxidation for energy thus no indication of fatty acid oxidation 
defect is seen. In fact, it has been documented that a blood glucose level of below 
3 mmol/1 is necessary to clearly discriminate fatty acid oxidation defects by 
correlations of 3HB against glucose178 (see section 4.1.4).
The normality of the lactate levels for both patients is indicative of an unaffected 
gluconeogenesis.
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4.1.2.3 Glycogen storage and mobilisation defects
Patient 69, represented by point 6, shows a defect in the storage or mobilisation of 
glycogen. This results in depressed glycogenolysis and therefore abnormally low  
glucose during fasting. However, although glucose values are slightly low on the 
fasting profile (figure 3.19.), the point is not clearly distinguishable from the 
control group probably due to homeostatic conservation of glucose as previously 
explained. However, the high value on the fasting profile for FFA (figure 3.20.) 
does suggest an increased reliance on fatty acids as a fuel source. FFA and 3HB 
levels in relation to glucose appear normal (figures 3.02 and 3.06). Although data 
for lactate and carnitine were not available one would also expect these to follow 
the normal trend of the control values. Carnitine values after twelve hours of fast 
were available and showed normal levels. These were not included in the plots 
due to the sample selection procedure (see section 2.5.3).
A similar normal pattern is suggested for patient 95 (point 2) diagnosed as 
suffering from glycogen storage disease type 1A. In this disease a deficiency of 
microsomal glucose-6-phosphatase severely suppresses glucose-6-phosphate 
conversion to glucose. Therefore, again glycogenolysis is diminished. Very high 
lactate levels are also usually exhibited. Unfortunately data on this patient is 
limited to just 3HB and FFA. From the plot between these two metabolites (figure 
3.15.) it appears that this patient was not fasted as long as patient 69 that is to say 
FFA and 3HB are much lower. As such the demand on glycogenolysis for glucose 
was not as great and therefore any defect would not be as prominent. This would 
explain the closeness of this point to the control values. The importance of 
sufficient fasting times in order to distinguish such defects on paired correlation 
plots is discussed further in section 4.1.4.1.
The position of this defect is not encompassed by the metabolites measured in the 
study and therefore, the correlation plots cannot be used to distinguish the 
position. However, even in these circumstances, correlation results can still 
supply evidence of a defect.
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4.1.2.4 Isolated glucocorticoid deficiency
As mentioned in section 1.2.1, the glucocorticoids facilitate FFA release from 
adipose tissue9. Further, adrenalectomy in rats has been reported to cause an 
increase in ketone body levels187 which is probably due to the use of ketone bodies 
as an alternative fuel source. A deficiency of these hormones will therefore result 
in insufficient FFA levels at times of metabolic stress but elevated 3HB in relation 
to the FFA that are released. These points are reflected in patient 96 (point 3). An 
inappropriate FFA level with respect to that of glucose is shown in figure 3.02.
The normality of the stages between FFA reaching the liver and their acyl-CoA 
esters being converted to acylcarnitine is reflected in a normal free carnitine 
against FFA plot, figure 3.13.. Total carnitine and therefore %CE values were not 
available. Finally, elevated 3HB in relation to FFA levels is indicated in figure 3.15. 
reflecting the rise in ketone levels in the absence of the adrenal cortex hormones.
Both free carnitine against glucose (figure 3.04) and 3HB against free carnitine 
(figure 3.17) plots are on the upper limit of normal but there is no distinct 
departure from the normal values. Usually, one would expect inappropriate FFA 
compared with glucose and raised 3HB production to result in raised values for 
free carnitine against glucose and 3HB against free carnitine respectively.
However, the way in which the corticoids suppress ketone levels is by inhibition 
of fi-oxidation. The site of this inhibition is thought to be that of carnitine 
palmitoyl transferase I and the method by an elevation in the malonyl-CoA level. 
Therefore, the absence of elevated 3HB against free carnitine may be a reflection of 
an inhibited acyl carnitine production maintaining a high free carnitine level. An 
inhibited carnitine esterification should further increase free carnitine with respect 
to glucose. Surprisingly, this is not seen in figure 3.04 and the reason for this is 
unclear. An increase in the rate of gluconeogenesis, in an attempt to supply the 
energy that a suppressed fi-oxidation cannot, may enhance glucose levels 
counteracting any elevated free carnitine value. However, such a glucose 
enhancement is not evident in figure 3.02 and would presumably result in a 
further increase in free carnitine.
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4.1.2.5 Hyperinsuiinaemic hypoglycaemia
A number of patients, clinically consistent with the diagnosis of hyperinsuiinaemic 
hypoglycaemia, have been included into the study (point 4's). None were fasted 
but the nature of the disease supplied the required hypoglycaemia.
In this disease there is an abnormally high level of insulin, a pancreatic hormone 
that plays a key role in the control of the direction of flow through the metabolic 
pathways. It increases synthesis of glycogen, fatty acids and proteins and 
promotes glycolysis. In this way the blood glucose level is decreased and FFA 
release is inhibited.
A primary indication of this disease is very low plasma FFA and glucose. This is 
clearly shown in FFA against glucose correlation (figure 3.02.). Naturally, if FFA 
in comparison to glucose is low so too will be the levels (in relation to glucose) of 
the related metabolites further along the fatty acid metabolic pathway, namely 
carnitine esters and 3HB whilst free carnitine will be elevated. Again this can be 
seen in the relevant correlations against glucose (figures 3.04., 3.05. and 3.06.), 
although, three points show almost normal free carnitine against glucose plots. 
This is discussed later in this section.
From the plots of lactate against glucose (figure 3.01.) all the points, whilst 
exhibiting a distinct shift because of the extremely low glucose levels, span the 
whole of the control range of lactate levels with some showing elevated values. A 
particularly high lactate is seen for (patient 133). Insulin does decrease 
gluconeogenesis by lowering the activities of some of the enzymes involved such 
as pyruvate carboxylase and fructose-6-diphosphatase. Therefore, a high lactate 
level in respect to low glucose may occur. However, as discussed in section 
4.1.1.4., it is difficult to predict the type of correlation between lactate and the 
other metabolites.
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Carnitine values were available for five of the patients, 115, 116, 122, 132 and 134 . 
All showed inappropriate %CE in relation to their glucose levels (figure 3.05) as 
mentioned above. Three showed low total carnitine values which seemed to 
counteract the depressed %CE against glucose to produce normal free carnitine 
against glucose (figure 3.04.). They also either showed normal (patients 132 and 
114) or high (patient 134) %CE in relation to FFA and 3HB (figures 3.14. and 3.18 
respectively). It is likely that this, along with the low total carnitine level, is the 
reason for the low free carnitine in relation to FFA and 3HB (figures 3.13. and 
3.17.). Such values for the other two of the five patients were normal.
The reasons for an apparent carnitine deficiency in three of the hyperinsuiinaemic 
hypoglycaemic patients, and also for the elevated %CE in relation to FFA and 3HB 
for patient 134 are unclear. These patients tended to be very young at sampling 
and much younger than most of the control children. Therefore, any comparison 
against the controls should be treated with caution.
All patients showed normal 3HB against FFA plots (figure 3.15.).
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4.1.3 FAIRED METABOLITE CORRELATION PLOTS AND FASTING 
PROFILES WITH UNKNOWN DEFECTS OF FATTY ACID 
OXIDATION
Four patients suspected of having a defect in energy production during times of 
low blood glucose levels were included in the study. They provided examples of 
the use of paired metabolite correlation in diagnosing such defects and the way in 
which an overall picture such as that in figure 4.03. can be formed. Figure 4.03. is 
a simplified diagrammatic representation of the way in which the seven 
metabolites, measured in the study, are linked. It should be noted that it is not a 
representation of the reactions of the metabolic pathway.
Lactate ---------------------- > Glucose
I2 I I
*FFA
3 Y
Acyl + Free <— Tot. earn. earn. earn.
4 ;V
Ketones
Fig.4.03. An example of the type of overall picture that can be built up from evidence provided by paired metabolite correlation studies. (KEY: 1 = gluconeogenesis; 2 = production of FFA in response to plasma glucose levels; 3 = passage of FFA into the cell and their incorporation into acyl carnitine; 4 = the transport of acyl carnitine into the mitochondria, the incorporation of the acyl groups into ketogenesis and the production of 3- hydroxybutyrate.
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4.1.3.1 Defect in gluconeogenesis
For patient 9 (point 5) two steps on figure 4.03. appear abnormal. High lactate 
and low glucose levels suggest a defect in gluconeogenesis (step 1) whilst an 
inappropriately low FFA value in comparison to glucose (figure 3.02) indicates a 
defect in FFA production or mobilisation in response to hypoglycaemia (step 2).
Free and esterified carnitine values in relation to FFA and 3HB appear normal 
(figures 3.13, 3.14, 3.17 and 3.18). This indicates an unaffected transfer of acyl 
groups across the mitochondrial membrane and ketone production (steps 3 and 4 
respectively).
It is possible that there exists a threshold rate of free fatty acid release from 
adipose tissue. If glucose levels were to fall below that which would lead to this 
maximum rate of free fatty acid release (as may be the case with defective 
gluconeogenesis) then it may appear that there was a defect in FFA response to 
hypoglycaemia. This is exactly what is observed for this patient. However, the 
apparent capability of some patients to liberate much more free fatty acids in 
response to equivalent or lower glucose levels seems to contradict this postulate. 
Alternatively a real second defect may be present in this patient.
Therefore, patient 9 results are consistent with a defect in gluconeogenesis with 
the possibility of a second defect in FFA production or mobilisation.
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4.1.3.2 Defect in acetoacetate utilisation
Separation of patient 43, represented by point 7, from the controls is not so clear.
Lactate and glucose values are normal suggesting a normal step 1 on figure 4.03. 
The FFA against glucose plot (figures 3.02.) appears normal reflecting appropriate 
FFA release in relation to glucose (step 2 on figure 4.03). The 3HB against glucose 
plot (figure 3.06.) lies on the limit of the control group but there is no definite 
separation. Whilst %CE is slightly elevated in relation to FFA (figure 3.14) all 
other carnitine plots against FFA and glucose (figures 3.03 to 3.05, 3.12, 3.13) show  
borderline-normal positions. This indicates that acyl transfer into the 
mitochondria (step 3 on figure 4.03) is probably normal. 3HB against esterified 
carnitine (figure 3.18.) appears borderline-normal reflecting an appropriate ketone 
production (step 4 on figure 4.03). Most noticeable is the 3HB against FFA plots 
(figure 3.15.). Here the point is elevated.
A suppressed ketone body utilisation will result in a concomitant build up of both 
acetoacetate and 3HB. During early stages of fast as fi-oxidation exists as the 
major energy source a defect in ketone utilisation will pass largely unnoticed. As 
the fast progresses into the second and third day an increased reliance on ketones 
as fuel sources will magnify any inherent defect. Upper borderline 3HB levels are 
evident in the intermediary metabolite plots but because of a limited fast time 
(less than 16 hours) the contribution of ketogenesis to the patients overall energy 
supply is insufficient to create any outstanding effect.
These results indicate a normal fatty acid metabolism with all steps on figure 4.03. 
appearing normal. High 3HB in respect to FFA may be a result of defective 
ketone body utilisation although this does not explain the apparent normality of 
the other 3HB plots or the elevated %CE against FFA plot. This disorder has 
subsequently been associated, by alternative methods, with a defect in acetoacetate 
utilisation.
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4.1.3.3 Spontaneous hypoglycaemia
Patient 119, point 8, was entered into the study as a control. Eight days later she 
suddenly developed spontaneous hypoglycaemia, without fast. Extremely low 
glucose levels are apparent in all glucose plots indicating the hypoglycaemia. 
Lactate levels appear borderline agreeing with a normal gluconeogenic utilisation 
(step 1 on figure 4.03).
The FFA against glucose plot (figure 3.02.) is suppressed suggesting a metabolic 
defect lying within the release of FFA during times of low blood glucose (step 2 
figure 4.03).
Total carnitine levels are high but esterified carnitine production in accordance to 
the glucose level (figure 3.05.) is low despite an abundance of free carnitine. This 
reinforces the idea of defective free fatty acid generation (step 2). %CE increase 
with increasing FFA appears normal (figure 3.14) indicating normal acyl-CoA 
conversion into carnitine esters (step 3 figure 4.03).
3HB production compared to the level of %CE is normal (figure 3.18), evidence for 
good fi-oxidation-ketone production interplay (step 4 figure 4.03.) and 3HB against 
FFA (figure 3.15.) are quite normal again echoing the normality of fatty acid 
metabolism following free fatty acid arrival at the mitochondria.
In summary, paired metabolite correlation plots for patient 119 provide evidence 
of a fatty acid metabolic defect lying in liberation of free fatty acids from adipose 
tissue in response to low carbohydrate levels in the blood.
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4.1.3.4 Defects in gluconeogenesis and 3-hydroxybutyrate production
For patient 121, represented by the point U, the glucose level is very low and that 
of lactate elevated. This suggests a possible gluconeogenic defect (step 1 on figure
4.03.). The FFA and free and esterified carnitine levels in relation to glucose all 
appear normal as does that of %CE (figures 3.02, 3.04, 3.05) and %CE against FFA 
(figure 3.14). This indicates a normal fatty acid release and acyl group transport 
into the mitochondrial matrix (point 2 and 3 figure 4.03). 3HB levels are very 
much suppressed in relation to glucose (figure 3.06.), free fatty acids (figure 3.15) 
and %CE (figure 3.18) indicating a suppressed ketogenesis (point 4 figure 4.03).
Further evidence for the gluconeogenic defect is given by the similarities between 
points for this patient and those of patient 9 represented by point 5 (see section 
4.1.3.1).
Paired metabolite plots therefore provide evidence for the presence of two defects 
in fatty acid metabolism. One lies within the gluconeogenic incorporation of 
lactate. The second lies in the production of ketones in conjunction with high fi- 
oxidation flux. Such a duel block would explain the difficulty in diagnosis of this 
child's defects up to her inclusion into the study.
4.1.4 POSSIBLE FUTURE DEVELOPMENTS
4.1.4.1 Exact fasting times
Although, exact fast times would be particularly useful on the fasting profiles, one 
can see that they are not essential for paired metabolite correlation studies. 
However, it is important that the length of fast is sufficient to exert enough 
pressure on fat metabolism and ketosis to elicit any defect. This period would 
seem to be typically more than six hours or, more specifically, until glycaemia 
levels fall below 3mmol/l. Although most of the abnormal samples were below 
this limit, the vast majority of normal patients exhibited glucose values between 3 
and 5mmol/l. Normal data collected over a wider range of fast would increase 
definition of the correlations and therefore would be a possible refinement for 
further studies.
4.1.4.2 Necessary correlations
It should also be noted, as suggested in section 4.1.2.1, that not all the correlation 
plots used in this study are necessary for an assessment of the defect of a patient. 
Usually if all metabolite levels are known only the correlations between adjacent 
metabolites on figure 4.03. are necessary with the remainder serving only to 
reinforce any conclusions. Also paired metabolite correlations can prove useful 
even if the metabolites involved do not encompass the position of the defect as 
shown in section 4.1.2.3.
4.1.4.3 Dependence on age
JP Bonnefont and co-workers178 have shown that levels of oxidation metabolites 
during fast differ with age depending on the quality of glucose homeostasis. They
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slate that children older than 7 years show better glucose conservation and later 
onset of fatty acid metabolism as a result of starvation. In this study, although all 
patients were young, records were too sparse to collect an 'age' variable. Perhaps 
this should be considered in further studies.
4.1.4.4 Increase in sample size
If paired metabolite plots were set up within the clinical laboratory, data could be 
continuously added to build up a substantial sample size. Correlations would no 
doubt become much clearer against which data from suspected fatty acid 
oxidation defects could be easily compared. The biochemist would therefore have 
a quick, reliable and easy to use indicator as to the metabolic step or region 
presenting abnormal. Relevant treatment and further testing could then be carried 
out. Also, the inclusion of more data from diagnosed patients would strengthen 
the reliability of these procedures as well as highlight their limitations, a very 
important factor.
A number of samples may be collected from a subject and in this way fasting 
profiles could be set up for single individuals and compared with the fasting 
profiles calculated from multi-patient populations included in this study. 
Unfortunately, although in some cases such multiple samples from individual 
patients were collected the data was too sparse to permit any sensible 
investigation in this area.
As sample size increases and the difference between normal and abnormal 
becomes more defined computerisation of the whole process may be an option. 
This on-line facility could then refer back to the clinician any patients producing 
anything other than completely normal plots.
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4.2 GENERALISED DICARBOXYLIC ACIDURIA
INVESTIGATION
4.2.1 THE ASSOCIATION WITH THREE POSSIBLY RELATED FACTORS
From the Fisher's two tailed analysis of the connection between generalised DCA 
and sibling history of SIDS, feed and gender (table 3.05.) one can see high p values 
for the association of sibling history of SIDS (0.77) and gender (0.73) with 
generalised DCA. This suggests no association, whilst that for the method of 
feeding (0.08) is appreciably lower providing evidence of a possible relationship, if 
only at the 10% level of significance. Also, from table 3.06. there are similar 
percentages of males and females and similar percentages of siblings and non­
siblings of SIDS within each of the two classes 'presence' and 'absence of 
generalised DCA'. The percentage of breast fed neonates exhibiting generalised 
DCA is more than three times that for bottle feeders and the percentage of bottle 
fed neonates that show no such urinary pattern is more than twice that for breast 
feeders.
These findings indicate that sibling history of SIDS and gender are not associated 
with generalised DCA but there is evidence that the method of feeding is 
connected to the phenomenon. It should be noted that sample sizes are low and 
whilst Fisher's exact test is an accepted test to use on such small numbers any 
statistical conclusions should be treated with caution.
4.2.2 URINARY CARNITINE REFERENCE RANGE EVALUATIONS
The frequency diagrams and basic statistics (figures 3.25. to 3.27. and tables 3.07. 
to 3.09.) show skewed distribution for all carnitine evaluations. In a normal 
healthy baby, as the time difference between birth and sampling increases, the 
remaining metabolic stress produced by birth will diminish. Hence, any abnormal 
carnitine values resulting from this stress will return to normal as time progresses. 
Maebashi et al181 reported a return to normal carnitine excretion within 5 days 
following a several fold elevation due to a 5 day fast. A variation of sampling age 
may therefore create skewed distributions. However, figures 3.28. to 3.30. do not 
indicate any significant relationship between carnitine values and age. It is likely 
that such a short time period following birth is not sufficient to create any 
detectable change in carnitine levels. Perhaps larger sample size would have 
supplied a more normal distribution.
Reference ranges obtained from the subset containing both generalised DCA and 
non DCA patients are in good agreement with published data for children 3 
months and upwards182 (see table 4.01.). Variations in normal range 
representations coupled with differences in the units of the reported data often 
created complications in such comparisons. In table 4.01. unit conversion was 
based on a creatinine molecular weight of 113 AMU and %CE values were 
calculated from the limits of the normal ranges quoted for total and acylcarnitine. 
It should also be noted that Chalmers quoted his normal ranges as mean ± 
standard deviation rather than mean ± 2(standard deviation) which is statistically 
more comparable to the 2.5th to 97.5th percentile range approximations used in 
this study.
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Table 4.01. Normal ranges quoted by Chalmers et al182.
Carnitine value Normal range
5.6 — 22.6 flmol/mmol creat
1.3 - 10.3 pmol/mmol creat
54.4 - 76.8 %
Total
Free
Esters
4.2.3 THE CONNECTION BETWEEN CARNITINE VALUES AND
GENERALISED DICARBOXYLIC ACIDURIA
Data from table 3.11 show that the levels of urinary free and percent esterified 
carnitine may be related to the presence/absence of generalised DCA at the 5 
percent level of significance. Indeed, the probability of being incorrect in 
assuming a difference in percent esterified results is very low (p = 0.0002). 
Therefore, there is significant evidence, at the 5% level, that the percent esterified 
proportion of urinary carnitine is greater in neonates showing generalised DCA 
than those showing no DCA within the first five days of life.
A logistic regression analysis of the data was carried out. This test, whilst outside 
the statistical scope of this thesis, is specifically designed to analyse the 
interdependence of a number of variables within a population. The results can be 
found in table 4.02..
Table 4.02. Logistic regression analysis results on data from the generalised DCA investigation.
Variable Interdependence with Generalised DCA
Sibling history of S.I.D.S. No
Bottle or artificial feed Yes
Gender No
Total carnitine No
Free carnitine Possible
% Esterified carnitine Yes
Number of days after birth Possible
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A possible link between type of feed and generalised DCA is shown and supports 
theories discussed later. A connection between %CE and generalised DCA is also 
indicated and supports previous conclusions. A possible dependence of DCA on 
the number of days after sampling, agrees well with previously published 
observations177.
The p values from table 3.12. suggest that there is no difference in carnitine values 
dependant on sibling history of SIDS.
A p value of approximately 0.03 (table 3.13.) for total carnitine with type of feed 
suggest a significantly higher urinary total carnitine value in breast fed neonates 
than in those bottle fed (at the 5% level of statistical significance). Artificial feeds 
have been shown in some cases to be deficient in carnitine. This may result in 
higher carnitine excretion by breast fed neonates in comparison to those bottle fed 
as the renal threshold is surpassed by oral intake. However, this is not to say that 
all extra carnitine in breast milk is excreted. There does not appear to be any 
difference in free carnitine (p=0.62) suggesting that the extra total carnitine is 
incorporated into acyl esters. However, a p value of 0.08 for association between 
%CE and feed supports this theory at the 10% level of significance but not at the 
5% level.
In the case of the sex of the infant (table 3.14.) it appears, at the 5% level, that 
urine total carnitine values are higher for female newborns than males. There is 
no apparent difference in free and %CE. Published data for unstressed subjects 
between 16 and 60 years181,183,184 agree with a difference in carnitine excreted across 
the sex's but show males to possess the highest values. Unfortunately these 
values were quoted in m g/day and therefore could not be compared 
quantitatively to the results of this study.
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4.2.4 POSSIBLE FUTURE DEVELOPMENTS
The significance of the generalised DCA is as yet unknown. It is thought to be a 
harmless anomaly reflecting an immaturity of the fatty acid metabolic pathway. 
However, it would seem natural to assume that as the pattern is very similar to 
the more enhanced DCA accepted as part of an indicative trait in medium chain 
acyl-CoA dehydrogenase (see section 1.10.4), it would be preferable to avoid such 
a situation. Inclusion of L-carnitine supplement in artificial feed may help to 
alleviate the problem. Further studies with the inclusion of carnitine supplements 
in the feed of babies presenting with generalised DCA and measurement of their 
plasma as well as urine carnitine values would provide further information about 
the connection between carnitine and generalised DCA.
The presence of generalised DCA is not thought to be a problem in the organic 
acid diagnoses of acyl-CoA dehydrogenase deficiencies where similar patterns are 
much more exaggerated.
4.3 RADIO-ENZYMATIC ASSAY TO QUANTITATE
CARNITINE
4.3.1 CHOICE OF ASSAY MATERIALS
In order to achieve acceptable results for this assay it was necessary to investigate 
the effects of many conditions. 15ml Reactavials were used because of the small 
volumes of liquid encountered during the assay. Such volumes were kept to a 
minimum in order to concentrate the label and stabilise resultant scintillation 
counts. In order to maintain small volumes Picofluor 40 scintillation fluid was 
chosen because of its high aqueous volume capacity ( 5 - 6  cm3 aqueous in 10 ml 
scintillation fluid). Consideration was also given to the material used for the 
elution column container. Glass columns (Pasteur pipette) were selected over 
plastic (1ml syringe) to avoid the possibility of any retention of the label by the 
plastic. Length of column and amount of washing were carefully investigated 
before the 4cm depth and two 0.75ml washes were chosen based on intra-batch 
variation and recovery values.
The actual column material was chosen to be Dowex 1-X8 (chloride form) as used 
by Jalaludin Bhuiyan et al185. It was found essential that this Dowex was 
pretreated with sodium hydroxide before use and brought back to neutrality with 
saline. Otherwise, scintillation counts became spurious providing poor duplicates 
and unreliable results. The hydroxide washing had the effect of cleaning and 
fining the dowex. As a result of an excess of hydroxyl ions some of the chloride 
ions on the resin particles may have been displaced. It was these chloride groups 
that were exchanged for the acetyl-CoA in order to retain the unreacted 
[14C]acetyl-CoA during the elution stage of the assay. Such a displacement by 
hydroxide ions would be limited by the resins stronger affinity for chloride ions. 
However, to ensure the resins former chloride state neutrality was returned by 
washing with physiological saline rather than deionised water.
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4.3.2 POSSIBLE FUTURE DEVELOPMENTS
As this assay becomes more routinely used there are a number of areas that could 
become more 'automated'. For example, the use of multi-pipettes or a premixed 
cocktail of most of the reagents (excluding the enzyme) to reduce the number of 
pipette actions per sample. This would help to standardise the assay more thus 
decreasing intra- and inter-batch variations and increasing reliability and accuracy.
4.4 PREPARATION OF ISOTOPE INTERNAL STANDARDS 
FOR THE QUANTITATION OF URINARY GLYCINE 
CONJUGATES BY GAS CHROMATOGRAPHY / MASS 
SPECTROMETRY
4.4.1 RESPONSE TO DEUTERATION METHODS
For SG the abundance of 43% for the 2H4 compound relative to the total 
abundance for the 6 isotopic compounds 2H0 to 2H5 was good.
Table 3.20. shows the results of a single ion monitoring GC/MS analysis of both 
deuterated hexanoic acid and the final deuterated HG produced. Di-deuterated 
hexanoic acid was seen to be the most abundant isotope and therefore, not 
surprisingly, the 2H4-glycine conjugate dominated in the final product. A relative 
abundance of 73% was extremely good. The greater success of the deuteration of 
this molecule in comparison with that of the SG would be partially attributable to 
HG's shorter carbon chain length. The greater the chain length the more stable 
the molecule and the less prone are the hydrogen groups to replacement by 
deuteriums. Even though a small amount of non-deuterated compound still 
remained at the end of the synthesis (1.07% of the total HG) this was accepted as 
insignificant and infact was undetectable during calibration (table 3.27 and figure 
3.38)
A lower relative abundance for 2H4-PPG of 31%, again was probably a reflection of 
the larger carbon chain length responding poorly to such forced exchange 
synthesis.
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4.4.2 DEUTERATED STANDARD CALIBRATION
As already mentioned calibration results for all three deuterated compounds 
produced good linearity (table 3.27 and figures 3.37 to 3.39) but unfortunately 
poor reproducibility. The non zero peak area ratio for the zero standard on figure 
3.37 indicates the presence of non-deuterated SG in the deuterated sample. The 
regression lines for HG and PPG (figures 3.38 and 3.39) also do not pass through 
zero but in considering the inter-assay variation, suggested by the scatter of the 
plots, this does not necessarily indicate presence of non-deuterated HG or PPG in 
the deuterated sample. Further, actual zero results were recorded for the zero 
standards for HG and PPG.
However, in using such calibration curves the presence of background levels of 
non-deuterated conjugates in the deuterated standard would not effect 
quantitation results.
4.4.3 FUTURE DEVELOPMENT
More success has subsequently been achieved with the same stock isotopes by use 
of methyl ester derivatisation190, as used by Ramsdell and Tanaka191, rather than 
trimethylsilyl derivatisation, initially chosen as this was the method already in 
place for regular urine organic acid analysis.
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CLOSING SUMMARY
The intermediary metabolites investigation shows that paired metabolite 
correlation plotting can provide a clear indication of abnormal relationships and 
defect positions. In many cases a more evident picture than would be gained 
from interpretation of the individual laboratory results. This, along with the 
reduced need for exact knowledge of metabolic status, suggests that such plots can 
be useful in the diagnosis of fatty acid oxidation defects prior to more specific 
tests such as enzyme analyses.
Reference data correlations between the plasma intermediary metabolites glucose, 
free fatty acids, percent esterified carnitine and 3-hydroxybutyrate were good 
indicating significant inter-relationships during fasting. Plots involving more 
distantly related metabolites, such as lactate, provide weaker and therefore less 
useful correlations. Control of external factors that may affect metabolic states, 
such as exercise and age, may enhance correlations.
Separation of abnormal values resulting from errors in fatty acid oxidation was 
sufficiently clear to allow confident predictions of the general positions of the 
majority of the defects investigated. One requirement for a position to be clearly 
identified is that the metabolites either side of the position must be included in 
appropriate correlation plots. However, it has been shown that, in some cases, 
evidence of defect positions not encompassed by the metabolites measured can 
also be provided. A primary necessity in using paired metabolite correlations is 
the induction of sufficient metabolic stress, in this case carefully supervised 
fasting, to ensure the manifestation of any abnormality. Results may appear 
completely normal during times of minimal fatty acid oxidation flux.
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The general dicarboxylic acid investigation provides evidence that the occurrence 
of neonatal generalised DCA is not associated with sibling history of SIDS or 
gender. However, it is associated with breast feeding, as opposed to feeding with 
artificial milk compounds. Also, urine total and percent esterified carnitine values, 
on the whole, seem to be higher in urine exhibiting generalised DCA. Additional 
investigations involving carnitine supplementation and analysis of the association 
between carnitine values and types of feed would provide more information.
The occurrence of generalised DCA may be related to a depletion of tissue 
carnitine limiting fi-oxidation. Dicarboxylic acids would then be produced via co- 
oxidation. The pattern diminishes within a few days after birth and current 
thinking regards it
as a harmless result of an immaturity in the fatty acid oxidation pathway.
The radio-enzymatic assay of carnitine proved to be a reliable and cost effective 
means of measuring urine and plasma carnitine levels with the possibility of 
extension to differentiate between long and short chain length acylcarnitines.
The preparation of glycine conjugate isotope internal standards was very 
problematic. Difficulties were encountered in reproducing calibration results 
using trimethylsilyl derivatives. More success has since been achieved using 
methyl ester derivatisation.
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APPENDIX 1
CRYOGENIC STORAGE 
AND
FIBROBLAST TISSUE CULTURE
OF
SKIN BIOPSIES
1.1 SAMPLE SELECTION
Skin biopsies (approx. 2mm in diameter if possible) were routinely collected post 
mortem from children at Sheffield Childrens Hospital and transported to the 
laboratory in sterile culture media (see appendix section 1.3). The biopsy was 
selected for culture if subsequent liver microscopy revealed evidence of fatty 
infiltration. In a number of cases the biopsy was cryogenically preserved until 
clinical evidence merited culture (see appendix section 1.6).
The explant was set up for culture or cryogenic storage within a few hours of 
collection (typically within one hour).
1.2 ENVIRONMENTAL CONTROL
Aseptic conditions were facilitated by the use of a laminar flow cabinet (MDH 
Intermed).
1.3 MEDIA PREPARATION
Growth media was prepared by mixing 100ml culture media (Hams F10 nutrient 
mixture with 2mM hepes buffer and L-Glutamine, Flow laboratories) with 30ml 
sterile foetal bovine serum (Flow laboratories; stored at -20°C) and 1ml penicillin /  
streptomycin mix (50pg/ml streptomycin sulphate: 100 U /m l benzylpenicillin, Evans 
Medical Ltd, in PBS). The mixture was then filtered through cellulose acetate filters 
(Flowpore D26, pore size 0.2pm, pyrogen free; Flow laboratories) and stored at 4°C 
until required. A sample was incubated at 37°C for a few days before use to ensure 
the absence of visible bacterial growth.
Trypsinisation solution. 0.2g Ethylenediamine tetra-acetic acid disodium salt (EDTA, 
BDH) was added to 400ml phosphate buffered saline (PBS, 1 tab to 100ml deionised
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water) and autoclaved at 115°C for 20 min on a Dent & Hellyer labclave (Intermed 
MDH). 2.5% Sterile lyophilised trypsin (GIBCO) was first dissolved in 20ml of the 
EDTA solution and then mixed with the rest. The solution was then stored in batch 
size aliquots at -20°C.
Cryogenic storage solution. An initial 40% v /v  dimethyl sulphoxide (DMSO, Sigma) 
in PBS solution was diluted 1 in 5 with growth media to create a 10% v /v  solution.
1.4 FIBROBLAST INITIALISATION
The biopsy was cut into small pieces. 3-5 pieces were placed into each of three nunc 
tubes (Nunclon delta Intermed) and a flamed, cooled cover slip laid on top to prevent 
their movement. 2ml growth media was then added to cover the biopsy sections and 
the arrangement incubated at 37°C. Three times a week the tubes were examined 
under the microscope (CK Olympus Tokyo, magnification anomalous) for signs of 
fibroblastic growth and the growth media replaced with fresh. The time taken to 
initialise fibroblastic growth varied but was typically 1 - 2  weeks.
1.5 TRANSFER OF FIBROBLASTS - TRYPSINISATION
When fibroblastic growth was sufficient to cover the whole of the flat surface of the 
nunc tube, the fibroblasts were then transferred into a culture vessel(50ml wide 
canted neck with 25cm2 growth area and plug sealed screw cap, Falcon Labware; 
supplied by Fahrenheit laboratory supplies) as follows.
The growth media was replaced with 3ml trypsinisation solution and left for 
approximately 1 minute until the cells were seen to be beginning to loose their 
elongated shape and lift off the surface of the tube. The majority of the enzyme 
solution was then removed and the cells left in the remnants of the solution for 5 to 
10 minutes at 37°C to totally break their adhesion to the surface. 5ml Of growth
-183-
media was then added washing the fibroblasts off the sides of the tube. This solution 
was poured into a culture vessel and feeding continued as before. When growth was 
confluent over the surface of the vessel the cells were retrypsinised and either split 
into two such vessels or transferred into a larger vessel.
1.6 CRYOGENIC STORAGE OF FIBROBLAST CELLS
After 3 or 4 passages (sufficient to establish normal growth but to avoid excessive 
multiplication of anomalies caused by culturing) the cells were trypsinised and 
resuspended in 2ml cryogenic storage solution. The fibroblast solution was placed 
in a high chemical resistant polypropylene cryogenic vile (Bibby) and gently frozen, 
initially to -80°C before placing in liquid nitrogen vapour.
1.7 RECOVERY OF FROZEN CELLS
The thawing of fibroblasts was carried out quickly to avoid hypotonic shock. The 
cryotube was placed at 37°C and the cell suspension transferred to a nunc tube with 
10ml PBS. After centrifugation at 1000 rev/min for 5 minutes the supernatant was 
removed and the cells washed again with a further 10ml PBS, centrifuged and the 
supernatant removed. The pellet was resuspended in growth media and after 24 
hours incubation, when the cells had adhered to the surface of the tube, the growth 
media was renewed to remove any remaining trace of DMSO. The cells were then 
cultured as previously described.
1.8 TESTING FOR MYCOPLASMA INFESTATION
Prior to cryogenic storage or before use for assay the fibroblast culture was tested to 
ensure the absence of mycoplasma. These contaminating microorganisms metabolise 
substrates such as butyric and octanoic acid (but not palmitate192). Any extraneous
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metabolic activity would result in falsely elevated enzyme activity results from assays 
such as C 02 release.
The method used was a modification of that described by Russel et al193. A coverslip 
was placed in nunc tube containing a suspension of the cells to be tested. After a few 
days incubation the cells settled and adhered to the cover slip. Incubation continued 
until adequate growth was seen i.e. approximately a monolayer covering the majority 
of the cover slip. Any more and the density of the cells would swamp the detection 
procedure, any less and the cells would be too sparse to provide confident results.
The growth media was then replaced with a 3:1 ethanol: glacial acetic acid fixative, 
and left at room temperature for at least twenty minutes. The fixative was removed 
and the cells washed twice with l-2ml Gurrs buffer (BDH). To 5 ml Gurrs buffer in 
each tube 0.05ml of 5 x 10~5 g /m l Hoescht 33258 stain (bis-benzimide, Sigma) was 
added. After incubation at 37°C for 30 minutes the cover slip was removed, placed 
inverted on a microscope slide and examined under a fluorescence microscope 
(Vickers Fluorescence Microscope M17, magnification xlOO, with very low  
fluorescence submersion oil, blue filter exciter 2, FICT 5 +GG455 [3mm] OG515 
[3mm]).
The stain binds to the DNA of both cell nuclei and mycoplasma (largely DNA) and 
fluoresces on excitation with U.V light.
A brilliant mottled effect within the cytoplasm is indicative of mycoplasma 
infestation.
1.9 TREATMENT FOR MYCOPLASMA INFESTATION
On detection of mycoplasma the appropriate sanitation procedures of all materials 
used were carried out with careful quarantining of the infected cell lines. The 
treatment kit B.M. Cyclin marketed by Boehringer Manhiem was used as directed by
-185-
the manufacturers. This treatment has been seen to temporarily suppress C-oxidation 
by up to 70% but full activity is regained after a few days away from treatment186.
1.10 CRYOGENIC STORAGE OF SKIN BIOPSIES
This method was adapted from that of K.J. Fowler173. Skin biopsies arriving at the 
laboratory were immediately placed in a 10% v /v  solution of culture medium and 
DMSO. After approximately 1 hour to allow penetration of DMSO into the cells thie 
arrangement was frozen at -80°C.
1.11 RECOVERY OF CRYOGENICALLY STORED BIOPSY
As with cultured cell recovery, thawing was carried out quickly to avoid cellular 
damage. The frozen medium and biopsy were placed at 37°C and the biopsy 
removed as soon as it was free from the frozen solution. The biopsy was placed in 
growth media to wash and prepared for culture whilst submerged in fresh medium. 
After 24 hours incubation the growth medium was carefully replaced to remove any 
further trace of DMSO. Culturing procedures then continued as normal.
1.13 RESULTS AND DISCUSSION OF CRYOGENIC STORAGE OF
BIOPSIES
Ten skin biopsy samples were cryogenically stored and recovered. Storage times 
ranged from 1 to 12 months. Two of the biopsies that had been stored for 12 months 
failed to grow after thawing whilst a third showed quite normal viability for culture 
in all three nunc tubes. All other biopsies were cultured successfully although in one 
case cultures in only two of the three tubes survived whilst for another biopsy 
growth in one tube was significantly suppressed.
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Although these results are very preliminary and are not a thorough viability 
investigation they do show that it is possible to store skin biopsies in this way for 
much longer than the initial 23 days published by Fowler.
Storage of biopsy material in liquid nitrogen vapour as are skin fibroblast cells may 
result in extending possible storage times without losing the capacity for culture. 
This would then provide much more scope for retrospective studies using assays 
requiring tissue culture and again limit the costs involved in culture that is 
subsequently deemed unnecessary (as mention in section 1.11.5).
APPENDIX 2
DATA OBTAINED DURING THE 
INTERMEDIARY METABOLITES 
INVESTIGATION
Table A 2 .1. A description of the variable names used in the intermediary metabolite investigation.
Variable
name
i
Description
PATIENT Patient number
DIAGNOSE Diagnosis of patient
SAMPLE Sample number
FASTCOM Comment associated with length of fast
FAST Length of fast (hours)
GLUC Glucose (mmol/l)
LACT Lactate (mmol/l)
HB 3-Hydroxybutyrate (mmol/l)
FFA Free fatty acids (mmol/l)
FFA3HB Free fatty acids / 3-hydroxybutyrate
CARNF Free carnitine (^mol/l)
CARNT Total carnitine (/onol/l)
CARNE % Esterified carnitine
Table A 2 .2. A list of all values for the variable DIAGNOSE and the corresponding diagnosis decode.
DIAGNOSEValue Representative disease
0 No diagnosed disorder of fatty acid metabolism
1 Medium chain acyl—CoA dehydrogenase deficiency
2 Glycogen storage disease type 1A
3 Isolated glutacorticoid deficiency
4 Hyperinsulinaemic hypoglycaemia
5 Defect in gluconeogenesis
6 Limited glycogen stores or mobility
7 Defective acetoacetate utilisation
8 Spontaneous hypoglycaemia
U Duel defect
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Table A 2 .3. A list of all values for the variable FASTCOM and the corresponding decode.
FASTCOMvalue Description
* Unconfirmed fast time
> Fast time greater than value of variable FAST
6 to Fast time between 6 and value of variable FAST
6 or Fast time either 6 or value of variable FAST
approx Fast time only approximately equal to the valueof variable FAST
OBS PATIENT DIAGNOSE SAMPLE FASTCOM FAST GLUC LACT HB FFA FFA3HB CARNT CARNF
1 1 0 1 * 18 5.8 1.2 1.00 1.06 1.06000 15 13
2 2 0 2 . 3.8 1.3 0.70 0.72 1.02857 30 24
3 3 0 3 * > 6 4.3 1.0 0.30 0.54 1.80000 . .
4 4 0 4 7 4.4 1.6 0.20 1.26 6.30000 40 37
5 5 0 5 * 5 4.5 1.4 0.50 1.05 2.10000
6 6 0 6 8 4.3 1.4 0.90 0.97 1.07778
7 7 0 7 * 6 4.6 1.4 0.30 1.31 4.36667
8 8 0 8 > 6 4.0 1.0 1.00 1.31 1.31000
9 9 5 109 * 18 2.1 7.5 0.40 0.80 2.00000 20 15
10 10 0 10 > 7 4.9 1.8 1.40 0.96 0.68571
11 11 0 11 * 8 4.3 1.3 .
12 12 0 12 8 4.3 1.2 . 1.68 .
13 13 0 13 * 4 10.4 6.2 0.05 0.08 1.60000 45 38
14 14 0 14 8 3.5 1.0 1.50 0.89 0.59333
15 15 0 15 8 4.1 1.1 0.20 0.70 3.50000
16 16 0 16 6 3.9 1.0 1.20 0.99 0.82500
17 17 0 17 > 6 3.6 1.2 0.30 0.24 0.80000
18 18 0 18 * 6 4.6 2.0 1.40 0.11 0.07857
19 19 0 19 6 4.8 1.0 0.70 1.00 1.42857
20 20 0 20 6 5.8 1.4 0.50 0.47 0.94000
21 21 0 21 * 8 4.3 0.6 0.60 0.93 1.55000
22 22 0 22 8 5.0 1.2 0.60 0.70 1.16667
23 23 0 23 * 8 4.4 1.6 0.90 1.56 1.73333
24 24 0 24 * 6 4.9 2.0 0.20 0.76 3.80000
25 25 0 25 . 3.9 1.3 1.40 1.88 1.34286
26 26 0 26 * 6 5.3 1.3 0.20 0.28 1.40000
27 27 0 27 * > 6 5.8 1.3 0.90 0.19 0.21111
28 28 0 28 6 7.0 2.4 0.20 0.68 3.40000
29 29 0 29 6 4.9 1.0 0.70 1.09 1.55714
30 30 0 30 . 4.4 1.3 1.00 1.13 1.13000
31 31 0 31 6 6.1 0.8 0.40 0.53 1.32500
32 32 0 32 * 8 4.7 1.6 0.30 1.19 3.96667
33 33 0 33 6 to 8 4.7 1.0 0.80 0.79 0.98750
34 34 0 34 8 3.6 1.6 0.40 0.75 1.87500
35 35 0 35 * > 8 4.3 1.1 0.30 0.57 1.90000
36 36 0 74 8 6.0 2.3 0.05 0.23 4.60000
37 37 0 37 8 5.1 1.5 0.05 0.34 6.80000
38 38 0 38 * > 8 4.4 1.0 0.90 0.86 0.95556
39 39 0 39 * > 8 4.9 0.6 0.50 0.87 1.74000
40 40 1 40 . 1.5 2.7 1.30 3.42 2.63077 18
41 41 0 41 * > 6 5.5 2.7 0.40 1.16 2.90000
42 42 0 42 * > 8 4.3 1.1 0.40 0.76 1.90000
43 43 7 43 * 6 or 16 4.2 1.2 2.50 0.56 0.22400 43 21
44 44 0 44 . 4.9 4.5 0.10 0.87 8.70000 48 31
45 45 0 61 * > 8 . 0.9 0.20 0.72 3.60000
46 46 0 46 4.2 0.9 1.40 0.26 0.18571
47 47 0 47 4.2 0.7 0.80 0.88 1.10000
48 48 0 48 4.5 1.2 0.05 0.14 2.80000
49 49 0 49 4.8 2.4 0.70 1.12 1.60000
50 50 0 50 4.7 1.0 0.30 1.03 3.43333
51 51 0 58 . 1.8 0.10 0.96 9.60000
52 52 0 52 6.5 1.5 1.20 0.86 0.71667
53 53 0 53 4.8 1.4 1.20 1.56 1.30000
54 54 0 104 . . 0l50 0.57 1.14000
55 55 0 55 . 1.1 0.30 0.65 2.16667
56 56 0 56 . 1.5 0.40 1.09 2.72500
CARNE
13.3333
20.0000
7.5000
25.0000
15.5556
61.1111
51.1628
35.4167
OBS PATIENT DIAGNOSE SAMPLE FASTCOM FAST GLUC LACT HB FFA FFA3HB CARNT CARNF CARNE
57 57 0 57.0 4.4 . 1.30 0.45 0.3462
58 58 0 58.0 5.9 0.94 0.40 0.75 1.8750
59 59 0 59.0 * > 12.00 5.7 0.92 0.70 0.60 0.8571
60 60 0 60.0 4.4 1.06 1.60 1.22 0.7625
61 61 0 61.0 5.1 0.94 0.30 0.49 1.6333
62 62 0 79.0 5.8 1.21 0.60 0.56 0.9333
63 63 0 63.0 5.7 2.02 0.77 1.51 1.9610
64 64 0 64.0 * 6.00 4.4 1.31 0.66 0.77 1.1667
65 65 0 65.0 4.3 1.21 1.20 0.98 0.8167
66 66 0 66.0 12.00 5.6 1.65 0.10 0.52 5.2000
67 67 0 67.0 approx 12.00 4.4 1.37 1.50 0.80 0.5333
68 68 0 68.0 3.9 1.13 0.85 0.89 1.0471
69 69 6 69.1 12.00 3.5 . 2.70 2.68 0.9926 33 13 60.6061
70 69 6 ' 69.2 18.00 1.8 . 2.83 3.94 1.3922 . .
71 70 0 70.1 12.00 6.2 . 0.16 0.89 5.5625 33 23 30.3030
72 70 0 70.2 18.00 4.7 . 0.48 1.07 2.2292 33 21 36.3636
73 71 0 71.0 4.6 1.30 0.43 1.04 2.4186
74 72 0 72.0 4.9 1.38 0.99 1.11 1.1212
75 73 0 73.0 4.2 1.30 1.01 1.40 1.3861
76 74 0 74.0 6.1 1.37 0.08 0.26 3.2500
77 75 0 75.0 4.7 1.25 0.07 0.23 3.2857
78 76 0 76.0 4.9 1.78 0.04 0.34 8.5000
79 77 0 77.0 . 1.27 1.05 1.11 1.0571
80 78 0 78.0 . 1.68 1.79 0.65 0.3631
81 79 0 79.0 4.3 1.12 0.42 0.75 1.7857
82 80 0 80.0 . 1.55 0.12 0.42 3.5000
83 81 0 81.0 6.2 1.41 . 0.66 .
84 82 0 82.0 4.4 . 2.50 .
85 83 0 83.0 4.5 2.22 0.21 0.71 3.3810
86 84 0 84.0 5.6 0.99 0.65 0.76 1.1692
87 85 0 85.0 4.8 1.77 0.02 0.32 16.0000
88 86 0 86.0 4.3 0.89 0.93 1.18 1.2688
89 87 0 87.0 4.6 2.29 0.39 0.96 2.4615
90 88 0 88.0 5.2 1.82 0.65 1.55 2.3846
91 89 0 89.0 3.8 1.05 1.54 1.03 0.6688
92 90 0 90.0 . 1.13 . . . 58 45 22.4138
93 91 0 91.0 . 0.71 4.63 2.30 0.4968
94 92 0 92.0 . . 0.89 0.73 0.8202
95 93 0 93.0 . 4.49 0.00 0.10 .
96 94 1 94.0 7.6 2.22 1.35 1.95 1.4444
97 95 2 95.1 . . 0.03 0.81 27.0000
98 95 2 95.2 . . 0.00 0.71 .
99 95 2 95.2 . . 0.00 0.81 .
100 96 3 96.0 1.2 1.33 3.53 1.22 0.3456 18
101 97 0 97.0 2.7 2.33 4.00 . . .
102 98 0 98.0 5.0 2.28 0.00 . . 33 28 15.1515
103 99 0 99.1 11.00 4.1 1.96 0.51 0.57 1.1176 40 34 15.0000
104 99 0 99.2 14.00 3.9 1.98 1.46 1.17 0.8014 45 30 33.3333
105 99 0 99.3 18.00 3.3 2.03 2.41 1.81 0.7510 . .
106 100 0 100.1 13.00 4.3 1.21 0.48 0.85 1.7708 . .
107 100 0 100.2 15.50 3.9 1.23 1.92 1.15 0.5990 30 22 26.6667
108 100 0 100.3 18.75 2.0 2.28 4.09 2.44 0.5966 35 16 54.2857
109 101 0 101.0 3.6 1.21 . . . . 25
110 102 0 102.0 5.4 0.57 0*53 0.59 1 ..1-132- 30 24 20.0000
111 103 0 103.0 5.3 1.41 0.02 0.33 16.5000 18 22 -22.2222
112 104 0 104.1 16.00 4.2 1.30 0.40 2.10 5.2500
OBS PATIENT DIAGNOSE SAMPLE FASTCOM FAST GLUC LACT HB FFA FFA3HB CARNT CARNF CARNE
113 104 0 104.2 22.0 3.0 1.60 3.02 3.10 1.0265 .
114 105 0 105.1 15.0 4.5 1.50 0.85 1.25 1.4706 26 15.0 42.3077
115 105 0 105.2 8.0 4.0 1.40 1.82 1.55 0.8516 24 13.0 45.8333
116 106 0 106.1 15.0 4.8 1.30 1.39 1.23 0.8849 40 30.0 25.0000
117 106 0 106.2 18.0 4.7 1.20 2.14 1.38 0.6449 38 23.0 39.4737
118 107 0 107.1 . . 1.64 2.00 0.45 0.2250 55 32.0 41.8182
119 107 0 107.2 . 4.0 4.07 2.00 0.76 0.3800 63 36.0 42.8571
120 108 0 108.1 12.0 4.4 3.37 0.60 0.88 1.4667 34 23.0 32.3529
121 108 0 108.2 15.0 4.2 4.39 0.77 1.11 1.4416 38 21.0 44.7368
122 109 0 109.0 . 3.7 1.99 0.37 0.77 2.0811 38 28.0 26.3158
123 110 0 110.1 12.5 3.1 2.68 1.20 1.02 0.8500 44 24.0 45.4545
124 110 0 110.2 16.5 2.0 2.69 2.40 1.61 0.6708 40 19.0 52.5000
125 111 0 111.1 8.0 4.5 1.16 0.10 0.70 7.0000 30 25.0 16.6667
126 111 0 111.2 12.0 4.0 1.49 0.60 1.65 2.7500 33 26.0 21.2121
127 112 0 112.1 8.0 3.7 2.20 0.05 0.28 5.6000 35 31.0 11.4286
128 112 0 112.2 12.0 3.3 1.52 1.00 0.89 0.8900 33 21.0 36.3636
129 113 0 113.1 17.0 3.3 1.02 1.53 1.40 0.9150 24 11.0 54.1667
130 113 0 113.2 24.0 3.8 2.65 2.60 2.70 1.0385 24 10.0 58.3333
131 114 4 114.0 . 1.3 2.40 0.06 0.10 1.6667 18 14.0 22.2222
132 115 4 115.0 . 1.0 3.72 0.10 0.30 3.0000 35 29.0 17.1429
133 116 0 116.1 9.0 4.2 1.43 0.48 1.20 2.5000 36 30.0 16.6667
134 116 0 116.2 12.0 3.7 2.23 0.68 1.20 1.7647 40 30.0 25.0000
135 117 0 117.1 17.0 3.9 2.71 0.45 0.90 2.0000 30 25.0 16.6667
136 117 0 117.2 20.0 3.7 2.07 0.64 0.80 1.2500 33 22.0 33.3333
137 118 0 118.0 . 3.8 1.70 0.65 0.60 0.9231 . . .
138 119 0 119.1 21.0 1.6 1.30 3.90 2.40 0.6154 45 12.0 73.3333
139 119 8 119.0 . 0.4 3.30 0.62 1.10 1.7742 65 33.0 49.2308
140 120 0 120.0 . 3.5 1.40 1.90 1.30 0.6842 35 17.0 51.4286
141 121 U 121.0 . 1.0 6.50 0.22 3.30 15.0000 19 3.5 81.5789
142 122 4 122.0 . 0.6 4.60 0.66 0.30 0.4545 40 33.0 17.5000
143 123 0 123.1 . 2.5 5.04 0.30 0.60 2.0000 38 25.0 34.2105
144 123 0 123.2 . 2.5 2.34 1.06 0.60 0.5660 35 23.0 34.2857
145 124 0 124.1 . 4.2 1.70 0.34 0.90 2.6471 30 22.0 26.6667
146 124 0 124.2 . 3.8 1.87 1.42 1.10 0.7746 28 15.0 46.4286
147 125 0 125.1 12.0 4.2 1.02 0.21 0.60 2.8571 33 24.0 27.2727
148 125 0 125.2 17.0 4.0 1.25 0.50 1.24 2.4800 28 22.0 21.4286
149 126 0 126.0 . 3.2 2.31 0.85 0.91 1.0706 43 27.0 37.2093
150 127 0 127.0 . 1.0 1.12 3.62 3.34 0.9227 88 26.0 70.4545
151 128 0 128.0 . 4.6 2.30 0.97 0.97 1.0000 48 24.0 50.0000
152 129 0 129.0 . 3.6 1.95 0.73 0.88 1.2055 34 25.0 26.4706
153 130 4 . 0.0 1.6 . 0.08 0.03 0.3750 . . .
154 131 4 . 0.0 1.5 . 0.01 0.10 10.0000 . . .
155 132 4 . 0.0 0.8 3.30 0.06 0.02 0.3333 13 10.0 23.0769
156 133 4 . 0.0 0.5 8.97 0.12 0.03 0.2500 . . .
157 134 4 . 0.0 0.4 4.08 0.02 0.03 1.5000 14 7.0 50.0000
158 135 4 . 0.0 1.6 . . 0.10 . . . .
159 136 4 . 0.0 0.5 . . 0.12 . . . .
160 137 4 . 0.0 2.1 . 0.09 0.60 6.6667 . . .
161 138 4 . 0.0 2.0 1.86 0.01 0.30 30.0000 . . .
162 139 4 . 0.0 1.6 1.45 0.01 0.82 82.0000 . . .
163 140 4 . 0.0 0.9 2.00 0.01 0.10 10.0000 . . .
164 141 4 0.0 2.0 0.20 0.10 # . .
APPENDIX 3
DATA OBTAINED DURING THE 
GENERALISED DICARBOXYLIC
ACIDURIA
INVESTIGATION
Table A3.1. A  description of the variable names used in the generalised dicarboxylic aciduria investigation.
Variable
name
Description
PATIENT Patient number
MF Male(1) or female(O)
SC Sibling(1) or control(O) (C=cousin of SIDS)
BA Breast(1) or artificial(O) feed (B=both)
DCANON Generalised DCA present(1) or absent(O)
DAY Age at sampling (days)
CREAT Urine creatinine
T Urine total carnitine
TC Total carnitine / creatinine
LOGTC Log (Total carnitine / creatinine)
F Urine free carnitine
FC Free carnitine / creatinine
LOGFC Log (Free carnitine / creatinine)
AC % Esterified carnitine
LOGAC Log (% Esterified carnitine)
DBS PATIENT MF sc BA DCANON DAY CREAT T TC LOGTC F FC LOGFC AC LOGAC
1 1 1 1 1 3 17.0 308.0 18.118 1.25810 20.0 1.1765 0.07058 93.5065 1.97084
2 2 1 1 1 7.4 78.0 10.541 1.02286 6.0 0.8108 -0.09108 92.3077 1.96524
3 3 1 1 1 7.7 134.0 17.403 1.24061 15.0 1.9481 0.28960 88.8060 1.94844
4 3 1 1 4 9.3 145.0 15.591 1.19289 10.0 1.0753 0.03152 93.1034 1.96897
5 4 1 1 1 11.4 150.0 13.158 1.11919 9.0 0.7895 -0.10266 94.0000 1.97313
6 4 . 1 1 2 1.2 18.0 15.000 1.17609 3.0 2.5000 0.39794 83.3333 1.92082
7 5 1 1 1 1 9.0 103.0 11.444 1.05859 10.0 1.1111 0.04576 90.2913 1.95565
8 6 1 1 1 5.5 138.0 25.091 1.39952 13.0 2.3636 0.37358 90.5797 1.95703
9 6 # 1 1 3 1.4 40.0 28.571 1.45593 10.0 7.1429 0.85387 75.0000 1.87506
10 7 1 1 1 1 5.1 140.0 27.451 1.43856 11.0 2.1569 0.33382 92.1429 1.96446
11 8 0 1 1 1 2.4 39.0 16.250 1.21085 4.0 1.6667 0.22185 89.7436 1.95300
12 8 0 1 1 3 3.8 74.0 19.474 1.28945 4.0 1.0526 0.02228 94.5946 1.97587
13 8 0 1 1 5 1.0 20.0 20.000 1.30103 2.0 2.0000 0.30103 90.0000 1.95424
14 9 1 1 1 3.8 48.0 12.632 1.10146 5.0 1.3158 0.11919 89.5833 1.95223
15 9 1 1 3 3.5 55.0 15.714 1.19629 3.0 0.8571 -0.06695 94.5455 1.97564
16 9 # 1 1 5 1.0 15.0 15.000 1.17609 2.0 2.0000 0.30103 86.6667 1.93785
17 10 0 1 1 1 14.4 233.0 16.181 1.20899 13.0 0.9028 -0.04442 94.4206 1.97507
18 11 1 1 1 1 6.4 70.0 10.938 1.03892 5.0 0.7812 -0.10721 92.8571 1.96782
19 11 1 1 1 3 2.8 48.0 17.143 1.23408 3.0 1.0714 0.02996 93.7500 1.97197
20 11 1 1 1 5 1.6 20.0 12.500 1.09691 3.0 1.8750 0.27300 85.0000 1.92942
21 12 1 0 1 1 8.7 121.0 13.908 1.14327 7.0 0.8046 -0.09442 94.2149 1.97412
22 13 0 0 1 1 5.5 110.0 20.000 1.30103 7.0 1.2727 0.10474 93.6364 1.97144
23 13 0 0 1 3 1.1 28.0 25.455 1.40577 3.0 2.7273 0.43573 89.2857 1.95078
24 14 0 1 1 1 11.5 206.0 17.913 1.25317 11.0 0.9565 -0.01931 94.6602 1.97617
25 14 0 1 1 3 0.7 180.0 257.143 2.41017 10.0 14.2857 1.15490 94.4444 1.97518
26 14 0 1 1 5 0.9 41.0 45.556 1.65854 38.0 42.2222 1.62554 7.3171 0.86434
27 15 0 0 1 1 3.3 113.0 34.242 1.53456 4.0 1.2121 0.08355 96.4602 1.98435
28 15 0 0 1 3 10.3 236.0 22.913 1.36007 14.0 1.3592 0.13329 94.0678 1.97344
29 15 0 0 1 5 1.6 34.0 21.250 1.32736 4.0 2.5000 0.39794 88.2353 1.94564
30 16 0 1 1 1 5.2 95.0 18.269 1.26172 7.0 1.3462 0.12909 92.6316 1.96676
31 16 0 1 1 3 10.3 290.0 28.155 1.44956 13.0 1.2621 0.10111 95.5172 1.98008
32 16 0 1 1 5 1.3 25.0 19.231 1.28400 2.0 1.5385 0.18709 92.0000 1.96379
33 17 . 1 1 1 2.0 49.0 24.500 1.38917 4.0 2.0000 0.30103 91.8367 1.96302
34 17 . 1 1 2 2.2 168.0 76.364 1.88289 48.0 21.8182 1.33882 71.4286 1.85387
35 18 1 1 1 1 6.0 92.5 15.417 1.18799 5.0 0.8333 -0.07918 94.5946 1.97587
36 19 0 1 1 1 4.2 70.0 16.667 1.22185 9.0 2.1429 0.33099 87.1429 1.94023
37 20 . 1 1 1 2.9 81.0 27.931 1.44609 5.5 1.8966 0.27796 93.2099 1.96946
38 20 . 1 1 3 1.0 25.0 25.000 1.39794 3.0 3.0000 0.47712 88.0000 1.94448
39 20 . 1 1 5 * 1.3 58.0 44.615 1.64948 20.0 15.3846 1.18709 65.5172 1.81636
40 21 1 1 1 2 2.7 85.0 31.481 1.49806 2.0 0.7407 -0.13033 97.6471 1.98966
41 21 1 1 1 3 0.7 18.0 25.714 1.41017 1.0 1.4286 0.15490 94.4444 1.97518
42 22 1 1 1 1 5.4 78.0 14.444 1.15970 10.0 1.8519 0.26761 87.1795 1.94041
43 22 1 1 1 3 7.5 133.0 17.733 1.24879 7.0 0.9333 -0.02996 94.7368 1.97652
44 23 1 . 6.5 131.0 20.154 1.30436 7.0 1.0769 0.03218 94.6565 1.97615
45 24 1 4.2 64.0 15.238 1.18293 8.0 1.9048 0.27984 87.5000 1.94201
46 25 1 1 1 5.5 128.0 23.273 1.36685 10.0 1.8182 0.25964 92.1875 1.96467
47 26 1 5 2.6 33.0 12.692 1.10354 12.0 4.6154 0.66421 63.6364 1.80371
48 27 1 2 3.3 45.0 13.636 1.13470 5.0 1.5152 0.18046 88.8889 1.94885
49 28 1 1 6.6 7.5 1.136 0.05552 1.5 0.2273 -0.64345 80.0000 1.90309
50 28 1 3 2.0 30.0 15.000 1.17609 3.0 1.5000 0.17609 90.0000 1.95424
51 28 1 5 0.9 14.0 15.556 1.19189 2.0 2.2222 0.34679 85.7143 1.93305
52 29 1 1 1 2.5 51.0 20.400 1.30963 1.5 0.6000 -0.22185 97.0588 1.98704
53 30 1 1 1 2 6.0 119.0 19.833 1.29740 8.0 1.3333 0.12494 93.2773 1.96978
54 30 1 1 1 3 2.6 45.0 17-308 _1_238?4._4-5 .1.7308._GL23824-90-OOQO 1-95AZ4
55 30 1 1 1 5 1.0 18.0 18.000 1.25527 2.0 2.0000 0.30103 88.8889 1.94885
56 31 0 0 1 1 2.3 28.0 12.174 1.08543 3.0 1.3043 0.11539 89.2857 1.95078
57 31 0 0 1 5 2.1 36.0 17.143 1.23408 2.5 1.1905 0.07572 93.0556 1.96874
O B S P A T IE N T  MF S C  BA DCANON DAY
58 32 0 1 1 1 2
59 32 0 1 1 1 4
60 33 0 0 1 1 3
61 34 1 1 0 1 1
62 34 1 1 0 1 3
63 34 1 1 0 1 5
64 34 . 0 1 1 1
65 35 0 1 . 1 1
66 36 1 1 1 1 1
67 37 1 1 1 1 5
68 38 1 0 1
69 39 1 0 1
70 40 1 0 1
71 40 1 0 3
72 40 1 0 5
73 41 1 0 1
74 42 1 0 1
75 42 1 0 2
76 42 1 0 4
77 43 1 0 1
78 44 1 0 2
79 45 1 0 1
80 45 1 0 3
81 45 1 0 5
82 46 1 0 1
83 47 1 0 1
84 48 0 0 3
85 48 0 0 5
86 49 0 1 1 0 3
87 49 0 1 1 0 5
88 50 0 1 . 0 1
89 51 . 0 . 0 1
90 52 0 1 B 0 3
91 53 1 1 . 0 1
92 54 . 1 1 0 1
93 55 . 0 . 0 3
94 55 . 0 . 0 5
95 56 0 1 0 0 2
96 56 0 1 0 0 3
97 56 0 1 0 0 4
98 57 . 1 0 0 2
99 58 0 1 . 0 5
100 59 1 0 B 0 3
101 59 1 0 B 0 5
102 60 1 1 0 3
103 60 1 1 0 5
104 61 1 . 0 3
105 62 1 . 0 3
106 62 1 . 0 5
107 63 1 0 0 1
108 64 0 . 0 1
109 64 0 . 0 3
110 64 0 . 0 5
111 -65 1 0 0 2
112 65 1 0 0 5
113 66 1 1 0 0 2
114 67 . 1 0 0 4
:reat T TC LOGTC F
1.3 200 153.846 2.18709 14.0
10.2 20 1.961 0.29243 6.0
2.1 41 19.524 1.29056 9.0
1.7 16 9.412 0.97367 3.0
2.3 36 15.652 1.19457 5.0
1.0 23 23.000 1.36173 5.0
7.6 91 11.974 1.07823 10.0
7.6 76 10.000 1.00000 4.0
4.4 98 22.273 1.34777 10.0
0.7 11 15.714 1.19629 1.5
3.1 36 11.613 1.06494 5.0
7.6 58 7.632 0.88261 5.0
5.8 40 6.897 0.83863 15.0
5.6 70 12.500 1.09691 8.0
0.9 19 21.111 1.32451 8.0
6.9 58 8.406 0.92458 9.0
3.3 31 9.394 0.97285 7.0
2.8 35 12.500 1.09691 7.0
1.1 15 13.636 1.13470 3.0
2.8 25 8.929 0.95078 3.0
1.5 33 22.000 1.34242 3.0
4.0 78 19.500 1.29003 9.0
2.2 38 17.273 1.23736 4.0
1.3 26 20.000 1.30103 3.5
1.4 20 14.286 1.15490 2.0
2.3 16 6.957 0.84239 4.0
2.2 24 10.909 1.03779 12.0
1.3 19 14.615 1.16481 10.0
2.0 49 24.500 1.38917 2.0
0.4 13 32.500 1.51188 1.5
1.7 31 18.235 1.26091 3.0
0.6 16 26.667 1.42597 2.5
0.5 9 18.000 1.25527 1.0
2.7 34 12.593 1.10012 5.0
1.1 13 11.818 1.07255 1.0
2.1 46 21.905 1.34054 14.0
1.2 66 55.000 1.74036 41.0
1.5 19 12.667 1.10266 2.0
1.4 20 14.286 1.15490 1.5
1.3 18 13.846 1.14133 4.5
1.6 48 30.000 1.47712 3.5
1.7 35 20.588 1.31362 5.0
1.1 15 13.636 1.13470 4.0
0.8 14 17.500 1.24304 1.0
1.0 40 40.000 1.60206 6.0
1.0 20 20.000 1.30103 5.0
1.0 19 19.000 1.27875 4.0
0.7 14 20.000 1.30103 2.0
1.0 31 31.000 1.49136 15.0
1.3 14 10.769 1.03218 1.0
1.7 23 13.529 1.13128 1.0
0.8 16 20.000 1.30103 6.0
0.5 26 52.000 1.71600 18.0
0.5 21 42.000-JL62325_10„O
1.2 86 71.667 1.85532 58.0
1.9 16 8.421 0.92537 4.0
5.3 23 4.340 0.63745 5.0
FC LOGFC AC LOGAC
10.7692 1.03218 93.0000 1.96848 
0.5882 -0.23045 70.0000 1.84510 
4.2857 0.63202 78.0488 1.89237
1.7647 0.24667 81.2500 1.90982 
2.1739 0.33724 86.1111 1.93506
5.0000 0.69897 78.2609 1.89354 
1.3158 0.11919 89.0110 1.94944 
0.5263 -0.27875 94.7368 1.97652 
2.2727 0.35655 89.7959 1.95326 
2.1429 0.33099 86.3636 1.93633 
1.6129 0.20761 86.1111 1.93506 
0.6579 -0.18184 91.3793 1.96085 
2.5862 0.41266 62.5000 1.79588
1.4286 0.15490 88.5714 1.94729 
8.8889 0.94885 57.8947 1.76264 
1.3043 0.11539 84.4828 1.92677 
2.1212 0.32658 77.4194 1.88885
2.5000 0.39794 80.0000 1.90309 
2.7273 0.43573 80.0000 1.90309
1.0714 0.02996 88.0000 1.94448
2.0000 0.30103 90.9091 1.95861
2.2500 0.35218 88.4615 1.94675 
1.8182 0.25964 89.4737 1.95170
2.6923 0.43012 86.5385 1.93721
1.4286 0.15490 90.0000 1.95424 
1.7391 0.24033 75.0000 1.87506 
5.4545 0.73676 50.0000 1.69897
7.6923 0.88606 47.3684 1.67549
1.0000 0.00000 95.9184 1.98190 
3.7500 0.57403 88.4615 1.94675
1.7647 0.24667 90.3226 1.95580 
4.1667 0.61979 84.3750 1.92621
2.0000 0.30103 88.8889 1.94885 
1.8519 0.26761 85.2941 1.93092 
0.9091 -0.04139 92.3077 1.96524 
6.6667 0.82391 69.5652 1.84239
34.1667 1.53360 37.8788 1.57840 
1.3333 0.12494 89.4737 1.95170
1.0714 0.02996 92.5000 1.96614 
3.4615 0.53927 75.0000 1.87506 
2.1875 0.33995 92.7083 1.96712 
2.9412 0.46852 85.7143 1.93305 
3.6364 0.56067 73.3333 1.86530
1.2500 0.09691 92.8571 1.96782
6.0000 0.77815 85.0000 1.92942
5.0000 0.69897 75.0000 1.87506
4.0000 0.60206 78.9474 1.89734 
2.8571 0.45593 85.7143 1.93305
15.0000 1.17609 51.6129 1.71276 
0.7692 -0.11394 92.8571 1.96782 
0.5882 -0.23045 95.6522 1.98069
7.5000 0.87506 62.5000 1.79588
36.0000 1.55630 30.7692 1.48812
20.0000 1.30.103_52^38.10 1.71917 
48.3333 1.68425 32.5581 1.51266
2.1053 0.32331 75.0000 1.87506 
0.9434 -0.02531 78.2609 1.89354
O B S P A T I E N T  MF S C  BA  DCANON DAY CREAT T TC LOGTC F FC LOGFC AC LOGAC
115 67 • 1 0 0 5 0.7 18 25.7143 1.41017 9.0 12.8571 1.10914 50.0000 1.69897
116 68 1 1 0 0 1 1.2 10 8.3333 0.92082 4.0 3.3333 0.52288 60.0000 1.77815
117 68 1 1 0 0 3 1.0 13 13.0000 1.11394 1.0 1.0000 0.00000 92.3077 1.96524
118 68 1 1 0 0 4 0.4 6 15.0000 1.17609 1.0 2.5000 0.39794 83.3333 1.92082
119 69 1 • 0 2 3.5 40 11.4286 1.05799 2.0 0.5714 -0.24304 95.0000 1.97772
120 69 1 0 3 1.5 16 10.6667 1.02803 1.5 1.0000 0.00000 90.6250 1.95725
121 69 # 1 • 0 5 0.6 6 10.0000 1.00000 1.0 1.6667 0.22185 83^3333 1.92082
122 70 0 0 1 0 1 3.8 68 17.8947 1.25273 9.0 2.3684 0.37446 86.7647 1.93834
123 71 • 1 . 10.2 405 39.7059 1.59885 15.0 1.4706 0.16749 96.2963 1.98361
124 72 • 1 . 5.4 96 17.7778 1.24988 9.0 1.6667 0.22185 90.6250 1.95725
APPENDIX 4
URINARY CARNITINE NORMAL RANGES 
FOR THE GENERALISED DICARBOXYLIC 
ACIDURIA INVESTIGATION BASED ON 
NORMAL DISTRIBUTIONS AND 
NORMAL LOGARITHMIC 
DISTRIBUTIONS
See section 2.6.4 for an explanation of the ranges and calculations shown here.
Table A4.1 Normal ranges based on normal distributions of the raw data
Carnitine Value
Total Free % Ester
DCA & Non DCA 19.1 ± 36.1 2.3 ± 5.4 8 6 . 8 ± 2 0 . 2
Generalised DCA 21.6 ± 45.8 1.8 ± 3.4 90.5 ± 12.4
Non DCA 16.1 ± 18.0 2.9 ± 6.9 82.4 ± 24.0
Normal ranges calculated as; (mean) ± 2 (standard deviations).
Table A 4 .2 Normal ranges based on normal distributions of the logarithmic results.
Carnitine Value
*Log(Total) *Log(Free) *Log (100 — %Ester)
DCA & Non DCA 1.2 ± 0.5 0 . 2 ± 0 . 6 1 . 0  ± 0 . 6
Generalised DCA 1 . 2 ± 0 . 6 0 . 1 ± 0 . 6 0.9 ± 0.5
Non DCA 1.1 ± 0.4 0.3 ± 0.7 1 . 2  ± 0 . 6
vTotal vFree ¥% Ester
DCA & Non DCA 5 . 0 to 50 .1 0.4 to 6.3 60.2 to 97.5
Generalised DCA 4.0 to 63.1 0.3 to 5.0 74.9 to 97.5
Non DCA 5.0 to 31.6 2.5 to 10.0 36.9 to 96.0
"Normal logarithmic ranges calculated as; (mean) ± 2 (standard deviations).vRanges converted back from logarithmic values to non- logarithmic values.
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